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PREFACE
May this project aide in taking our worries away, decreasing the number of lives lost to suicide,
and allowing us all to live our lives to the fullest and enjoy every day.

“We love them. We miss them. We grieve them. And so, we live our lives to make them proud.”
– Anonymous

“Those we love don’t go away; they walk beside us every day, unseen, unheard, but always
near, still loved, still missed, and very dear.” - Anonymous
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ABSTRACT
Generalized anxiety disorder (GAD) is highly prevalent in the United States with at least 12% of
the population affected (Edmund & Sheppard, 2018). GAD can pose significant distress and
debilitation throughout the lifespan (Bystritsky, Khalsa, Cameron, & Schiffman, 2013; Edmund &
Sheppard, 2018). Barriers to treatment include adverse effects, inaccessibility, and expense.
The purpose of this project was to implement an evidence-based protocol involving combination
therapy with self-administered cognitive behavioral therapy (CBT) and selective serotonin
reuptake inhibitor (SSRI) medication in order to improve patient outcomes through more
accessible, affordable, and standardized treatment of GAD. The Neuman Systems Model and
Stetler Model were utilized to guide this project among a sample population of 20 adults with
GAD at a nurse practitioner-owned family practice clinic in Northwest Indiana. In fulfillment of
the protocol, each participant was prescribed an SSRI in combination with independent
completion of a CBT workbook for anxiety over 12 weeks. Anxiety symptoms via the
Generalized Anxiety Disorder 7-item (GAD-7) Scale and depression symptoms via the Patient
Health Questionnaire (PHQ-9) were measured at baseline, week 4, week 8, and week 12. A
one-way repeated-measures analysis of variance (ANOVA) indicated that while mean GAD-7
scores decreased from baseline (M = 4.20, SD = 4.32) to week 12 (M = 1.60, SD = 2.12), there
was no statistically significant decrease found (F(3,27) = 1.94, p > 0.05). Mean PHQ-9 scores
decreased from baseline (M = 4.80, SD = 3.58) to week 12 (M = 1.90, SD = 2.81), and there
was a statistically significant decrease found (F(3,27) = 4.34, p < 0.05). Participants were
satisfied (44.4%), very satisfied (33.3%), and extremely satisfied (22.2%) with self-administered
CBT. Providers are recommended to implement combined self-administered CBT and SSRI
medication as a cost-effective, accessible, and effective method to decrease anxiety and
depression symptoms among patients with GAD.

x

xi
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CHAPTER 1
INTRODUCTION
Background
As one of the most common psychiatric illnesses addressed in the primary care setting,
generalized anxiety disorder (GAD) is highly prevalent in the United States as well as in other
countries and poses a significant problem for not only adults, but also for children and
adolescents (Edmund & Sheppard, 2018). As many as 264 million people suffered from an
anxiety disorder worldwide in 2015 (World Health Organization, 2017). This indicated a 15% rise
since 2005 in the number of individuals affected with further rise expected. The lifetime
prevalence of GAD alone is reportedly 12% in the United States with a higher prevalence
suspected due to a lack of care sought by affected individuals (Edmund & Sheppard, 2018).
Despite many invisible and intangible characteristics of GAD, it can cause significant debilitation
(Bystritsky, Khalsa, Cameron, & Schiffman, 2013). GAD is “…characterized by excessive worry
or anxiety about everyday events and problems to the point at which the individual experiences
considerable distress and difficulty in performing day to day tasks” (Campbell, 2016, p. 1).
Decreased quality of life, decreased productivity, negative impact on well-being, increased
morbidity and mortality, and increased abuse of drugs and alcohol are often associated with
GAD (Bystritsky et al., 2013; Edmund & Sheppard, 2018). Approximately 32.3% of individuals
with GAD reportedly have serious impairment, 44.6% have moderate impairment, and 23.1%
have mild impairment (National Institute of Mental Health, 2017). Anxiety is considered the sixth
largest contributor to global disability (World Health Organization, 2017). The impact of anxiety
on functional impact has led to a total of 24.6 million years lived with disability according to 2015
data.
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
provides specific diagnostic criteria for GAD (American Psychiatric Association, 2013). In order
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to classify as a diagnosis of GAD, A) such excessive anxiety and worry about multiple events or
activities must be present for a majority of days throughout a time period of at least 6 months, B)
the worry is difficult to control, C) the anxiety and worry are associated with three or more of the
following six symptoms in adults or one or more of the following six symptoms in children: 1.
feeling restless or on edge, 2. easily fatigued, 3. difficulty concentrating or remembering
thoughts, 4. irritability, 5. muscle tension, 6. sleep disturbance (trouble falling or staying asleep,
restlessness during sleep, feeling unsatisfied with sleep), D) significant impairment in
functioning, social, and/or occupational aspects, E) the anxiety, worry, and symptoms are not
associated with the use of a substance (drug abuse or medication use) nor another medical
condition, F) there is a lack of a better explanation for such difficulty including another medical
disorder, mental disorder, or anxiety disorder (American Psychiatric Association, 2013).
There is evidence to support the influence of both environmental and genetic factors
associated with GAD. Individuals with parents who have been diagnosed with an anxiety
disorder are more likely to develop an anxiety disorder themselves (Edmund & Sheppard,
2018). Overprotective or overcontrolling and negative or highly critical parenting styles can also
contribute to the development of GAD in adolescents. Disturbances among norepinephrine,
serotonin, and gamma-aminobutyric acid may also be responsible. Data support that
dysregulation in areas of the brain that control emotional processing, such as the anterior limbic
network, may contribute to the development of GAD (McBride, 2015). Such brain structures
among individuals with GAD react easily to stimuli that elicit fear and other strong emotions
among individuals with GAD. The development of GAD is associated with behavioral inhibition,
which is defined as the likelihood to feel distress and to withdraw from unfamiliar or new stimuli.
The median age of onset of GAD is characterized as 30 years old, but symptoms may
begin years sooner (Edmund & Sheppard, 2018). Women are affected twice as often as men.
Poverty, loss, other mental disorders, and life events perceived as negative increase the
likelihood of GAD development. There are conflicting data regarding the relationship of
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socioeconomic status and the risk of GAD development with some studies indicating that lower
occupational status, income, and education level are associated with higher risk of GAD
development and others indicating that lower socioeconomic status is linked to lower rates of
GAD than those of higher statuses (McBride, 2015). Additional risk factors for GAD include
personality characteristics of behavioral inhibition, negative affect, low self-esteem, decreased
adaptability, and poor self-regulation. Conflict among parents and children or among siblings as
well as interparental violence, separation, and divorce can increase GAD risk. Report of suicidal
ideation and past attempts of self-harm are more common among adolescents with GAD than
those without. Additional risks associated with GAD in adolescence include alcohol and
cigarette abuse, academic difficulties, conflicts at home, struggles in social situations, negative
self-image, rejection by peers, and being left out of activities with peers. Adolescents with GAD
may have fewer friendships and be less liked by their peers as a result of such relationship
struggles. Being the victim of bullying, in particular, is the most influential factor among peer
relationships in the development of GAD. Depressive disorders are highly correlated with GAD
(Edmund & Sheppard, 2018). The correlation is so great that coexisting depression among
patients with symptoms of GAD is not only possible, but likely probable. In 2015, approximately
322 million individuals suffered from depression worldwide (World Health Organization, 2017).
Depression also strongly correlates with suicide deaths, which total approximately 800,000 per
year. Common psychiatric comorbidities of individuals with GAD include substance use/abuse,
social anxiety disorder, obsessive compulsive disorder, post-traumatic stress disorder, and
bipolar disorder (Edmund & Sheppard, 2018).
Statement of the Problem
Data from the Literature Supporting Need for the Project
Anxiety disorders are the most prevalent mental health disorders, which supports the
need to make them a priority to help a large number of individuals (Bystritsky et al., 2013).
Anxiety disorders are such a significant problem in the United States, yet they often do not
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receive as much recognition and care as other psychological disorders. There are a multitude of
challenges associated with understanding, diagnosing, and treating GAD in primary care. Many
symptoms of GAD can be associated with other disorders, such as anemia, hyperthyroidism,
cardiac dysrhythmias, or substance abuse, contributing to the misdiagnosis and underdiagnosis
of GAD that often occurs (Edmund & Sheppard, 2018). The physical symptoms that patients
with GAD report may be nonspecific, confusing, or ill-defined, and they may be variable,
disappearing on the weekends or during vacations (McBride, 2015). In addition, other health
conditions and comorbidities often take priority over the treatment of GAD, leading to a lack of
timely and proper treatment. Another challenge is the lack of affected individuals seeking care
with only a reported one third of individuals with GAD presenting for help (Edmund & Sheppard,
2018). Further adding to these dilemmas include the barriers associated with treatment, such as
a lack of cognitive behavioral therapy (CBT) therapists or cost-prohibitive CBT services
(Bystritsky et al., 2013). These challenges lead to the underdiagnosis and undertreatment of
GAD.
According to the American Psychiatric Association, combination pharmacotherapy and
psychotherapy, especially CBT, elicits great response rates in the majority of patients (Edmund
& Sheppard, 2018). Such combination therapy has been shown to yield the best results and
helps to reduce relapse, relieve symptoms, and develop coping strategies (Edmund &
Sheppard, 2018; McBride, 2015). Approximately 81% of patients with GAD have responded well
to combination CBT and pharmacotherapy compared with a 60% response rate for CBT alone
and 55% response rate for pharmacotherapy alone (McBride, 2015). Therefore, patients with
GAD should be provided with these options for treatment.
CBT is a form of psychotherapy that aims to modify thinking in order to combat
dysfunctional thinking and encourage positive thoughts (Bystritsky et al., 2013; McBride, 2015).
It allows patients to change their negative and distorted thoughts into more positive and realistic
ones and to confront the situations and beliefs that cause them to feel anxious and fearful. Side
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effects of CBT are minimal but may include emotional vulnerability, emotional discomfort,
frustration, crying, anger, feeling physically drained, temporary stress, and temporary anxiety as
a result of addressing such sensitive thoughts (May Clinic, 2018a). CBT is a long-term therapy
that typically yields success with higher patient engagement and attendance (Bystritsky et al.,
2013). It often involves the use of manuals or daily homework to promote the learning of
methods to reduce negative reactions to anxiety, modification of irrational thoughts, and
development of coping skills. There are many different types of CBT programs. However,
efficacy and long-term outcomes are comparable among those most commonly used (McBride,
2015). Due to the lack of available CBT therapists and affordable sessions, there is a call for
making CBT more accessible in primary care through education and training (Bystritsky et al.,
2013). Self-administered CBT currently serves to help fill this void. There is evidence to support
the effectiveness of self-administered CBT, and its efficacy via different methods of
dissemination continues to be further explored through research and evidence-based practice
(EBP).
Evidence supports the effectiveness of pharmacologic therapy for GAD with selective
serotonin reuptake inhibitors (SSRIs), which are classified as antidepressant medications
(Edmund & Sheppard, 2018). SSRIs are considered first-line therapy. Several weeks of SSRI
use may be necessary to achieve maximal effects. SSRIs work by increasing serotonin activity
(Hirsch & Birnbaum, 2019). Serotonin, or 5-hydroxytrptamine (5-HT), is a neurotransmitter
released in the brain. The pharmacodynamics of SSRIs allows them to decrease action of the
presynaptic serotonin reuptake pump by 60-80%, increasing the amount of time that serotonin is
thus available at the synapse. This, in turn, increases serotonin activity by increasing the
number of receptors occupied by serotonin at the postsynaptic neuron. Examples of SSRI
medications include fluoxetine, paroxetine, citalopram, escitalopram, and sertraline. Side effects
of SSRIs may include gastrointestinal symptoms such as nausea and diarrhea, sexual
dysfunction such as decreased libido or erectile dysfunction, insomnia, headache, blurred
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vision, drowsiness, dry mouth, nervousness, agitation, restlessness, dizziness, and possible
weight gain (Edmund & Sheppard, 2018; Mayo Clinic, 2018b). Drug interactions, serotonin
syndrome, and pregnancy risks are associated with some SSRIs. Paroxetine and escitalopram
are the only Food and Drug Administration (FDA) approved SSRIs. Other medications often
used in the treatment of GAD that are not first-line agents include serotonin-norepinephrine
reuptake inhibitors (SNRIs) and benzodiazepines. Examples of SNRIs include venlafaxine,
desvenlafaxine, and duloxetine. SNRIs may cause side effects including weight gain, nausea,
insomnia, constipation, sweating, and increased blood pressure. Venlafaxine and duloxetine are
the only FDA approved SNRIs. Buspirone is another medication often used. However, it is often
incorrectly prescribed as needed rather than on a scheduled basis. Despite its efficacy, it can
increase the risk of serotonin syndrome in patients taking additional serotonergic medications.
Benzodiazepines also are effective yet pose a multitude of risks including the potential for
dependence, tolerance concerns, difficulty weaning or discontinuing, and adverse reactions of
amnesia, rebound anxiety, diminished psychomotor performance, or withdrawal symptoms.
Additional information regarding anti-anxiety medications is presented in Table 1.1 (Bystritsky,
2019; Hirsch & Birnbaum, 2019).
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Table 1.1
Anti-Anxiety Medications
Medication

Class

Use

Examples

Risks

Side Effects

Selective
Serotonin
Reuptake
Inhibitors
(SSRIs)

Antidepressant

First line

Citalopram
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline

Generally well
tolerated and
safe; risks –
serotonin
syndrome,
drug
interactions,
pregnancy

Gastrointestin
al symptoms
such as
nausea and
diarrhea,
sexual
dysfunction
such as
decreased
libido or
erectile
dysfunction,
insomnia,
headache,
blurred vision,
drowsiness,
dry mouth,
nervousness,
agitation,
restlessness,
dizziness,
weight gain

SerotoninNorepinephrin
e Reuptake
Inhibitors
(SNRIs)

Antidepressant

NOT first line

Desvenlafaxin
e
Duloxetine
Levomilnacipr
an
Milnacipran
Venlafaxine

Benzodiazepin
es

Sedative/
Hypnotic/
Anxiolytic

NOT first line

Alprazolam
Clonazepam
Diazepam
Lorazepam

Weight gain,
nausea,
insomnia,
constipation,
sweating,
increased
blood pressure

Potential for
dependence,
tolerance
concerns,
difficulty
weaning or
discontinuing

Amnesia,
rebound
anxiety,
diminished
psychomotor
performance,
or withdrawal
symptoms
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Serotonin
Modulators

Antidepressant

NOT first line

Nefazodone
Trazodone
Vilazodone
Vortioxetine

Drowsiness,
orthostatic
hypotension,
QTc
prolongation,
gastrointestina
l upset, weight
gain, sexual
dysfunction

Tricyclic and
Tetracyclic
Antidepressan
ts (TCAs)

Antidepressant

NOT first line

Amitriptyline
Amoxapine
Clomipramine
Desipramine
Doxepin
Imipramine
Maprotiline
Nortriptyline
Protriptyline
Trimipramine

Anticholinergic
effects,
drowsiness,
insomnia,
agitation,
orthostatic
hypotension,
QTc
prolongation,
gastrointestina
l upset, weight
gain, sexual
dysfunction

Atypical
Agents

Antidepressant

NOT first line

Agomelatine
Bupropion
Mirtazapine

Drowsiness,
anticholinergic
effects,
insomnia,
agitation, QTc
prolongation,
gastrointestina
l upset, weight
gain, sexual
dysfunction

Monoamine
Oxidase
Inhibitors

Antidepressant

NOT first line

Isocarboxazid
Phenelzine
Selegiline
Tranylcypromi
ne

Anticholinergic
effects,
drowsiness,
insomnia,
agitation,
orthostatic
hypotension,
gastrointestina
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l upset, weight
gain, and
sexual
dysfunction

Azapirones

Anxiolytic/
Antipsychotic

NOT first line

Buspirone
Gepirone
Ispaprione

Dizziness,
nausea,
headache,
insomnia,
agitation
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There is a call among the literature for providers to be more aware of the prevalence and
severity of GAD, express greater sensitivity in the treatment of mental health, be more diligent
and knowledgeable in assessing and diagnosing those affected, make treatment of GAD a
priority, and provide better and earlier management of GAD among children, adolescents, and
adults (McBride, 2015). This call also includes a need for more knowledgeable administration of
effective interventions in primary care and the communication of such effective treatment to the
public (Bystritsky et al., 2013). It is important to raise awareness that GAD is treatable and to
widely disseminate best practice (McBride, 2015). There is overwhelming support that the best
treatment for GAD is the combination of an SSRI and CBT. The development of a trusting
relationship between the provider and patient with a team-based approach including patient
involvement in treatment decisions has been shown to be beneficial (Edmund & Sheppard,
2018). Effective treatment requires time and effort on behalf of both the provider and patient.
There is much evidence to support a need for this project, which includes all of these necessary
components based upon best practice and aims to improve these shortcomings in current
clinical practice.
Data from the Clinical Agency Supporting Need for the Project
The clinical agency where this EBP project was conducted was a family practice clinic in
Northwest Indiana (E. Strutz, personal communication, July 10, 2018). This clinic is owned by a
nurse practitioner (NP) who is the sole provider in office. A collaborative agreement with a
physician located outside of the practice is in place who reviews 5% of the patient charts. Two
medical assistants also provide patient care. The NP and office manager approved the project
and served as the site facilitators. Clinical agency data were provided by the office manager.
This primary care office was opened in April 2012. Care is provided to an age range of infants to
adults, from birth to death. Approximately 105 patients are seen in the office each week, and
approximately 15% of these patients have depression and/or anxiety, with data remaining rather
consistent throughout the entire year.
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The rural town in which this clinical agency is located has a population of approximately
909 residents with a diversity index of 20, which represents the likelihood on a scale from 0 to
100 that two people selected at random from the town will be of different race or ethnicity (Home
Town Locator, Inc. 2018). A population consisting of only one race and one ethnic group would
have a diversity index of 0, indicating a lack of diversity. When there is an even distribution of
two or more race or ethnic groups in an area, the diversity index is 100. When compared to
other Indiana towns, this town is considered to be within the upper quartile for diversity. The
average household income of residents is $54,153, the average home value is $146,272, and
the average family size is three (Home Town Locator, Inc., 2018). The unemployment rate in
this town is 7.6%, and 8.7% live in poverty. Approximately 45.5% of residents have obtained a
high school diploma, and approximately 6.2% have obtained a bachelor’s degree. The median
age of town residents is 29.6 compared to 37.4 for the state of Indiana (Stats America, 2016).
The clinical agency provides care to patients from this town as well as neighboring towns.
The office manager, NP, and medical assistants at this office have passionately
supported this EBP project, its goals, and its great need in practice since initial contact and
proposal of the project (L. K***, personal communication, June 11, 2018). They discussed that a
significant number of patients present to their office with GAD, and the stigma and barriers to
treatment pose great challenges. They have mentioned their struggles with and reservations in
prescribing benzodiazepines for patients as well as the reluctance of some patients to fulfill their
referrals to psychiatric care and counseling. As a result of such challenges, they have
expressed their difficultly in consistently following best practice recommendations. A protocol
such as the one developed by this EBP project has not been previously implemented nor
currently exists at the practice. The staff has expressed their interest in the help that this project
can provide them in effectively treating patients with GAD and improving patient outcomes. The
project manager and staff at the clinical agency believe that this project can be very beneficial to
this practice, make a difference in the quality of life and symptomology of their patients with

GENERALIZED ANXIETY DISORDER PROTOCOL

12

GAD, and help serve as a guide for NPs to facilitate such positive outcomes and proper
treatment plans. This is congruent with the mission statement of the clinical agency which
expresses this practice’s commitment to high quality of life (K. Family Medicine, 2018).
Purpose of the Evidence-Based Practice Project
Compelling Clinical Question
The purpose of this EBP project titled, Anxiety is Something to Worry About: The Effects
of a Cognitive Behavioral Therapy and Selective Serotonin Reuptake Inhibitor Intervention
Protocol on Generalized Anxiety Disorder, was to improve treatment of GAD by developing and
implementing an evidence-based protocol including CBT and SSRI use. Thus, a protocol for
NPs and other providers to utilize in order to provide proper and consistent treatment of patients
with GAD via SSRI use and CBT to yield best patient outcomes was provided. The project
explored the effects of SSRI use and self-administered CBT on symptoms of GAD experienced
by patients across much of the lifespan. The aims of the project included decreasing patient
symptoms of GAD, increasing knowledge of providers regarding appropriate care of patients
with GAD, and raising awareness for GAD and its treatable nature. EBP involves the translation
of the best available evidence into clinical practice in order to foster the highest quality of care
and best patient outcomes. It begins with clinical inquiry, which entails gathering data to
evaluate available treatment in order to determine the best choice. Such clinical inquiry led to
the development of the following compelling clinical question (Melnyk & Fineout-Overholt,
2015). What is the best way to decrease symptoms of generalized anxiety disorder (GAD)
among affected adults in primary care?
PICOT Question
Clinical questions are often clearly posed in PICOT format with (P) standing for patient
population/disease of interest, (I) for intervention or issue of interest, (C) for comparison
intervention or issue of interest, (O) for outcome of interest, and (T) for time over which the
population is observed (Melnyk & Fineout-Overholt, 2015). The following PICOT question was
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developed to guide the EBP project: Among adults presenting with generalized anxiety disorder
(GAD) in the family practice setting (P), does the introduction of an intervention protocol to treat
patients with a selective serotonin reuptake inhibitor (SSRI) and self-administered cognitive
behavioral therapy (CBT) via bibliotherapy (I) compared to the current practice of no protocol
(C), improve GAD symptoms as measured by patient-reported scores on the Generalized
Anxiety Disorder 7-item (GAD-7) scale (O) over a 12-week period (T)?
Significance of the EBP Project
As treatment of GAD often begins in primary care, providers in this setting have a vital
role in ensuring that those affected receive proper care. This project aimed to implement a
practice change based on current, quality evidence-based practice recommendations. Such
practice change consisted of a protocol including SSRI and CBT use for the best treatment of
patients affected by GAD in the family practice setting. This EBP project aimed to fight the
stigma associated with mental illness and to give GAD the recognition it deserves in order for
individuals with GAD to receive timely care that allows them to live healthier lives. Accurate
measurement of outcomes provided greater understanding of interventions and their effects on
a multitude of different aspects, including symptom severity, comorbid depression, acceptability
of treatment, and much more. The project ultimately served to significantly reduce worry,
decrease the rate of suicide, and allow individuals affected by GAD to gain back control of their
lives and enjoy every day. As application of this protocol expands to other family practice
settings, it can assist providers in gaining further knowledge and skills regarding appropriate
treatment of GAD and thus, better equip them to care for this population. This will aide in
continuity and quality of care provided, as there is currently much discourse and lack of unity in
the treatment of GAD. In addition, this will support early treatment of GAD and help to prevent
delays in care. Finally, by implementing such best practice recommendations, patients can
receive greater relief of GAD symptoms, which may translate into improvement of many areas
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of their lives, including greater quality of life. By facilitating a focus on self-care, wellness can be
achieved.

GENERALIZED ANXIETY DISORDER PROTOCOL

15

CHAPTER 2
THEORETICAL FRAMEWORK, EBP MODEL, AND REVIEW OF LITERATURE
Theoretical Framework
After thorough review of many theoretical frameworks and EBP models, the Neuman
Systems Model and Stetler Model respectively, were selected to aide in the development of this
EBP project based on their applicability to the core components of the project. The Neuman
Systems Model was highly applicable due to its premise of environmental stressors eliciting a
reaction in a person based in part on his or her ability to cope with such stressors as well as the
model’s aim for the person to achieve their highest level of wellness possible (Neuman &
Fawcett, 2011). These components are important as this project included the incorporation of
best practice for the treatment of GAD in order to help patients learn to cope with stressors that
cause them anxiety to yield improved quality of life. The Stetler Model served as a guide for the
EBP process of this project with its five detailed steps for development, implementation, and
analysis in order to foster successful integration of practice change and worthwhile conclusions
(Melnyk & Fineout-Overholt, 2015). A comprehensive review of the literature was performed in
order to determine best practice interventions for the treatment of GAD as well as details
regarding their efficacy and the best methods of implementation. A description, appraisal, and
synthesis of such literature will be presented in order to disseminate best practice
recommendations in the form of a protocol for patients with GAD.
Overview of Theoretical Framework
The Neuman Systems Model was utilized to guide this endeavor due to its ideal
relevance to examining the influence of the use of SSRIs and self-administered CBT among
patients presenting with GAD. This model’s development began in 1970 by Betty Neuman after
her efforts in teaching University of California, Los Angeles (UCLA) graduate students led her to
the conclusion that nurse educators and practitioners were in need of a comprehensive

GENERALIZED ANXIETY DISORDER PROTOCOL

16

framework to guide a variety of nursing contexts (Neuman, 1982). It served an initial purpose as
a teaching tool and a way to unify student learning (Neuman & Fawcett, 2011). The model was
first published in 1972 in an article in Nursing Research, and in 1982, Neuman published the
first edition of a book detailing the model and its application to nursing.
A holistic, wellness-oriented focus can describe the Neuman Systems Model, which has
an overall nursing goal to “facilitate optimal wellness for the client through retention, attainment,
or maintenance of client system stability” (Neuman & Fawcett, 2011, p. 3). Optimal wellness is
deemed the highest degree of system stability at any given point in time, and wellness is
gauged on a continuum from the highest degree of wellness to severe illness or death (Neuman
& Fawcett, 2011). The client is viewed as an open system and can refer to individuals, groups,
families, communities, or societies. The client system considers a holistic perspective that
includes the following five variables: physiological, psychological, sociocultural, developmental,
and spiritual. The model is based on the client’s continuous relationship with and potential
reaction to stressors within the environment. The open system includes input, output, and
feedback and allows for an individual to adjust to internal and external environmental stressors.
Thus, flexibility and change exist to help the client conquer challenges and meet the model’s
goal of attaining stability.
The model is pictorially represented by a centrally located basic structure that is
surrounded by concentric circles depicting lines of resistance and defense (Neuman & Fawcett,
2011). The basic structure possesses characteristics common to all organisms, including human
processes, genetic features, and survival factors, as well as characteristics that are unique to
each client, including the five aforementioned variables. The lines of resistance surround the
basic structure. The normal line of defense surrounds the lines of resistance. The flexible line of
defense surrounds the normal line of defense. A greater degree of protection is provided
amongst the outer most concentric circle as compared to the inner most concentric circle. The
lines of resistance are called to action when the normal line of defense has been invaded by
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stressors. These resistance lines, which are made of internal and external resources that the
client may be consciously aware of or unaware of, strive to protect the integrity of the system.
The normal line of defense denotes the stability and integrity of the system and is dynamic as
the client faces different stressors at different times of life. The flexible lines of defense are also
dynamic and form a protective barrier to prevent stressors from impacting the client’s state of
stability. When such lines of defense are unsuccessful in preventing penetration by stressors, a
reaction is elicited by the client. Coping methods, lifestyle, and developmental, spiritual, and
cultural factors influence the success or failure of the lines of resistance and defense.
Application of Theoretical Framework to EBP Project
There is a strong relationship between the concepts of stress and anxiety. Stress can be
defined as the interaction between environmental stimuli, or stressors, and stress response
systems. Anxiety is characterized by behavioral, cognitive, and physiologic responses that occur
when faced with uncertain or threatening stimuli (Chen, George, & Liberzon, 2017). Anxiety may
characterize a client’s response to stress or may serve as a potential stressor. The Neuman
Systems Model “takes into account all variables affecting a client’s possible or actual response
to stressors and explains how system stability is achieved in relation to environmental stressors
imposed on the client” (Neuman & Fawcett, 2011, p. 3). Thus, the Neuman Systems Model is
applicable to this EBP project centered upon utilizing best practice interventions implemented by
NPs to decrease symptoms and feelings of anxiety among patients presenting with GAD in the
family practice setting. Thus, the best practice interventions of SSRIs and CBT contribute to the
model’s goal of attaining stability as their purpose is to help patients identify, respond to, and
cope with their environmental stressors in a healthy manner that can be maintained.
Neuman believed in using her philosophy of “helping each other live” in order to
contribute to the development of this model (Neuman & Fawcett, 2011). This philosophy is
upheld by the NPs assessing, diagnosing, treating, and evaluating patients with GAD as their
goal is to help patients with anxiety live better and achieve and maintain an optimal level of
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wellness through coping with and reducing anxiety levels. The Neuman Systems Model can
help guide practicing nurses and NPs caring for patients with GAD as it allows them to explore
complexities of the individual and develop assessment and intervention skills that stem from
such nursing model. It is also useful in guiding the education and practical training of nursing
students and helps teach them to treat clients as individuals. GAD is often unique to each
individual and complex in nature to treat due to a multitude of factors, including the challenge of
addressing the mind, which can be considered intangible and invisible. Thus, use of the
Neuman Systems Model can greatly aide in the treatment of GAD.
Strengths and Limitations of Theoretical Framework for EBP Project
Strengths of the use of the Neuman Systems Model as the theoretical framework for the
EBP project include its global applicability, which allows for its use among the variety of cultures
present at the project site as well as for generalizability across all cultures (Neuman & Fawcett,
2011). In addition, the model has a holistic perspective, which is at the forefront of the discipline
of nursing. The four concepts of the nursing metaparadigm, including human beings,
environment, health, and nursing, are related to the main concepts of the model. The model’s
goal of forming a relationship between clients and caregivers and establishing desired “goals for
optimal health retention, restoration, and maintenance” is consistent with the goal of the EBP
project (Neuman & Fawcett, 2011, p. 12). The EBP project aimed to establish a trusting
relationship between patient and NP in the treatment of GAD utilizing best practice interventions
and patient motivation in order to minimize the damage cause by stressors by decreasing
anxiety. This was achieved through the use of this model due to such congruent values.
Limitations of the use of the Neuman Systems Model include the risk of oversimplifying
its application and failing to address all parts and subparts of the system as well as their
relationship to one another and the environment (Neuman & Fawcett, 2011). “When used
correctly, however, a systems model dramatically and convincingly demonstrates the nature of a
process, which leads to better understanding and more accurate prediction of outcomes”
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(Neuman & Fawcett, 2011, p. 9). Thus, this advocates for proper use of the theoretical
framework and the consideration of complex phenomena, such as that of GAD. It may be
difficult to view client system variables and boundaries clearly due to their dynamic and everchanging nature. However, each part and subpart of the system must be studied individually in
order to understand its role in relationships and stability of the whole system. Thus, continually
adapting to changing stressors and causes of anxiety throughout the patient’s lifespan is vital to
maintenance of stability and optimal wellness.
Evidence-based Practice Model
Overview of EBP Model
In addition to a theoretical framework, an EBP model, the Stetler Model, was also
selected to facilitate this EBP project. The Stetler Model has transformed through numerous
revisions since its debut in 1976 and has broadened its focus from that of research utilization to
evidence-based nursing practice (Melnyk & Fineout-Overholt, 2015). While the model originally
only referred to the application of research findings to practice, the latest version encompasses
research findings, quality improvement data, operational data, and “…the consensus of
recognized experts and affirmed experience to substantiate practice” [Stetler et al., 1998, p.
49])” (Melnyk & Fineout-Overholt, 2015, p. 279). The inclusion of external evidence, which
results from rigorous research, as well as internal evidence, which results from projects within
the clinical practice setting is a key component. The model is centered on the movement of
evidence to practice, utilization of critical thinking, improvement in current practice, change in
current ways of thinking, and implementation of safe and effective findings.
It “outlines a series of steps to assess and use research findings to facilitate safe and
effective evidence-based nursing practice” (Melnyk & Fineout-Overholt, 2015, p. 279). These
five steps are clearly delineated and described and include 1) preparation, 2) validation, 3)
comparative evaluation/decision making, 4) translation/application, 5) evaluation, which
contribute to the ease with which this model can be followed in order to implement an EBP
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project successfully (Melnyk & Fineout-Overholt, 2015). Detailed graphics of these steps
provided by the model aide in its understanding. The preparation phase is characterized by
determining a need worth addressing and beginning a relevant literature search. The validation
phase includes a critical appraisal of each piece of evidence as well as synthesizing this
evidence. During the comparative evaluation/decision making phase, utilization criteria are used
to determine whether evidence should be used for the practice change. The next phase of
translation/application requires planning and implementing an EBP change by converting
findings into operational use. Finally, during the evaluation phase, goals are evaluated for
completion, and implementation of the plan is reviewed.
There are many important assumptions of the Stetler Model (Melnyk & Fineout-Overholt,
2015). The model assumes that research findings can be utilized in the clinical setting.
Consideration of patient individuality and preferences is necessary to implement the model
appropriately for each patient. Practitioners who are competent in research utilization and EBP
can use this model to improve practice, alter ways of thinking, and develop new strategies.
Advanced-level practitioners are better equipped to accomplish such advances in clinical
practice due to their advanced critical thinking skills and knowledge. Baccalaureate-prepared
providers should be encouraged to contribute to these endeavors in collaboration with
advanced-level providers. Another assumption of the model is the ability to use research
findings and other evidence in varying ways. Strength of the evidence must be considered for
safe use of evidence in multiple ways.
Application of EBP Model to EBP Project
The Stetler Model is applicable to this EBP project for a variety of reasons. The evidence
supporting the interventions of CBT and an SSRI for the reduction of anxiety symptoms among
with GAD strongly calls for the inclusion of patient preferences, which is also a central
component of this model (Melnyk & Fineout-Overholt, 2015). Facilitating safe and effective
evidence-based nursing practice through the translation of evidence to practice describes the
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purpose of the Stetler Model, which also is the purpose of the EBP project with an aim to
change current treatment of GAD in accordance with best practice recommendations to yield
the most effective outcomes.
The five steps of the Stetler Model served as a detailed guide for the project. During the
preparation phase, the project manager identified a problem with current treatment of GAD and
a need to address this after experience in the clinical setting with a significant number of
patients presenting with GAD. An exhaustive literature search was completed in order to
determine best practice that included a search of seven databases as well as citation chasing.
The validation phase of the model fostered a critical analysis, quality appraisal, and summary of
the evidence by the project manager, which yielded sources of good and high quality evidence
that supported best practice via combined CBT and SSRI use. Throughout the comparative
evaluation/decision making phase, the evidence was organized and a decision to use the
evidence was made based on sufficient, strong, and current available evidence. The
translation/application phase allowed the project manager to apply these findings to practice
and implement a feasible plan in a family practice clinic with the support of NPs who were
greatly invested in the project. Finally, the evaluation phase was utilized to evaluate outcomes
of the practice change, attainment of goals, success of the implementation, overall effect of the
intervention on symptoms of anxiety and other measures, and sustainability of the practice
change.
Strengths and Limitations of EBP Model for EBP Project
Limitations of the use of the Stetler Model to guide the EBP project include its complex
appearance via graphic representation including the five steps, numerous components within
each step, and multi-directional arrows to indicate fluidity (Melnyk & Fineout-Overholt, 2015). A
thorough review of the model is necessary to facilitate understanding and obtain clarity. While
the model helps to anticipate important needs and aspects regarding the intended practice
change, certain variables may be unpredictable. Thus, despite adequate use of the five phases
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of the Stetler Model, a level of flexibility must be maintained, and changes to the original plan
may be necessary. For example, the model was used by Romp and Kiehl (2009) in order to
improve a nursing preceptor program at a large medical facility. After careful development using
the appropriate stages of the model, it was discovered during implementation that many
preceptors were unable to attend scheduled classes while interest in the classes continued.
Thus, additional classes as well as both individual and group sessions were scheduled to aide
in this unforeseen problem that occurred.
Strengths of the Stetler Model as a guide for the EBP project include its revisions to
remain current and encompass not only research findings, but also EBP (Melnyk & FineoutOverholt, 2015). The model is useful for individual practitioners, including NPs with knowledge
in their area of practice, and also for groups to translate research to practice (Snyder et al.,
2011). Its detailed steps emulate the nursing process and can be followed to increase the
likelihood of successful practice change and to answer the clinical question at hand. In addition,
the model encourages the evaluation of such practice change and promotes further research.
The model strongly supports critical thinking as well as changes in ways of thinking (Snyder,
Facchiano, & Brewer, 2011; Stetler, 2001). It involves making decisions regarding feasibility,
applicability, and the substantiality of evidence and aims to reduce barriers to practice change.
The study by Romp and Kiehl (2009) showed that by exploring a multitude of aspects among
each of the five phases of the Stetler Model, considerations that may have been otherwise
overlooked were able to be addressed in order to help avoid challenges and failures. Successful
outcomes were yielded as the Stetler Model helped to develop a detailed plan, thoughtful
preparation, and effective application of EBP to increase nurses’ satisfaction with their
preceptors and ultimately, increase rates of nurse retention with an improved nursing preceptor
program. Positive outcomes were also elicited by another study conducted by Snyder and
colleagues (2011) in which the Stetler Model was followed in order to change practice by
increasing screening for anxiety among patients with Parkinson’s Disease. This model allowed
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for several quality aspects to be upheld through this translation of EBP to practice, including
patient safety, effectiveness of interventions, patient-centered care, timely and early recognition
and treatment, efficient utilization of best practice, and equal opportunity for care.
Literature Search
Sources Examined for Relevant Evidence
An exhaustive relevant literature search was performed in order to support the spirit of
inquiry regarding best practice for the treatment of GAD in the family practice setting by NPs. A
total of seven databases were searched, including CINAHL, ProQuest, MEDLINE via EBSCO,
Joanna Briggs Institute, National Guideline Clearinghouse, PsycINFO, and Cochrane Library.
CINAHL, ProQuest, and MEDLINE were selected based on their ability to yield large volumes of
individual studies. The Joanna Briggs Institute and Cochrane Library were utilized due to their
inclusion of high levels of evidence of multiple studies. The National Guideline Clearinghouse
was selected as it includes clinical guidelines regarding a wide variety of healthcare topics.
PsycINFO was utilized based on its applicability to the psychological topic of GAD upon which
the project centers. Citation chasing from the results yielded was also utilized in order to explore
all relevant evidence. After trialing a multitude of searches in each database, the keywords
selected for the final best literature search yielding the most relevant and appropriate quantity of
results were “generalized anxiety disorder*” OR “anxiety disorder*” AND (treat* OR manag*)
AND (“primary care” OR “family practice”). MeSH (medical subject heading terms) and CINAHL
subject headings in CINAHL, MEDLINE via EBSCO, ProQuest Nursing and Allied Health
Database, and PsycINFO for generalized anxiety disorder and anxiety disorders were used in
the search to encompass all terms describing such topic. Truncation symbols, quotation marks,
and parentheses also helped to yield all relevant sources.
Inclusion criteria for the literature search consisted of scholarly, peer-reviewed sources,
date range of 2013 to 2018 for sources published within the last five years, English language,
and age groups of child: 6-12 years, adolescent: 13-18 years, adult: 19-44 years, middle aged:
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45-64 years, aged: 65+ years, and aged, 80 and over. It was decided that such criteria would
lead to the most trustworthy, current, understandable, and applicable evidence. Additional
inclusion criteria included evidence that pertained to the primary care, family practice, or
outpatient setting, a population of children, adolescents, and/or adults, and a population
diagnosed with anxiety disorder or generalized anxiety disorder. Exclusion criteria was defined
as pertaining to the hospital or inpatient setting, population of infants or children under 6-yearsold, outcomes comparing anxiety levels prior to and after surgical procedures, poor initial quality
appraisal, and diagnoses of depression only, social anxiety disorder only, panic disorder only,
post-traumatic stress disorder only, health anxiety only (also known as hypochondriasis), or
mental health disorder with no further classification of generalized anxiety disorder or anxiety
disorder specified. Initially, it was determined to exclude sources focused on anxiety related to
health conditions or diseases, such as cancer. However, this was revised after further
exploration as comorbidities are very prevalent in the United States and often cause or
exacerbate anxiety in patients, and a patient’s stated reason for anxiety is always valid as it is
his or her own feeling. After a thorough literature search indicated that the majority of available
evidence supported interventions including SSRIs and CBT, pieces of evidence detailing
treatment focused on diet, exercise, mindfulness interventions, or classes of medications other
than SSRIs were excluded. Evidence related to CBT was individually evaluated for relevance to
self-administered CBT in the form of workbooks for anxiety and excluded if deemed irrelevant or
inapplicable to such administration method. Exceptions were made on a case by case basis
when literature was deemed worthy of inclusion despite lack of self-administration method of
CBT. Some evidence regarding CBT in general, without specification of administration method,
was included.
An initial literature search began in the Joanna Briggs Institute database. A search using
the keyword anxiety and a publication date within the last five years (2013 to current) proved too
broad as 774 results were yielded. After modifying the search with the keywords generalized
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anxiety disorder and the same date range limiter, an acceptable quantity of 21 results to review
was populated. However, upon review of titles, it was determined that this search was too
narrow. After many different search attempts, the most appropriate, relevant, and inclusive
search was deemed as the aforementioned best search, which encompassed both generalized
anxiety disorder and anxiety disorder as well as plural forms of the word disorder, the goal of the
EBP project to treat or manage the condition, and the intended setting of primary care or family
practice. A total of 17 sources were yielded, and four were accepted for inclusion in the final
literature review.
A thorough search of the Cochrane Library was then performed. A minor modification in
the search terms utilized for this database was approved by the Valparaiso University library
liaison, Kim Whalen, who assisted the literature search process. The terms “primary care” and
“family practice” were omitted from the search to allow for inclusion of the most relevant pieces
of evidence as several applicable pieces were not yielded when these terms were included. The
final search yielded a total of 23 results, and 8 were deemed worthy of further review after
assessing titles. Several were eliminated based on method of delivery of CBT intervention
inapplicable to the EBP project, protocol only available, and treatment irrelevant to CBT or
SSRIs. One was accepted to provide supporting evidence for the EBP project.
The National Guideline Clearinghouse was searched for clinical guidelines to support the
EBP project utilizing the initial best search. Although the National Guideline Clearinghouse
database was no longer available after July 16, 2018, the EBP project manager decided to take
advantage of the limited opportunity remaining as worthwhile, high quality, high level evidence
can be obtained from this database. Twenty-two results populated, and upon initial review, it
seemed than there were no applicable sources. However, further exploration led to further
review and acceptance of two clinical guidelines for inclusion in the literature review.
Upon continuing the literature search, the database CINAHL was searched for relevant
evidence. Prior to implementing subject headings into the search, thousands of results were
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yielded. Thus, after receiving guidance from Valparaiso University’s library liaison, it was
deemed necessary to utilize CINAHL headings, which greatly refined the search. The final
search utilizing (MH “Generalized Anxiety Disorder”) OR (MH “Anxiety Disorders”) AND (treat*
OR manag*) AND (“primary care” OR “family practice”) with limiters of scholarly, peer-reviewed
sources, published within the last five years, English language, and age groups of child: 6-12
years, adolescent: 13-18 years, adult: 19-44 years, middle aged: 45-64 years, aged: 65+ years,
and aged, 80 and over yielded a total of 28 results. After further review of 10 pieces of evidence,
three were selected for the literature review.
A search of the database MEDLINE via EBSCO included the MeSH subject heading
(MH “Anxiety Disorders/CL/DI/DT/NU/PC/TH”). Such abbreviations stand for subheadings that
were utilized to further narrow the search and include classification (CL), diagnosis (DI), drug
therapy (DT), nursing (NU), prevention and control (PC), and therapy (TH). Such refining of the
search helped to yield a sufficient number of relevant articles of which to review. Specifically,
152 articles were yielded. After removing duplicates that had previously been reviewed through
CINAHL and reviewing articles that were deemed worthy of further review, two were chosen as
supporting evidence for the EBP project.
ProQuest Nursing and Allied Health Database were then searched for applicable
evidence using the MeSH subject heading Exact (“Anxiety Disorders”) as well as additional
keywords and limiters aforementioned. A total of 42 articles were populated from this search. A
total of seven duplicate articles that had already been found in CINAHL and/or MEDLINE were
removed. After review of titles and abstracts of several pieces, no articles were deemed worthy
of final inclusion.
To conclude the literature search, the database PsycINFO was explored. Subject terms
including DE “Generalized Anxiety Disorder” OR DE “Anxiety Disorders” were included in the
search. Age groups selected were consistent with the other searches but had minor variances in
categorization and those selected were school age (6-12 years), adolescence (13-17 years),
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adulthood (18 years and older), young adulthood (18-29 years), thirties (30-39 years), middle
age (40-64 years), aged (65 years and older), and very old (85 years and older). This yielded
145 results. Although a large quantity of results, it was deemed that the search was
appropriately narrowed and such a large amount of information regarding anxiety disorders
could be expected to be found in a database related to psychological topics. After accounting for
and removing a large total of 59 duplicates as well as reviewing relevant sources, no pieces
were included as evidence for the project.
Nine additional pieces of evidence were obtained via citation chasing from the reference
lists of results yielded. Three were deemed worthy of inclusion. One was obtained from a
citation chase of a Cochrane Library systematic review. A version of the review published in
2016 was withdrawn from the Cochrane Library due to the review being “passed onto a new
group of authors.” A 2003 version of this review was then found via citation chasing of the 2016
piece, and an exception to accept this evidence with an older publication date was granted due
to the circumstances and the meeting of inclusion criteria. Another systematic review was
citation chased from an accepted evidence summary and met inclusion criteria. A third piece of
evidence, a randomized controlled trial (RCT), was found via citation chasing through a relevant
excerpt of the study found through CINAHL.
In total, 436 pieces of evidence were yielded from the literature search. A review of titles
led to the elimination of many sources due to failure to meet inclusion or exclusion criteria or
irrelevance to GAD or the proposed interventions. Duplicate articles were accounted for and
removed. Upon further review of titles and abstracts, 74 sources were deemed as warranting
further, more extensive review based on inclusion criteria, applicability to the EBP project, and
initial quality appraisal. After such review, a decision was made to include 15 of these pieces of
evidence in the final literature review based on their ability to provide strong support for the EBP
project. Data regarding the evidence search results are depicted in Table 2.1.
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Table 2.1
Evidence Search Table

Database

Yielded

Duplicates

Reviewed

Accepted

JBI

17

0

9

4

Cochrane

23

0

8

1

NGC

22

0

4

2

CINAHL

26

0

10

3

MEDLINE

152

10

19

2

ProQuest

42

7

4

0

PsycINFO

145

59

11

0

Citation Chase

9

0

9

3

Total

436

76

74

15

Note. Databases are listed in order of searches performed. JBI is Joanna Briggs Institute. NGC
is National Guideline Clearinghouse. ProQuest is ProQuest Nursing & Allied Health Source.
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Levels of Evidence
In order to rank each piece of evidence appropriately by strength, Melnyk and FineoutOverholt’s (2015) Hierarchy of Evidence was utilized for this project. Such seven-level ranking
system guides categorization among different types of literature in order to appraise the strength
of the evidence. Greater strength of the evidence indicates a higher level of confidence that the
evidence is likely to reliably answer a clinical question. This Hierarchy of Evidence includes
Level I through Level VII evidence listed in order from highest level of evidence to lowest. This is
currently depicted as a table with Level I evidence listed at the top as the highest level of
evidence and Level VII evidence listed at the bottom as the lowest level of evidence. To begin,
Level I evidence is evidence from systematic reviews or meta-analyses of all relevant RCTs,
and level II evidence refers to evidence obtained from well-designed RCTs. Proceeding through
the table, Level III evidence is characterized as evidence obtained from well-designed controlled
trials without randomization while Level IV evidence includes evidence from well-designed casecontrol and cohort studies. Level V evidence is described as evidence from systematic reviews
of descriptive and qualitative studies whereas Level VI evidence is evidence from single
descriptive or qualitative studies. Finally, level VII evidence is defined as evidence from the
opinion of authorities and/or reports of expert committees. Fifteen total pieces of evidence were
included for the final review of literature, including three evidence summaries (Level I), four
systematic reviews (Level I), two clinical guidelines (Level I), four RCTs (Level II), one nonrandomized controlled trial (Level III), and one evidence summary (Level V). The levels of the
selected pieces of evidence are illustrated in Table 2.2.

Table 2.2
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Levels of Evidence

Level

Included

Quality

Design

I

9

A (6)
B (3)

Evidence Summary (3)
Systematic Review (4)
Clinical Guideline (2)

II

4

A (2)
B (2)

RCT (4)

III

1

B (1)

Non-Randomized
Controlled Trial (1)

V

1

A (1)

Evidence Summary (1)

Appraisal of Relevant Evidence

GENERALIZED ANXIETY DISORDER PROTOCOL

31

In addition to ranking the evidence by level, a critical appraise of the quality of each
evidence was also conducted. Quality was appraised using the Johns Hopkins Research and
Non-Research Evidence Appraisal Tool as well as the Appraisal of Guidelines for Research &
Evaluation (AGREE II) Instrument. Permission was granted to utilize the Johns Hopkins
Research and Non-Research Evidence Appraisal Tool, and such documentation is presented in
Appendix B. The AGREE II Instrument is allowed to be reproduced and used for education and
quality appraisals. The AGREE II Instrument was used for quality appraisal of evidence
summaries and clinical guidelines, and the Johns Hopkins Research and Non-Research
Evidence Appraisal Tool was used for quality appraisal of the remainder of the evidence,
including systematic reviews, randomized controlled trials, and non-randomized controlled trials.
The Johns Hopkins Research and Non-Research Evidence Appraisal Tool provides a
thorough algorithm for determining the type of study design and assessing the quality of the
evidence through a multitude of yes/no questions about the evidence (Dearholt & Dang, 2017).
This tool delineates high quality (A) as evidence with “consistent, generalizable results;
sufficient sample size for the study design; adequate control; definitive conclusions; consistent
recommendations based on comprehensive literature review that includes thorough reference to
scientific evidence” (Dearholt & Dang, 2017, p. 286). Good quality (B) is considered evidence
with “reasonably consistent results; sufficient sample size for the study design; some control,
and fairly definitive conclusions; reasonably consistent recommendations based on fairly
comprehensive literature review that includes some reference to scientific evidence” (Dearholt &
Dang, 2017, p. 286). Low quality or major flaws (C) is defined as “little evidence with
inconsistent results; insufficient sample size for the study design; conclusions cannot be drawn”
(Dearholt & Dang, 2017, p. 286). Of the 15 pieces of literature accepted for inclusion, nine were
deemed of high quality, six were deemed of good quality, and none were deemed of low quality.
Table 2.3 presents a summary and appraisal of the relevant evidence listed in alphabetical
order by author.
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The AGREE II Instrument provides a detailed structured format consisting of a total of 23
items of consideration within six main domains as well as two items of global rating, or overall
assessment, for determining the quality of guidelines (AGREE Next Steps Consortium, 2017).
The six domains include scope and practice, stakeholder involvement, rigour of development,
clarity of presentation, applicability, and editorial independence. The 23 core items are each
scored via a 7-point Likert scale with 1 indicating strongly disagree and 7 indicating strongly
agree. Domain scores are calculated by adding the scores of the items in each domain and
using a mathematical equation including the obtained score and minimum and maximum scores
possible to yield a percentage. These scores can be used to compare the quality of different
guidelines. However, the tool has not differentiated scores indicating high, good, and poor
quality but rather recommends that the user should consider all aspects of the tool and make
this decision regarding quality.
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Table 2.3
Appraisal of Evidence

Citation (APA)

Purpose

Design

Sample

Measurement/
Outcomes

Results/Findings

Andersen, B. L.,
DeRubeis, R. J.,
Berman, B. S.,
Gruman, J.,
Champion, V. L.,
Massie, M. J.,
Holland, J. C.,
Partridge, A. H.,
Bak, K.
Somerfield, M. R.,
& Rowland, J. H.
(2014). Guideline
summary:
Screening,
assessment, and
care of anxiety
and depressive
symptoms in
adults with cancer:
An American
Society of Cllinical
Oncology
guideline
adaptation.
Journal of Clinical
Oncology, 32(15),
1605-1619. doi:

The purpose of
this clinical
guideline was to
present the best
screening,
assessment, and
care methods that
should be utilized
in the treatment of
anxiety and
depressive
symptoms among
adults with a
coexisting
diagnosis of
cancer.

This was a clinical
guideline adapted
from the American
Society of Clinical
Oncology.

The target sample
population
included adults 18
years of age and
older with any type
of cancer, any
disease stage, and
undergoing any
types of
treatments who
also were
experiencing
symptoms of
depression and
anxiety.

The Generalized
Anxiety Disorder
(GAD)-7 scale was
strongly
recommended to
measure
symptoms of
anxiety.

Patient
preferences,
shared decision
making, and both
pharmacologic
and
nonpharmacologic
treatments are
recommended.

Pharmacologic
and
nonpharmacologic
as well as
psychological and
psychosocial
interventions were
explored.

A thorough
systematic
literature search
was performed.

Anxiety should be
measured at the
initial visit and at
appropriate
intervals
depending on
clinical indication,
including change
in disease status
or transition to
palliative care.
Preferably,
outcomes should
be measured once
per month, but at a
minimum should
be measured pre

Psychological
interventions
should be based
on treatment
manuals that
explain content
and guide delivery.
If there is no
improvement in
symptomology
after 8 weeks of
treatment,
additional
treatments should
be added to the
treatment regimen,

Level/
Quality
Level I
High quality

GENERALIZED ANXIETY DISORDER PROTOCOL

34

10.1200/JCO.2013
.52.4611

Assessment and
Management of
Risk for Suicide
Working Group
(2013). Guideline
summary: VA/DoD
clinical practice
guideline for
assessment and
management of
patients at risk for
suicide.
Department of
Veterans Affairs,
Department of
Defense, 1-190.
Retrieved from
The National
Guideline
Clearinghouse.

The purpose of
this clinical
guideline was to
promote evidencebased
management of
patients at risk for
suicide.

Calleo, J. S.,
Bush, A. L., Cully,
J. A., Wilson, N.
L., KrausSchuman, C.,
Rhoades, H. M.,

The purpose of
this study was to
explore the
feasibility,
satisfaction, and
clinical outcomes

This was a clinical
guideline.
Interventions
discussed
included
psychotherapy
methods, including
CBT, and
medications,
including
antidepressants.

The sample
population
included adult
patients 18 years
of age or older at
risk for suicide
with or without a
mental disorder in
the Department of
Veterans Affairs
(VA) and
Department of
Defense (DoD)
clinical settings.

and posttreatment, in order
to assess
effectiveness,
patient
compliance, and
patient
satisfaction.

medication should
be changed, or the
patient should be
referred to
psychotherapy.

Patients with
anxiety disorders
should be asked
about suicidal
thoughts and
behavior directly.

Treatment with
CBT and
antidepressants
may be beneficial
for patients with
anxiety disorders
at risk for suicide.

Reassessment of
suicidal ideation
should regularly
occur, particularly
with changes in
circumstances.

A thorough
literature search
was performed.

The study design
was a nonrandomized
controlled trial.
Participants
engaged in CBT

The sample
included a total of
19 older adults
aged 60 years of
age and older with
GAD who were

Outcomes
measured
included feasibility
via attrition rates,
satisfaction via exit
interviews, worry

Level I
High quality

Close monitoring
of patients who
are prescribed
antidepressants is
necessary to
assess for the
emergence or
worsening of
suicidal thoughts
during the initiation
phase or after
change in dose.
Participants felt
satisfied with
treatment and felt
that it helped them
manage their

Level III
Good quality
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Novy, D. M.,
Masozera, N.,
Williams, S.,
Horsfield, M.,
Kunik, M. E., &
Stanley, M. A.
(2013). Treating
late-life
generalized
anxiety disorder in
primary care: An
effectiveness pilot
study. The Journal
of Nervous and
Mental Disease,
201(5), 414-420.
doi:
10.1097/NMD.0b0
13e31828e0fd6

associated with
CBT delivered by
experienced and
nonexperienced
counselors.

Campbell, J.
(2016). Evidence
Summary: Anxiety
disorders
(Generalized
Anxiety Disorder):
Pharmacotherapy.
The Joanna Briggs
Institute, 1-3.

The purpose of
this evidence
summary was to
determine the best
evidence for the
pharmacologic
treatment of GAD.

for 3 months
provided by
anxiety counselor
specialists (ACSs)
or counselors with
no previous
mental health
training or
experience.

35
recruited in
primary care
clinics in the
United States.

via the Penn State
Worry
Questionnaire
(PSWQ), and
anxiety severity
via the
Generalized
Anxiety Disorder
Severity Scale
(GADSS), the
Beck Anxiety
Inventory, and the
Structured
Interview Guide for
the Hamilton
Anxiety Scale.
Outcomes were
measured at
baseline, 3 months
after treatment
initiation, and 6
months after
treatment
initiation.

This was an
evidence
summary.
Interventions
consisted of
psychological
therapy,
medication, and

The sample
included patients
with GAD from
seven systematic
reviews, one
evidence-based
guideline, one
clinical guideline,
one prospective

Outcomes
measured
included the
efficacy and
tolerability of a
multitude of
medications
including
duloxetine (SNRI),

anxiety (mean
[SD], 3.61 [0.49]).
PSWQ and
GADSS scores
significantly
declined from
baseline to
3months among
those who
completed
treatment. Other
anxiety measures
did not yield
statistically
significant effect
size changes.
There were no
significant
differences in
results among
patients treated by
ACSs or
counselors without
training.
The use of
antidepressants
for the treatment
of GAD was given
a Grade A
recommendation.
Fluoxetine (SSRI)
was
recommended for

Level V
High quality
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self-care. CBT,
anticonvulsants,
antidepressants,
and antipsychotic
medications were
involved in many
of the studies
included.

36
trial, and one
qualitative study.

escitalopram
(SSRI), fluoxetine
(SSRI), lorazepam
(benzodiazepine),
paroxetine (SSRI),
pregabalin
(anticonvulsant),
sertraline (SSRI),
tiagabine
(anticonvulsant),
venlafaxine
(SNRI), buspirone,
and hydroxyzine.
Anxiety symptoms,
response rates,
and remission
status were also
measured.

its associated
response and
remission, and
sertraline (SSRI)
was
recommended for
its tolerability.
SSRIs were found
to reduce anxiety
symptoms and
should be
considered firstline treatment for
GAD.
CBT was also
recommended in
the treatment of
GAD with a Grade
B
recommendation.
The addition of
CBT to the
treatment regimen
of patients taking
an SSRI led to
sustained
remission from
symptoms of
anxiety and
prevented longterm
pharmacotherapy.
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Freshour, J. S.,
Amspoker, A. B.,
Yi, M., Kunik, M.
E., Wilson, N.,
Kraus-Schuman,
C., Cully, J. A.,
Teng, E. Williams,
S., Masozera, N.,
Horsfield, M.,
Stanley, M.
(2016). Cognitive
behavior therapy
for late-life
generalized
anxiety disorder
delivered by lay
and expert
providers has
lasting benefits.
International
Journal of
Geriatric
Psychiatry, 31(1),
1225-1232. doi:
10.1002/gps.4431

The purpose of
this study was to
explore the effects
of CBT delivered
by bachelorprepared lay
providers as
compared to CBT
delivered by PhD
expert providers.

This was a
randomized
controlled trial.
Participants were
randomly assigned
to three groups
including CBT
administered by
lay providers, CBT
administered by
expert providers,
or usual care.

37
A sample of 112
older adults aged
60 years or older
were included and
were recruited
from internal
medicine, family
practice, and
geriatrics clinics in
Texas.

Primary outcomes
measured worry
via the
Generalized
Anxiety Disorder
Severity Scale and
anxiety via the
State-Trait Anxiety
Inventory and the
Structured
Interview Guide for
the Hamilton
Anxiety Scale.
Secondary
outcomes
measured
included
depression via the
Patient Health
Questionnaire,
mental health
quality of life via
the Medical
Outcomes Study
Short Form, and
sleep via the
Insomnia Severity
Index.
Outcomes were
measured 6
months and 12
months post
initiation of
treatment.

There was no
significant
difference in
outcomes among
participants who
received CBT
delivered by
bachelor-prepared
lay providers and
those who
received CBT
delivered by PhD
expert providers
(p>0.05).
Improvements in
worry and anxiety
outcomes as well
as changes in
depression,
mental healthrelated quality of
life, and insomnia
were maintained
at 6 and 12 month
follow up.

Level II
High quality
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Glenn, D., Rose,
R. D., Stein, M. B.,
Bystritksy, A.,
Golinelli, D., RoyByrne, P.,
Sullivan, G., &
Sherbourne, C.
(2013). Who gets
the most out of
cognitive
behavioral therapy
for anxiety
disorders? The
role of treatment
dose and patient
engagement.
American
Psychological
Association, 81(4),
639-649, doi:
10.1037/a0033403

The purpose of
this study was to
explore treatment
dose and patient
engagement as
predictors of
treatment
outcome.

James, A. C.,
James, G.,
Cowdrey, F. A.,
Soler, A., &
Choke, A. (2015).
Cognitive
behavioural
therapy for anxiety

The purpose of
this review was to
explore the
effectiveness of
CBT in the
treatment of
childhood and

This study design
was a randomized
controlled trial.
Participants were
randomized to the
intervention group
or the usual care
group. Participants
randomized to the
intervention group
could then select
CBT only,
pharmacotherapy
only, or CBT and
pharmacotherapy
combined.

38

A total of 1,004
participants with a
diagnosis of panic
disorder,
generalized
anxiety disorder,
social anxiety
disorder, or
posttraumatic
stress disorder
were enrolled in
the study.

The primary
outcome of anxiety
was measured via
the Brief Symptom
Inventory.
Secondary
outcomes
measured
included
depression via the
Patient Health
Questionnaire and
functional status
via the Sheehan
Disability Scale.
Outcomes were
measured at
baseline, 12
months, and 18
months after the
start of treatment.

The study design
is a Cochrane
systematic review.
The CBT
intervention within
the studies
consisted of

A thorough
literature review
among multiple
databases was
performed.
A total of 41 RCTs
consisting of 1,806

The primary
outcome
measured was
remission via the
Anxiety Disorder
Interview
Schedule for
Parents, Children,

Results indicated
that at both 12 and
18 months,
participants with
low attendance in
CBT sessions had
higher scores on
all outcome
measures than
patients with high
attendance
(p<0.029).

Level II
Good quality

Participants who
were less
homework
adherent scored
significantly higher
on outcome
measures at 12
and 18 months
than those who
were more
homework
adherent
(p<0.012).
Findings
concluded that
58.9% of
participants who
received CBT
achieved
remission while
16% of

Level I
Good quality
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disorders in
children and
adolescents
(Review).
Cochrane
Database of
Systematic
Reviews, 2, 1-30.
doi:
10.1002/14651858
.CD004690.pub4

adolescent anxiety
disorders.

individual, group,
or family/parental
involvement
manualized, or
modular, CBT
alone or CBT with
medication.

39
participants were
included in the
review.
Participants within
the studies were
ages 4-19, met
diagnostic criteria
for an anxiety
disorder, and were
recruited from
research settings.

or Adolescents
and Parents.
The Clinical Global
Impression Scale
assessed
treatment
response.
Acceptability was
measured by the
number of
participants lost to
follow up.
Reduction of
anxiety symptoms
was measured by
several scales.
Outcomes were
measured at six
and 24 months.

Jayasekara, R.
(2016a). Evidence
Summary: Anxiety
disorders:
Psychotherapy.
The Joanna
Briggs Institute, 13.

The purpose was
to determine the
best evidence
regarding
psychotherapy for
patients with GAD.

This was an
evidence
summary.
Psychotherapy
interventions,
including CBT,
were utilized in the
studies included in
the evidence
summary.

Persons with GAD
including children,
adolescents,
adults, and older
adults from two
Cochrane
systematic
reviews, one
meta-analysis, two
systematic
reviews, and five
RCTs were

The effect of CBT
on anxiety levels,
relapse of anxiety
symptoms, and
secondary
symptoms of worry
and depression
was measured.

participants who
did not receive
CBT achieved
remission, but
these results were
not significant
(p=0.23).
There were no
differences
between the
outcomes of
individual, group,
or family CBT nor
between the rates
of participants lost
to follow up among
the CBT versus
control groups.
These findings
were significant
(p=0.02).

Use of CBT was
determined to be
effective for
children,
adolescents, the
working-age
population, and
older adults with
GAD and received
a Grade B
recommendation.
CBT reduced

Level I
High quality
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included in the
sample.

Jayasekara, R.
(2016b). Evidence
Summary: Anxiety
disorders: Self
help. The Joanna
Briggs Institute, 35.

The purpose of
this evidence
summary was to
determine the best
available evidence
regarding self-help
interventions for
patients with
anxiety disorders.

The study design
was an evidence
summary.
Self-help
interventions were
explored among
the studies
reviewed.

The sample
included persons
with anxiety
disorders,
including panic
disorders, social
anxiety disorder,
phobias,
generalized
anxiety disorder,
and post-traumatic
stress disorder.
Five metaanalyses, four
systematic
reviews, one
Cochrane review,
and one RCT were
included in the
evidence
summary.

anxiety levels,
symptoms of worry
and depression,
prevented relapse,
and results were
maintained at
follow up.
The effectiveness
of self-help
interventions was
the primary
outcome.
Symptoms of
anxiety and
depression were
measured.

Self-help CBT was
found to be
effective as
compared to
controls including
wait list, treatment
as usual, and
placebo, and the
effect size did not
vary depending on
the type of selfhelp CBT
administered,
including guided,
minimal contact, or
self-administered.
Participants
should work on
self-help materials
for at least six
weeks.
Self-help
bibliotherapy CBT
may serve as a
low-cost
intervention for

Level I
High quality
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persons with
anxiety.

Kapczinski, F., dos
Santos Souza, J.
J. S. S., Batista
Miralha da Cunha,
A. A. B. C., &
Schmitt, R. R. S.
(2003).
Antidepressants
for generalised
anxiety disorder
(GAD) (Review).
Cochrane
Database of
Systematic
Reviews, 2, 1-40.
doi:
10.1002/14651858
.CD003592

The purpose was
to assess
antidepressants
for their efficacy
and acceptability
in the treatment of
GAD.

Nguyen, D. H.
(2017). Evidence
Summary:
Generalized
anxiety disorder:
Management. The
Joanna Briggs
Institute, 1-4.

The purpose of
this piece of
evidence was to
explore the best
available evidence
for the
management of
GAD.

The design of the
study was a
Cochrane
systematic review.
Duration of
treatment with
antidepressants
among the
included studies
ranged from six to
28 weeks.

A thorough
literature search
within multiple
databases was
performed.
A total of 15 RCTs
regarding
antidepressants
were included in
the review.
Participants in the
studies were
outpatients. One
study included
children while all
others included
adults. Most trials
were conducted in
the United States.

This was an
evidence
summary.
Self-help,
pharmacological,
and psychological
therapy

The sample
included persons
with a diagnosis of
GAD from three
clinical practice
guidelines, six
Cochrane reviews,
two meta-analytic

Symptoms were
often measured
using the HAM-A.
GAD changes
were measured by
the Clinical Global
Impression score.
Acceptability of
treatment was
measured via
dropout rate and
side effects.

Participants who
received
antidepressants
were more likely to
exhibit treatment
response than
those who
received placebo.

Level I
Good quality

Paroxetine and
imipramine
showed similar
efficacy and were
well tolerated by
most patients.
Sertraline was
more effective
than placebo in
the treatment of
GAD among
children and
adolescents.

Effectiveness of
self-help,
pharmacological
therapy
(antidepressant
medication), and
psychological
therapy was
measured.

CBT-based
psychological
therapy effectively
reduced anxiety
symptoms and
was more effective
than placebo.
Pharmacological
interventions,

Level I
High quality
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interventions were
reviewed.
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reviews, and one
RCT.

Outcomes
measured
included anxiety
symptoms.

including the
prescribing of
SSRIs, were
supported with a
Grade B
recommendation
due to their cost
effectiveness,
efficacy, safety,
and ease of use.
Self-help
interventions,
including
bibliotherapy CBT,
were
recommended and
supported for
reducing barriers
to traditional CBT.
Considering
patient
preferences as
well as
implementing CBT
over a period of
four months
received a Grade
A
recommendation.

Piacentini, J.,
Bennett, S.,
Compton, S.,
Kendall, P.,

The purpose of
this study was to
explore response,
remission rates,

The design of the
study was a
randomized
controlled trial.

A sample of 488
children and
adolescents ages
7-17 years who

The Clinical Global
ImpressionImprovement

Participants who
received
combination
therapy (COMB)

Level II
High quality
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Birmaher, B.,
Albano, A. M.,
March, J., Sherrill,
J., Sakolsky, D.,
Ginsburg, G.,
Rynn, M.,
Begman, R. L.,
Gosch, E.,
Waslick, B.,
Iyengar, S.,
McCracken, J.,
Walkup, J. (2014).
24- and 36-week
outcomes for the
child/adolescent
anxiety multimodal
study (CAMS).
Journal of the
American
Academy of Child
and Adolescent
Psychiatry, 53(30,
297-310. doi:
10.1016/j.jaac.201
3.11.010

and anxiety
severity changes
among CBT, SSRI
use, and
combination
therapy among
youth.

Participants were
randomized to four
different groups:
CBT only (CBT),
sertraline only
(SRT), sertraline
and CBT
combined
(COMB), or pill
placebo (PBO).
CBT included
adaptation of the
“Coping Cat”
program. A
maximum daily
dose of 200 mg of
sertraline was
established.

43
met DSM-IV
criteria for
separation,
generalized, or
social anxiety
disorder were
included in the
study. They were
recruited from six
geographically
diverse sites.

(CGI-I) measured
response.
The Pediatric
Anxiety Rating
Scale (PARS) and
the Clinical Global
Impressions
Severity Scale
(CGI-S) measured
anxiety severity.

exhibited a
significantly higher
response rate on
the CGI-I than
CBT alone or SRT
alone.

The Children’s
Global
Assessment Scale
measured overall
functional
impairment.

There was no
significant
difference in study
attrition rates for
each treatment
group.

CBT, SRT, and
COMB were all
superior to PBO.

Most participants
maintained gains
at weeks 24 and
36.
Despite excellent
response rates,
COMB was unable
to achieve
statistical
significance over
SRT and CBT at
weeks 24 and 36
due to significant
improvement in
SRT and CBT
groups during that
time.
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Sawyer, M. C., &
Nunez, D. E.
(2014). Cognitivebehavioral therapy
for anxious
children: From
evidence to
practice.
Worldviews on
Evidence-Based
Nursing, 11(1), 6571. doi:
10.1111/wvn.1202
4

The purpose of the
review was to
explore available
evidence about
the effectiveness
of individual CBT
for children with
anxiety disorder.

Strawn, J. R.,
Dobson, E. T.,
Giles, L.L. (2017).
Primary pediatric
care
psychopharmacolo
gy: Focus on
medications for
ADHD,
depression, and
anxiety. Current

The purpose was
to explore
psychopharmacologic interventions
for the treatment
of anxiety, ADHD,
and depression in
pediatric care.

The design was a
systematic review.
CBT was the
primary
intervention
throughout the
studies included.
Eight of the ten
studies utilized a
manualized
version of the
Coping Cat
program.

The design of the
study was a
systematic review.
Psychopharmacologic interventions
explored included
SSRIs, particularly
sertraline,
SSNRIs,
stimulants, alpha 2
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A total of 10
studies were
included in the
review.
Participants within
these studies were
7 to 12 years of
age, male or
female, with
varying primary
anxiety diagnoses.
A range of races
and ethnicities
were included.

A total of 22
different
measurements
were utilized
across the studies
and were not
mentioned in
detail.

The sample
population
included youth
with depressive
disorders, anxiety
disorders, and/or
ADHD.

Outcomes
measured
included side
effects and
tolerability of
medications.

Several landmark
studies were
explored in the

Diagnostic
recovery and rates
of anxiety
diagnoses were
also measured.

Remission,
response to
treatment, and

Individual CBT
significantly
decreased the
rates of anxiety
diagnoses as
compared to
control groups.

Level I
High quality

Diagnostic
recovery rates for
individual CBT
were equal or
superior to
diagnostic
recovery rates of
control groups with
the exception that
combination
therapy of
sertraline and CBT
was significantly
more effective
than monotherapy.
Sertraline
effectiveness was
not statistically
significant from
that of CBT but
was statistically
significant in
comparison to
placebo.

Level I
Good quality
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Problems in
Pediatric and
Adolescent Health
Care, 47(1), 3-14.
doi:
10.1016/j.cppeds.
2016.11.008

agonists as well as
CBT.

45
review, including
the CAMS and
CAMELS studies.

relapse were also
measured.

Combination
therapy with
sertraline and CBT
led to better
outcomes than
either treatment
alone, and gains
were maintained
at follow up.
SSRIs and
SSNRIs have
similar side effect
profiles among
youth, including
headaches,
nausea, irritability,
restlessness, mild
disinhibition, and
insomnia.
Multiple metaanalyses did not
identify a link
between
antidepressant
use and increased
risk of suicide, but
appropriate
caution should be
taken.

Wetherell, J. L.,
Petkus, A. J.,
White, K. S.,
Nguyen, H.,

The purpose of
this study was to
determine whether
the addition of an

The study design
was a randomized
controlled trial.

The sample
included 73 adults
at least 60 years
of age with a

Anxiety outcomes
were measured
via the Hamilton
Anxiety Rating

Based on the
results of the Penn
State Worry
Questionnaire,

Level II
Good quality

GENERALIZED ANXIETY DISORDER PROTOCOL
Kornblith, S.,
Andreescu, C.
Zisook, S., Lenze,
E. (2013).
Antidepressant
medication
augmented with
cognitivebehavioral therapy
for generalized
anxiety disorder in
older adults.
American Journal
of Psychiatry,
170(7), 782-789.
doi:
10.1176/appi.ajp.2
013.12081104

antidepressant
medication to the
regimen of CBT
would increase
response and
prevent relapse in
older adults with
GAD.

All participants
received
escitalopram for
12 weeks and then
were randomly
assigned to one of
four different
groups: 1)
escitalopram and
CBT followed by
maintenance
escitalopram, 2)
escitalopram alone
followed by
maintenance
escitalopram, 3)
escitalopram and
CBT followed by
pill placebo, 4)
escitalopram alone
followed by
placebo.
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primary diagnosis
of GAD based on
DSM-IV criteria.
They were
recruited from
three outpatient
clinics.

Scale (HAM-A)
every four weeks
during the
augmentation
phase and every
two weeks during
the maintenance
phase.
Outcomes of
excessive and
uncontrollable
worry were
measured using
the Penn State
Worry
Questionnaire at
the initiation and
completion of the
augmentation and
maintenance
phases.

participants who
received CBT
were three times
more likely to
respond to
treatment than
those who did not
receive CBT
(p<0.05).
The effect size
was medium to
large regarding
CBT and worry
symptoms with
greater
improvements in
pathological worry
exhibited by
participants who
received
escitalopram
augmented with
CBT according to
the Penn State
Worry
Questionnaire.
According to the
HAM-A,
participants who
received CBT did
not show greater
improvement in
anxiety symptoms.
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Lower relapse
rates were
exhibited by
participants who
received
maintenance
escitalopram or
CBT with placebo
as compared to
participants who
did not receive
these treatments
respectively.
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Level I evidence. Nguyen (2017) published an evidence summary exploring the best
available evidence for the management of GAD. This evidence summary included three clinical
practice guidelines, six Cochrane reviews, two meta-analytic reviews, and one RCT. It was
addressed within this summary that clinical practice guidelines provide support that most often,
patients diagnosed with GAD can be well cared for in the primary care setting. Additional
conclusions made from U.S. clinical practice guidelines include that psychological therapy
provides the longest duration of treatment effect followed by the effects of pharmacological
therapy with antidepressants or self-help interventions. Cochrane reviews and clinical guidelines
supported that psychological interventions that are grounded in CBT are effective for short-term
treatment of GAD, have been shown to reduce symptoms of anxiety, and are more effective
than placebo. The addition of CBT to pharmacotherapy also demonstrated usefulness. Effective
pharmacological interventions include the use of SSRIs due to cost effectiveness, efficacy,
safety, tolerable side effects, and ease of use. There are many barriers to typical therapistguided CBT, including lack of time, transportation issues, negative stigma, lack of trained
clinicians, all of which lead to limited patient access to CBT. Thus, self-help, self-administered,
or distance delivery in the form of telephone or the internet has reduced such barriers.
Psychological therapy based on CBT principles in the form of books, known as bibliotherapy, is
recommended as such type of self-help intervention. A Grade B recommendation was assigned
to the use of an SSRI for the treatment of GAD unless contraindicated as well as to instruct
patients to take medication as directed to avoid discontinuation or withdrawal symptoms. A
Grade A recommendation was given to always taking patient preference in consideration for
care.
Thus, the evidence summary provided strong, well-supported, clear recommendations
from current sources (Nguyen, 2017). The objectives as well as the target population of the
evidence summary were cleared stated. A systematic search of the literature was performed.
There was a clear relationship between the evidence, conclusions, and recommendations
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made. Benefits as well as risks were addressed within the recommendations. Multiple options
for the management of GAD were provided based on patient eligibility, safety, and preference,
and barriers were discussed. Conclusions were consistent, generalizable, based on results, and
flowed logically in response to the clinical question. The evidence summary received high
scores within all six domains. This can be described as level I evidence of high quality based on
Melnyk and Fineout-Overholt’s (2015) Hierarchy of Evidence and the AGREE II Instrument
respectively.
Level I evidence. An evidence summary published by Jayasekara (2016a) was also
included in the review of literature due to its relevance to the EBP project. The purpose of the
summary was to answer the clinical question regarding the best evidence regarding
psychotherapy for patients diagnosed with GAD. Evidence found that CBT was able to reduce
anxiety levels more than treatment as usual for patients on a waiting list, and in addition, CBT
effectively reduced secondary symptoms of worry and depression. CBT was also found to help
prevent relapse of GAD symptoms. A meta-analysis reviewed found that CBT was more
effective than non-cognitive therapy in the treatment of worry and that such positive outcomes
were maintained at follow-up. Evidence supported the effectiveness of CBT for the treatment of
anxiety disorders in children, adolescents, the working-age population, and older adults. In
conclusion, the best practice recommendation for the use of CBT in the treatment of GAD
across the lifespan, including children, adolescents, adults, and older adults received a Grade B
recommendation.
This evidence summary received a high score for the scope and practice domain with
the objectives, clinical questions, and intended population for these recommendation clearly
delineated (Jayasekara, 2016). The evidence was well written, and content was easy to find
within the document. The stakeholder involvement domain also ranked high as the evidence
summary clearly identified that these recommendations were useful for children, adolescents,
adults, and older adults with GAD. A systematic search of evidence-based health care
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databases was underwent, and details of each piece of evidence were provided leading to a
strong score in the rigour of development domain. Details of each study were presented, and
one of the Cochrane systematic reviews included 38 RCTs and a total of 3,214 participants.
Recommendations were clear and suffice yielding a high score for the clarity of presentation
domain. Clear advice regarding implementing recommendations and implications for practice
were discussed among the multiple pieces of evidence included, which provided a strong rating
for the applicability domain. The editorial independence domain also scored high as it was
declared that there were no conflicts of interest. Thus, this level I evidence summary was
deemed of high quality with consistent, generalizable results across the lifespan, sufficient
sample size, and strong, definitive conclusions. This piece of evidence provided much support
for the CBT intervention focus and well as the intended population of the EBP project.
Level I evidence. Another evidence summary published by Jayasekara (2016b)
reviewed the best evidence for self-help interventions for patients with anxiety disorders. Selfhelp interventions include patients completing psychological treatment protocols independently.
Most of these self-help interventions are based on CBT, including exposure, cognitive
restructuring, and relaxation. They can be accessed through books, computers, televisions,
videos, or the Internet. It is unnecessary to interact with a therapist in order to participate in the
therapy. Five meta-analyses, four systematic reviews, one Cochrane review, and one RCT were
included in the evidence summary. Several different types of self-help were included in the
studies, including unguided self-help, self-help as partial replacement to face-to-face therapy,
and guided self-help. In conclusion, self-help interventions were recommended for the treatment
of anxiety disorders and received a Grade A recommendation. Multiple meta-analyses found
that bibliotherapy, including written texts, computer programs, or audio/video material, was more
effective than waiting lists, no treatment, or placebo. One meta-analysis in particular determined
that the effect size did not differ by the type of self-help intervention, including guided, minimal
contact, and self-administered. Self-help bibliotherapy can serve as a low-cost effective option
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for patients with GAD. However, overall, there are limited data regarding the cost and feasibility
of such bibliotherapy. Face-to-face CBT may be clinically superior, but self-help serves as an
available treatment option for patients when other services may be inaccessible.
This level I evidence summary included a thorough description of its scope and purpose
(Jayasekara, 2016b). The target population, interventions, and comparison were clearly
delineated. A comprehensive literature review that included reference to scientific evidence was
included, and sources ranged in publication dates between 2001 to 2016. Thus, not only was
current evidence included, but data and trends covering a large time period were available. The
systematic search was relevant and appropriate for the clinical question. Details of the studies
were presented clearly including brief descriptions of design, sample, methods, results,
outcomes, strengths, and limitations. Sample sizes for many included studies were large. The
evidence presented was strong, clear, and consistent and received a Grade A recommendation.
Thus, this evidence summary was appraised as being of high quality.
Level I evidence. Kapczinski, dos Santos Souza, Batista Miralha da Cunha, and
Schmidt (2003) published a systematic review exploring the efficacy and acceptability of the use
of antidepressants in the treatment of GAD. This publication was citation chased from the
version published in 2016. The title of the 2016 version was present within the results yielded
from the best search. However, the publication was withdrawn from the Cochrane Library
Database as it was passed on to new authors. Because the version published in 2003 was the
most recent one available at this time, an exception was made to include this piece of evidence.
Although it was not published within the last 5 years, it remains published within the last 15
years. This systematic review of RCTs only involved a search of multiple databases, including
Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register, the
Cochrane Central Register for Controlled Trials, MEDLINE, and LILACS for publications
published from 1966 to 2002. Additional inclusion criteria included relevant RCTs comparing
antidepressants to placebo or antidepressants to other pharmacological treatment. Non-
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randomized studies and patients with additional Axis I comorbidities other than GAD were
excluded. Thorough review was performed by one reviewer, who assessed studies for
relevance, inclusion and exclusion criteria, and quality. A total of 15 articles were included in the
review. Most of the included trials were conducted in the United States, and all included
outpatients. One trial was conducted among children, and the other trials were conducted
among adults. Duration of treatment ranged from 6 to 28 weeks.
Each of the trials included outcome measurement of symptoms via various symptoms
scales with the most common scale used by the Hamilton Anxiety Scale (HAM-A). Additional
outcomes measured included generalized anxiety changes at the end of the trial (extent of
response via a Clinical Global Impression (CGI) score) and acceptability of the treatment
(dropout rate and specific side effects). Data were analyzed by two reviewers. A third reviewer
solved any disagreement between the two primary reviewers. An analysis of results occurred
via the use of Review Manager Software 4.1. Relative risk and confidence intervals were
calculated. Evidence favored antidepressants over placebo and found that antidepressants
were more effective in treating GAD than placebo. Paroxetine and imipramine were compared
and shown to have similar efficacy and be well tolerated by most patients with GAD. Sertraline
was more effective than placebo in the treatment of GAD among children and adolescents. Side
effects more commonly occurred in the groups treated with antidepressants as compared to
placebo groups. Side effects included nausea, dry mouth, constipation, and drowsiness.
However, because dropout rates were not significant between antidepressant and placebo
groups, evidence supports that antidepressants are well tolerated. Therefore, this systematic
review provides support for the use of antidepressants in the treatment of GAD across the
lifespan and describes the efficacy and acceptability of many different antidepressants in
particular, which can aide in appropriate prescribing by NPs and other providers.
A good quality rating was assigned to this systematic review as variables of interest
were clearly identified, key search terms were stated, multiple databases were searched, and
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exclusion and inclusion criteria were stated (Kapczinski et al., 2003). The data were older than
the past 5 years, dating back to the past 15 years. This review excluded participants with
additional Axis I diagnoses other than GAD. This provided benefit in that it allowed for the
conclusion to be made that the effect of antidepressants to decrease symptoms of anxiety was
independent from its effects on depression or dysthymia. However, it hindered the
generalizability of the review as about 90% of patients with a diagnosis of GAD also have
another psychiatric comorbidity. The sample size for some of the trials, including the one
involving children and adolescent participants, was small. Definitive conclusions and consistent
recommendations were yielded from the results.
Level I evidence. A systematic review performed by Sawyer and Nunez (2014)
reviewed literature published between 2007 and 2012 in order to evaluate the effectiveness of
individual, manualized CBT for anxiety in the pediatric population. Four databases were
searched, including Cochrane, PubMed, CINAHL, and PsycINFO, and 10 studies were selected
for final review. Inclusion criteria consisted of evidence from peer-reviewed journals, English
language, CBT as the primary intervention, and school-age anxious children ages 7-12.
Exclusion criteria included a comorbid diagnosis of autism, disorder-specific CBT, computerassisted, group only, self-help, or school-based CBT, fewer than 10 participants, CBT in
combination with other therapies, only one component of CBT, any adult participants, and only
adolescent participants. An exception was made to include this piece of evidence as it was
determined to be relevant to the EBP project and self-help CBT as an individual, manualized
form of the Coping Cat program was explored. A total of 40 articles met inclusion and exclusion
criteria and were further reviewed for level of evidence, quality, and relevance. Of the 10 final
articles selected, two were systematic reviews, six were randomized controlled trials, and two
were quasi-experimental studies.
The interventions included in this review were individual CBT, with or without parental
involvement (Sawyer & Nunez, 2014). Eight of the ten studies utilized a manualized form of
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CBT, and most included the Coping Cat program. Coping Cat is a 14-to-20-session program
with 60-minute sessions. Additional individual CBT programs utilized in the studies included
Facing Your Fears, a 12-session program with 60-to-90-minute sessions and FRIENDS, a 14session program with 60-minute sessions. CBT sessions were one hour long, and most children
participated in at least 12 sessions. A total of 22 different tools were utilized among the studies
in order to measure the outcome of symptom reduction. These tools were not discussed in
detail but were described as having adequate reliability and validity. Diagnostic recovery was
also measured, which can be defined as remission from a disorder and no longer meeting
diagnostic criteria for the disorder. Compared to controls of group CBT, family CBT, education
or support, and medication, findings supported that individual, manualized, CBT significantly
decreased anxiety rates and was superior or equivalent to measures of diagnostic recovery.
There was an exception in that the combination of sertraline and CBT was significantly more
effective than individual CBT alone. This review called for further dissemination of CBT, costeffective programs, accessible manuals, training, and as well as evidence-based CBT programs
that can be implemented in brief sessions over less visits in the primary care setting in order to
overcome barriers. Overall, this systematic review provided strong, high level evidence to
support individual, manualized CBT for the treatment of anxiety disorders in children.
This level I systematic review was deemed of high quality after critical appraisal as a
result of its heterogeneity with the inclusion of both males and females and a variety of races
and ethnicities (Sawyer & Nunez, 2014). Thus, results are generalizable across the pediatric
population. An extensive literature review was performed with the inclusion of only high-level
sources, specifically level I and level II. Key search terms were stated, multiple databases were
searched, and inclusion and exclusion criteria were delineated. Details of included studies were
presented, including design, sample, method, results, outcomes, strengths, and limitations. This
review identified gaps in knowledge regarding CBT for anxiety, provided supporting evidence to
help close those gaps, and recommended further necessary research.
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Level I evidence. Andersen and colleagues (2014) presented a clinical guideline that
was adapted from the American Society of Clinical Oncology (ASCO). The purpose of the
guideline was to address appropriate screening, assessment, and care of symptoms of anxiety
and depression in adults who have cancer. The authors of the guideline stated that all patients
should be screened for anxiety symptoms when they are diagnosed and onward. Screening at
initial visits and times of disease status changes, such as post-treatment, recurrence,
progression, palliative, or end-of life care, was advocated as important. It was also noted that a
valid and reliable tool is necessary to both screen and assess for anxiety. The Generalized
Anxiety Disorder (GAD)-7 scale was strongly recommended. Providers should be aware of not
only anxiety symptoms that patients may present with but also other ways in which the disorder
may present including concerns or fears. Although it is expected for patients to have worries
regarding cancer, GAD is likely present when such worries do not align with the actual cancerrelated risk, including worry about symptoms that are not associated with cancer or cancer
treatments. In addition, a patient with GAD has worries about a large variety of other topics,
including non-cancer issues. The provider should assess the patient’s home environment,
relationships, social life, and occupational work to detect any impairments during the time in
which they experience anxiety symptoms. Referral to a psychiatrist, psychologist, physician, or
equivalently trained professional should occur if the patient expresses a risk of harm to oneself
and/or others, severe anxiety or agitation, or psychosis or delirium. Assessments should include
identifying signs and symptoms of anxiety (panic attacks, trembling, sweating, tachypnea,
tachycardia, palpitations, sweaty palms), symptom severity, potential stressors (impaired daily
living), risk factors, times of vulnerability, and potential underlying causes. A confirmation of
GAD via the DSM-5 criteria is necessary prior to the initiation of treatment.
Patient preferences and shared decision making should be incorporated into the
treatment plan, and both pharmacologic and/or nonpharmacologic interventions should be
considered (Andersen et al., 2014). Patients should be warned of potential adverse effects,
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tolerability, and potential interactions with other medications if prescribed medications.
Benzodiazepines should be used with caution, especially with long-term use, due to increased
potential for abuse and dependence and adverse effect of cognitive impairment. Support,
education, and information about anxiety, proper management, and when to call the provider
should be provided to the patient. Well-supported psychological interventions with clear
explanations regarding guided content and structure, delivery method, and duration of treatment
should be provided. Outcomes should be measured at various intervals, including a minimum of
pre- and post-treatment but preferably once per month or until symptoms subside, in order to
determine the effectiveness of the intervention, monitor patient compliance, evaluate the
practitioner, assess patient satisfaction with the treatment, and determine solutions to
compliance issues. After eight weeks of treatment, if there has been no symptom reduction or
poor patient satisfaction, a psychological or pharmacological intervention should be added, the
medication should be changed, or the provider should provide a referral to individual or group
psychotherapy. Detailed information for the treatment of depression was also discussed in the
guidelines but not thoroughly explained within this report due to the project’s main focus of
GAD. This clinical guideline provided thorough instructions to providers for the screening,
assessment, and treatment of GAD among adult patients with cancer and can help to aide in
achieving positive outcomes for patients when followed.
This level I evidence was deemed of high quality based on the AGREE II Instrument due
to its development by key stakeholders, including a highly regarded organization, the ASCO,
and its detailed conclusions (Andersen et al., 2014). Multiple databases were searched and
identified, including MEDLINE, EMBASE, the Cochrane Library, and medical specialty websites.
The target population was identified including clinical condition and comorbidities. Potential
harms and benefits were addressed. Recommendations were clear, grounded in supporting
evidence, and provided multiple options patients are likely to accept.
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Level I evidence. A clinical guideline by the Assessment and Management of Risk for
Suicide Working Group (2013) provided information for the assessment and management of
patients at risk for suicide. This is very applicable to patients with GAD, and the link between
GAD and risk for suicide is discussed frequently throughout available literature. In addition, in
contrast to best practice, benzodiazepines are often utilized in the treatment of GAD. The FDA
has added boxed warnings to benzodiazepines as their use combined with opioid medications
can lead to slowed or difficult breathing and death. Benzodiazepines should be used with
caution when prescribed for patients at risk for suicide due to this risk of respiratory depression
as well as addiction effects. This guideline recommends that any patient diagnosed with a
mental disorder be assessed for suicide risk. Depression is often a comorbidity with GAD.
Patients with high scores on depression screening tools should also be assessed for risk of
suicide. When symptoms of anxiety are present, providers should ask patients directly regarding
suicidal ideation. It is also important to consider that suicidal ideation can fluctuate, and
reassessment should regularly occur when circumstances change. Additional warning signs of
potential suicidal behavior includes anxiety in the form of agitation, irritability, angry outburst,
wanting to jump out of one’s own skin and dramatic mood changes or lack of interest in usual
activities or friends. Protective factors should also be assessed, including a patients’ will and
purpose to live and other factors that may decrease the risk of suicide, such as social support,
positive personal traits, good coping and problem-solving skills, and access to health care. A
detailed mental health history should also be obtained.
CBT and other psychodynamic therapies as well as antidepressants may be beneficial to
this patient population (Assessment and Management of Risk for Suicide Working Group,
2013). However, close monitoring of patients who are prescribed antidepressants is warranted
for the emergence or worsening of suicidal thoughts. Providers should be aware of overdose
risk and only provide a limited amount of medication at a time. There is no evidence to support
the use of antipsychotics to reduce suicide risk. In conclusion, there is a call for clinical training
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programs for mental health in order to help bridge the gap between research and practice and
to help solve the problem of a shortage of clinicians trained to provide evidence-based
psychotherapies. In conclusion, this guideline in applicable to the EBP project as it provides
important recommendations for treating the patient with GAD holistically, assessing for suicide
risk, and appropriately managing GAD via CBT and antidepressants.
After a quality appraisal of this level I clinical guideline was conducted, it was assigned a
rating of high quality in accordance with the AGREE II Instrument (Assessment and
Management of Risk for Suicide Working Group, 2013). Key terms searched were addressed,
including suicide and all related terms. Inclusion criteria were listed as peer-reviewed articles,
published in the English language, population of adults 18 years of age or older, and
appropriate sample sizes. RCTs, meta-analyses, and systematic reviews of RCTs were
included to provide the strongest levels of evidence in support of the guideline
recommendations. A total of 35 RCTs and 38 systematic reviews were included. Studies were
appraised for quality prior to making decisions to include or exclude. Patient preferences and
individual situations were considered. Conclusions were developed through a rigorous
approach.
Level I evidence. A Cochrane systematic review by James, James, Cowdrey, Soler,
and Choke (2015) served a purpose of examining the effectiveness of CBT for children and
adolescents with anxiety disorders as compared to wait lists, non-CBT interventions and
treatment as usual (TAU), medications, combination therapy, and placebo as well as the longterm effects of CBT. A search of multiple databases was performed including The Cochrane
Library, EMBASE, MEDLINE, and PsycINFO for evidence with a publication date of 1970-2012.
Inclusion criteria consisted of children and adolescents ages 4-19, meeting diagnostic criteria of
the DSM II or IV or ICD9 or ICD10 for anxiety disorder, research settings (i.e. university
outpatient clinics, inpatient services, community clinics, and schools), and comorbidities
allowable for anxiety disorders per DSM and ICD rules. Exclusion criteria consisted of PTSD,
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OCD, and simple phobias. A total of 41 RCTs met inclusion criteria, and each arbitrarily involved
at least nine sessions of CBT and direct contact with children. A total of 1034 participants and
921 controls were included within the 41 studies. Participants were recruited from outpatient
clinics, and all had a psychiatric diagnosis of an anxiety disorder ranging from mild to moderate
(SAD, overanxious disorder (OAD), SOP, panic disorder (PD), GAD, specific phobia (SP)) while
many had comorbid conditions (depression, conduct disorders (CDs), oppositional defiant
disorder (ODD), attention-deficit/hyperactivity disorder (ADHD)).
The intervention within the studies was required to include manualized, or modular, CBT
alone, or CBT with medication (James et al., 2015). Individual, group, or family/parental
involvement were ways in which CBT was administered. CBT was aimed at helping children
recognize feelings of anxiety and somatic reactions, clarify cognitions, develop coping skills, and
learn exposure training. Participants in waiting list, treatment as usual, treatment without CBT,
and placebo groups served as the controls. Placebo treatment included education or
bibliotherapy without CBT elements. The primary outcome measured was remission, which was
measured using the Anxiety Disorder Interview Schedule for Parents (ADIS-P), the Anxiety
Disorder Interview Schedule for Children (ADIS-C), or the Diagnostic Interview Schedule for
Children, Adolescents and Parents (DISCAP). The interviews were not carried out by the
treatment team to allow for blinding. The Clinical Global Impressions (CGI) Scale was also
utilized to assess treatment response. Acceptability was measured by the number of
participants lost to follow up. Reduction in anxiety symptoms was also measured using multiple
scales. Outcomes were assessed at follow up periods between 6 months and 24 months.
Demographic data, including heterogeneity between trials (age, gender, diagnosis, duration and
severity, comorbidities), were assessed using the Chi test and the I statistic. Only modest
variability was found. Meta-regression was utilized to determine the influence of disorder
severity prior to initiation of treatment on outcome.
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To summarize the results, 58.9% of participants who received CBT achieved remission
compared to 16% of controls, but these results were not significant (OR 1.51, 95% CI 0.77 to
2.96, Z=1.21, P=0.23) (James et al., 2015). The study supported a clear benefit for CBT (95%
CI), and there were no differences in outcomes for individual, group, or family CBT. There was
also no difference between the rates of participants lost to follow up among the CBT intervention
and control groups. Findings were significant and supported the efficacy of CBT over active
controls (OR 0.52, 95% CI 0.31 to 0.91, Z=2.28, P=0.02). Group and family/parental formats of
CBT were associated with greater reduction in symptoms than those produced by individual
CBT formats alone, but findings were not significant (Z=1.66, P=0.1).
Overall, this review offers support for the usefulness of CBT as well as its acceptability in
the treatment of anxiety disorders in children and adolescents (James et al., 2015). CBT was
shown to be superior to waiting list controls, but its superiority as compared to active controls
(psychoeducation, bibliotherapy, treatment as usual) could not be confirmed. It was unclear
whether children younger than 6 years of age have the cognitive maturity to participate in CBT.
This level I systematic review was deemed of good quality (James et al., 2015). The use
of multiple outcome scales did add complexity and posed some challenges to making
comparisons. All scales utilized were found to have good reliability, validity, and efficacy.
Included studies involved an age range of 4 to 18 years, but children younger than 7 years old
were underrepresented. Generalizability was enhanced by inclusion of both genders, a range of
socioeconomic classes, and multiple comorbidities. However, nine studies did not provide
details of ethnicity of participants, and generalization to those with severe anxiety was limited as
only mild to moderate cases were included in the review. A small sample size of 41 studies was
included. Details of the studies were clearly depicted. There was a potential for bias as
participants could not be blinded. Conclusions logically flowed from the results of the review and
were consistent with those of other reviews and meta-analyses.

GENERALIZED ANXIETY DISORDER PROTOCOL

61

Level I evidence. Strawn, Dobson, and Giles (2017) recently published a systematic
review addressing psychopharmacologic interventions utilized in pediatric care for the treatment
of anxiety as well as attention deficit hyperactivity disorder (ADHD) and depression. Medication
classes, including SSRIs, SNRIs, stimulants, and alpha 2 agonists, side effects and tolerability
concerns, and landmark trials of antidepressant medications in children and adolescents were
reviewed. The Child/Adolescent Anxiety Multimodal Study (CAMS) is one of the largest trials of
its kind and supports that sertraline has the greatest efficacy in the treatment of GAD in children
and adolescents. This study included 488 patients, and 78% of them had a primary diagnosis of
GAD. Randomization to groups occurred, and intervention groups included CBT only, sertraline
only, or CBT and sertraline in combination. Results indicated that sertraline effectiveness was
not statistically significant from that of CBT, but was statistically significant in comparison to
placebo. Combination treatment led to better outcomes than either treatment alone, and
patients maintained gains at follow up. After completing the 12-week CAMS trial, approximately
60% of those patients participated in the Child/Adolescent Anxiety Multimodal Extended Longterm Study (CAMELS). A total of 82 patients who had received combination therapy of sertraline
and CBT, 79 who received sertraline monotherapy, 83 who received CBT monotherapy, and 44
who received placebo continued into this trial. Six years following the initiation of the study,
approximately 47% of patients were in remission. Response to acute treatment was determined
to be a predictor of long-term outcomes. However, relapse also occurred in about 48% of
patients, as anxiety often fluctuates. In additional studies, lower likelihood of remission after
treatment with pharmacotherapy was found to be associated with older age, female gender,
minority status, lower socioeconomic status, poor family functioning, and severe anxiety at
baseline.
SSRIs and SSRNIs have similar side effect profiles among youth, including headaches,
gastrointestinal side effects (nausea), and activation, which is characterized by irritability, mild
disinhibition, increased restlessness, and insomnia (Strawn et al., 2017). Activation occurs more
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commonly in youth treated with SSRIs than with adults. Multiple meta-analyses did not identify a
link between antidepressant use and increased risk of suicide, but appropriate caution should
be taken. Paroxetine and venlafaxine may be more associated with this risk of increased suicide
due to their short half-lives, and as a result, are not first-line interventions for the treatment of
anxiety disorders in youth. Within the study, CBT was found to help mitigate the suicidalityrelated adverse events associated with venlafaxine.
This review supported the importance of early treatment of GAD in youth and celebrated
the growing volume of evidence for psychopharmacologic interventions in youth with anxiety
disorders (Strawn et al., 2017). It calls for providers to be astute regarding medication-specific
tolerability concerns and warnings when prescribing antidepressants. It also provides further
evidence for the effectiveness and sustained effects of combined CBT and antidepressant use,
specifically including the SSRI sertraline.
After critical appraisal, this level I systematic review was deemed of good quality (Strawn
et al., 2017). Information regarding key search terms, databases searched, and inclusion and
exclusion criteria were lacking. Details of included studies were briefly described. Methods for
appraising the strength of the evidence were not disclosed. Sample sizes of many included
studies were adequate and allowed for generalizable results across youth ages 7 to 17 years.
Adequate control was maintained among groups. Definitive conclusions and consistent
recommendations were based on scientific evidence and provided worthwhile contributions to
practice.
Level II evidence. Wetherell, Petkus, White, Nguyen, Kornblith, Andreescu, Zisook, and
Lenze (2013) conducted a randomized controlled trial exploring the effects of antidepressant
medication augmented with CBT for the treatment of GAD in the older adult population. The
purpose of the study was clearly stated as examining whether such interventions improve
symptom outcomes (boost treatment response) and decrease relapse rates in this population. A
sample of 73 adults greater than or equal to 60 years of age with a DSM-IV principal diagnosis
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of GAD participated in the study. Recruitment of participants occurred between 2008 and 2010
at primary care practices, mental health clinics, and advertisements at three sites in Pittsburgh,
San Diego, and St. Louis. Patients with comorbid depression or other anxiety disorders were
included in the study provided that GAD was their principal diagnosis. Exclusion criteria included
a history of substance abuse without a minimum of 6 months of full remission, lifetime history of
psychosis or bipolar disorder, cognitive impairment, current suicidal ideation, ongoing
psychotherapy, and medical instability. Psychotropic medications were tapered off two weeks
before the start of the study, and benzodiazepines and sleep aids were also tapered off or
continued at a consistent, lower dosage throughout the study. Participants were given a
thorough description of the study and provided written informed consent.
Treatment throughout the study was administered in three phases: acute, augmentation,
and maintenance (Wetherell et al., 2013). During the acute phase, participants received 12
weeks of treatment with escitalopram, an antidepressant categorized as an SSRI, starting at a
dosage of 10 mg per day. If symptoms were not improving, the dosage was increased to 20 mg
per day as tolerated after four weeks of treatment. After 12weeks, participants were randomly
assigned to one of four groups provided that they received at least a 20% improvement in
symptoms: 1) escitalopram for 16 weeks and 16 CBT sessions (augmentation phase), followed
by escitalopram for 28 weeks (maintenance phase); 2) escitalopram for 16 weeks without CBT,
followed by escitalopram for 28 weeks; 3) escitalopram for 16 weeks with CBT, followed by pill
placebo for 28 weeks; 4) escitalopram for 16 weeks without CBT, followed by pill placebo for 28
weeks. The CBT protocol, which was administered by six therapists with doctoral degrees,
included education modules regarding psycho-education/self-monitoring, relaxation training,
cognitive therapy, and problem-solving skills. Participants could invite one family member to
attend one session with them in order to educate them as well and provide support for the
participant.

GENERALIZED ANXIETY DISORDER PROTOCOL

64

Anxiety outcomes were measured using the Hamilton Anxiety Rating Scale (HAM-A), a
14-item scale conducted via interview by the clinician that measures anxiety by assessing
somatic symptoms, every four weeks during the augmentation phase and every two weeks
during the maintenance phase (Wetherell et al., 2013). The HAM-A is considered a gold
standard for measuring outcomes regarding GAD treatment with pharmacotherapy and has
excellent reliability with a correlation coefficient of 0.93. Outcomes of excessive and
uncontrollable worry were measured using the Penn State Worry Questionnaire at the initiation
and completion of the augmentation and maintenance phases. This self-report scale consisting
of 16 items is most commonly used in psychotherapy studies for GAD and has high internal
consistency with a Cronbach’s alpha of 0.87.
The study began with a total of 86 participants enrolled (Wetherell et al., 2013). Thirteen
participants withdrew from the study due to medication side effects or lack of efficacy or were
lost to follow up. A total of 69 of the 73 randomly assigned participants, or 95%, completed the
entire protocol. Demographic information of the treatment groups was clearly described and
depicted in a table. There was no difference among the four groups regarding demographic
variables, anxiety level, or worry level at pretreatment. It was determined that age, education,
and age at onset of diagnosis of GAD did not affect the results. Statistical analyses included chisquare tests for group differences at baselines, Kaplan-Meier survival analysis for HAM-A
scores and relapse rates, logistic regression for Penn State Worry Questionnaire data, and
linear mixed models for measuring improvement in anxiety and worry symptoms. Based on the
results of the Penn State Worry Questionnaire, participants who received CBT were three times
as likely to exhibit response to treatment in terms of improved symptoms than those who did not
receive CBT (odds ratio=3.19, 95% CI=1.00-10.14, p<0.05). A medium to large effect size of
CBT on worry symptoms was found. Participants who received escitalopram augmented with
CBT exhibited greater improvements in pathological worry than those who received
escitalopram only (p=0.01). Based on HAM-A scores, participants who received CBT did not
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exhibit greater improvements in anxiety symptoms (p=0.15). Participants who received
maintenance escitalopram had significantly lower relapse rates than those receiving placebo
(p<0.001). Participants who received CBT with placebo had lower relapse rates than those who
did not receive CBT (p=0.009). There was no statistical significance among relapse rates
between the participants who received maintenance medication without CBT and participants
who received CBT without maintenance medication (p=0.11). A total of 34.0% of particpants
receiving placebo relapsed, while no participants receiving maintenance medication relapsed.
Regarding participants receiving placebo, 42.9% of those who did not receive CBT relapsed
while 25.0% of those who received CBT relapsed.
This study provides strong evidence to support the combined use of CBT and SSRIs
(Wetherell et al., 2013). This sequenced combination treatment led to improved symptoms of
worry, although not improved symptoms of anxiety in this population. Both maintenance
medication and CBT were highly able to prevent relapse. Based on these results, the
augmentation of CBT can improve response to treatment and worry levels when an SSRI is
insufficient and may allow patients to discontinue long term medication use while remaining in
good control of GAD. Use of CBT and a maintenance SSRI also provides a safer and more
efficacious alternative to benzodiazepine use. The relapse prevention findings among older
adults in this study were found to also be generalizable to the young adult and middle-aged
population. In conclusion, this RCT provided much support for the addition of CBT after initiation
of an SSRI for the treatment of GAD in older adults. This was very applicable to the EBP project
as many patients with GAD at the facility had been taking an SSRI prior to the implementation of
the project, and thus, the addition of CBT was appropriate at the start of the project for such
patients. The results were also applicable to the project’s included population of older adults as
well as young and middle-aged adults.
Overall, this level II RCT was found to be of good quality after critical appraisal
(Wetherell et al., 2013). Moderate control was allocated to the groups as the demographics
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were similar in both the control and intervention groups, and the settings were similar as
aforementioned. The instruments utilized to measure data were reliable with a Cronbach’s alpha
greater than 0.70, and instrument validity was discussed. A high response rate of 95% was
achieved. Results were clear and consistent, and definitive conclusions were made. Limitations
of the study were discussed, including the small sample size, lack of control for the CBT
intervention, and moderately short maintenance phase of 7 months.
Level II evidence. Glenn and colleagues (2013) performed an RCT that examined
predictors of outcomes of CBT for anxiety disorders in regard to treatment dose and patient
engagement. A total of 1,620 patients with GAD, panic disorder, social anxiety disorder, or
posttraumatic stress disorder were recruited from primary care settings in the United States, and
1,004 of these were eligible for the study. Potential applicable participants were directly referred
for the study by primary care providers and clinical nursing staff. A trained clinician then
determined eligibility based on inclusion criteria including the requirements of attendance at a
participating clinic, age 18-75 years old, meeting of DSM-IV diagnostic criteria for the included
disorders, and a score on the Overall Anxiety Severity and Impairment Scale (OASIS) indicating
moderate or clinically significant anxiety symptoms. Exclusion criteria included patients with
unstable conditions, marked cognitive impairment, active suicidal intent or plan, psychosis, or
Bipolar I disorder, drug or alcohol dependence (abuse was permitted), patients already
receiving CBT, and patients who could not speak English or Spanish.
Using an automated program and stratified permutated block randomization, participants
were randomized to groups (Glenn et al., 2013). About half of the participants, 503 in total,
received the intervention. Participants could select their preference to receive pharmacotherapy,
computer-assisted CBT, or both. A total of 43 of the 503 participants chose to receive
pharmacotherapy only, 166 chose CBT only, and 273 chose both CBT and pharmacotherapy.
The CBT intervention was based on Coordinated Anxiety Learning and Management (CALM)
tools and contained eight modules in which the clinician and patient both viewed the program on
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the screen at the same time. CBT principles included cognitive restructuring, exposure, selfmonitoring, psychoeducation, fear hierarchy, breathing retraining, and relapse prevention.
Clinicians did not have expertise in anxiety management or CBT. Some had patient care
experience, and 8 of 14 had prior mental health experience. Six were social workers, five were
registered nurses, two were master’s-level psychologists, and one was a doctoral-level
psychologist.
Variables included number of CBT sessions attended, number of CBT modules in which
exposures were conducted to interoceptive cues, trauma memories, catastrophic images, or
feared or avoided situations, clinician rating of homework adherence, and clinician rating of
patient overall commitment to CBT per session (Glenn et al., 2013). The Brief Symptom
Inventory (BSI) 12-item scale was utilized to measure primary outcomes of psychic and somatic
anxiety and has high internally reliability and validity. Secondary outcomes measured included
depression via the PHQ-9 and functional status via the Sheehan Disability Scale (SDS). The
PHQ-9 has high internal reliability with a Cronbach’s alpha of .86 to .89 and high construct,
external, and criterion validity. The SDS measures impairment in work/school, social life, and
home life/family and has adequate internal reliability, construct validity, sensitivity, and
specificity among patients with anxiety disorders. Propensity score weighting was utilized to
eliminate differences in baseline characteristics between patients in the low and high CBT dose
and engagement groups. Demographics characteristics identified included ethnicity, age,
education, gender, and comorbidities.
Results included that participants who had lower attendance scored significantly higher
on all outcome measures (ps < 0.029) at both 12 and 18 months than those who had high
attendance. Patients who did not complete exposure modules were significantly more
symptomatic (ps < 0.004) across all measures at 12 and 18 months in comparison with those
who did complete exposure modules. Patients who were less adherent to homework scored
significantly higher (ps < 0.012) across all measures at 12 and 18 months than those who were
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more adherent to homework. Patients who exhibited low commitment to CBT scored
significantly higher across all measures at 18 months (ps < 0.006) but not at 12 months than
those who exhibited high commitment to CBT.
Findings supported that greater learning and storage strength of learning during CBT
occurred with greater treatment dose and engagement (Glenn et al., 2013). In addition, greater
reduction in symptoms and improvements in functioning occurred with higher CBT dose and
engagement, including completing at least one exposure exercise, having a high attendance
rate, and completing assigned homework. As a result of exposure completion and higher
attendance predicting better outcomes, the value of these aspects of CBT as predictors of
outcomes was emphasized. Further endeavors to make CBT more interesting, understanding,
and useable, such as through mobile phone applications or computer programs, were
recommended.
A quality rating of good was applied to this level II RCT (Glenn et al., 2013). The purpose
of the study and data collection methods were described clearly. The instruments were reliable
with a Cronbach’s alpha greater than 0.70. Tables were presented and consistent with the
narrative content. A thorough literature review was performed, but sources dated as far back as
1992. Limitations of the study were discussed, including overlap of variables, a lack of
assessment of the quality of homework, and some missing data due to clinician error. A
sufficient sample size was utilized, and results were generalizable due to the inclusion of
varying cultural and educational demographic information. Consistent recommendations were
yielded.
Level II evidence. A randomized controlled trial by Freshour and colleagues (2016)
explored the long-term effects of CBT delivered by bachelor-prepared lay providers and CBT
delivered by PhD expert providers on GAD severity, anxiety, quality of life, and other outcomes
among older adults. The lay providers were trained and supervised by a licensed psychologist.
Study participants included adults age 60 years or older who were recruited from internal
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medicine, family practice, and geriatric clinics in Texas. Inclusion criteria included meeting
diagnostic criteria for GAD as a principal or co-principal diagnosis. Exclusion criteria included
patients with active suicide intent, current psychosis or bipolar disorder, substance abuse within
the past month, or cognitive impairment. A total of 223 participants were enrolled in the study,
and 112 were randomly assigned to CBT and completed post-treatment assessments. Groups
included participants randomly assigned using a random number generator to CBT
administered by lay providers, CBT administered by expert providers, and usual care. CBT was
administered for a time period of 6 months. The first two sessions were administered in person,
and subsequent sessions were administered in person or via telephone in accordance with
patient preference. The first 3 months of CBT included education, awareness training,
motivational interviewing, deep breathing, coping self-statements, behavioral activation,
exposure, sleep management, problem solving, progressive muscle relaxation, thought
stopping, and cognitive restructuring. Patients were called weekly for the following month and
biweekly for the final two months of CBT to provide support and review of skills.
Outcomes were assessed using various scales (Freshour et al., 2016). Worry was
measured via the Generalized Anxiety Disorder Severity Scale (GADSS), a 6-item clinician
rated scale measuring DSM criteria with adequate reliability and validity among older adults.
Anxiety was measured using the trait subscale of the State-Trait Anxiety Inventory (STAI-T), a
20-item self-report measure of general anxiety with a Cronbach’s alpha of 0.92, as well as the
Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A), a clinician-rated scale
aimed at increasing the reliability of the Hamilton Anxiety Scale. Both scales demonstrate good
sensitivity when used with adults experiencing late-life anxiety. Secondary outcomes measured
included depressive symptoms via the Patient Health Questionnaire-8 (PHQ-8), mental health
quality of life via the Medical Outcomes Study Short Form (SF-12), and severity of insomnia via
the Insomnia Severity Index (ISI). Telephone calls by independent evaluators who were
unaware of the treatment assignments were used to measure outcomes 6 months and 12
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months after treatment. Demographic variables, clinical characteristics, and psychotropic
mediation use at post-treatment was analyzed via t-tests and chi-square analyses. Growthcurve models were created to analyze the effects of time, treatment group, and the interaction
among them.
Results indicated that improvements in both worry and anxiety outcomes were
maintained at both six- and 12-month follow up and that scores were equivalent for both CBT
administered by lay providers and CBT administered by expert providers (Freshour et al., 2016).
Therefore, this study provided support for the sustainable, long-term benefit of CBT for the
treatment of anxiety among older adults as well as for its administration by lay providers trained
and supervised by experts. This can allow for expanded access to CBT, a reduction in barriers
to proper treatment of GAD, and decreased costs of mental health services. In addition, as
experts can help determine patient appropriateness for CBT and provide training and
supervision of bachelor-prepared providers, the shortage of geriatric mental health experts can,
in part, be overcome.
This recently published level II RCT can be described as high quality (Freshour et al.,
2016). A power analysis indicated that the sample size was sufficient to detect a medium effect
size for differences among the groups with 97% power. Adequate control among the groups
was established. Instrument reliability and validity were discussed, and Cronbach’s alpha was
greater than 0.70. Well-qualified independent evaluators were utilized to measure outcomes and
were blinded to treatment assignments. They were well qualified in that they were masters-level
graduate students in clinical psychology and supervised by a licensed psychologist. Results
were presented clearly, and definitive conclusions were drawn from results.
Level II evidence. Piacentini and colleagues (2014) conducted the largest RCT to date
comparing the effects of CBT, SSRIs, and their combined treatment for childhood anxiety. This
study was aforementioned within the systematic review by Strawn and colleagues (2015). The
purpose of this study, which is known as the Child/Adolescent Anxiety Multimodal Study
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(CAMS), was to evaluate response, remission rates, and anxiety severity changes among
participants within the different groups. A total of 488 children and adolescents ages 7-17 years
who met DSM-IV criteria for separation anxiety disorder, GAD, and/or social phobia and lived in
six different geographically diverse areas were included in the study. Comorbid mood,
psychotic, or pervasive developmental disorder, one prior CBT trial failure, or two SSRI trial
failures for anxiety described the exclusion criteria.
Randomization to four different groups occurred: CBT only (CBT), sertraline only (SRT),
a combination of CBT and SRT (COMB), or pill placebo (PBO) (Piacentini et al., 2014). Blinding
occurred within the SRT and PBO groups while the COMBO and CBT groups included masking
to independent evaluator but not to patients and therapists. The CBT intervention was the
“Coping Cat” program adapted for the CAMS study and included fourteen 60-minute long
sessions throughout the 12 weeks of the acute phase (Phase I). Therapists were trained in the
“Coping Cat” program and received supervision throughout the study. The SRT group included
eight 30-minute long sessions discussing anxiety severity, treatment response, and adverse
events. A maximum daily dose of sertraline and matching placebo for these participants was
200 mg, and clinical response and tolerability were considered for dosing. Pharmacotherapists
were certified psychiatrists and nurse clinicians who received supervision throughout the study.
Participants in the COMB groups usually received both interventions during the same day.
Blinding did not occur among COMB psychiatrists in order to create a collaborate care
approach, which has been linked to improved outcomes and lower required medication doses.
An initial phase of acute treatment lasted for 12 weeks and was followed by a phase of 6
months of maintenance treatment (Piacentini et al., 2014). Participants remained in their
originally assigned groups for the maintenance period. CBT administered during the acute
phase included new material per session, and CBT administered during the maintenance phase
included monthly delivery without new material. Medication treatment during the acute phase
included weekly or biweekly clinic visits with dose increases when necessary while medication
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treatment during the maintenance phase included continuation of the dose established by the
end of the acute phase and dose decreases due to side effects if necessary. CBT and
medications were administered in ways equivalent to how they would be delivered in primary
care. Two adjunctive services/attrition prevention (ASAP) sessions were allowed during each
study phase. These additional sessions aimed to address emergent issues, such as significant
symptom worsening or environmental stressors that endanger safety or increase the risk of
study attrition. Participants who did not respond to acute phase treatment were referred to
community providers, and participants who did not respond to placebo were allowed to select
their choice of CAMS treatment. The study allowed participants to use off-protocol, or
concomitant, interventions during the maintenance phase, but use of these interventions was
closely monitored.
Demographic data, anxiety and comorbidities, and psychosocial functioning were
reported by participants and their parents at baseline and weeks 4, 8, 12, 24, and 36 (Piacentini
et al., 2014). Diagnostic criteria was established using the Anxiety Disorders Interview Schedule
for DSM-IV-TR, Child Version. Demographic data for the sample included a mean age of 10.7
years with 74.2% 12 years of age or younger. Most participants were white, middle class with
approximately half female and half male. Most had at least two primary anxiety disorders.
Response was measured by the Clinical Global Impression-Improvement Scale (CGI-I),
and those who were rated 1 (“very much improved”) or 2 (“much improved”) were considered as
responders (Piacentini et al., 2014). The CGI-I also helped to determine a measure of Excellent
Treatment Response with a score of 1 (very much improved). Anxiety severity was measured by
the Pediatric Anxiety Rating Scale (PARS), which demonstrated good to excellent internal
consistency and measures six items for the assessment of anxiety severity, frequency, distress,
avoidance, and interference over the previous week. Overall functional impairment was rated
via the Children’s Global Assessment Scale. The Clinical Global Impressions Severity Scale
(CGI-S) is a clinician rating for anxiety severity and helped determine Remission-Severity as no
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or only occasional symptoms and no impairment related to symptoms. Remission-Diagnosis
included the absence of GAD diagnosis. Treatment responders were further divided into
categories of either Always Responders, Always Non-Responders, New Phase II Responder,
Phase II Relapse, Phase II Regained, or Temporary Responders. There were some missing
data as 21.8% of participants did not complete 24-week follow-up, and 21.1% did not complete
36-week follow-up.
Results found that significantly higher response rates on the CGI-I were achieved with
COMB (80.7%) as compared to either CBT alone (59.7%) or SRT alone (54.9%) (Piacentini et
al., 2014). All active treatments were more effective than PBO, and response rates among CBT
alone and SRT alone did not differ significantly. Study attrition rates were not found to be
significantly different for each treatment group at week 24 (chi-square=1.18, p=0.55) nor week
36 (chi-square=2.50, p=0.29). COMB was superior to SRT alone and CBT alone at week 12.
The responded and excellent responder raters for COMB were maintained through weeks 24
and 36. However, the rates for both SRT alone and CBT alone improved so much during weeks
24 and 36 that COMB’s superiority was no longer statistically significant compared to the
monotherapies at weeks 24 and 36. Most of the participants who showed response to acute
treatment maintained gains at weeks 24 and 36. COMB treatment was superior over CBT and
SRT on all outcomes measures (PARS, CGI-S, CGAS) at weeks 24 and 36 with moderate to
large effect sizes. SRT only and CBT only participants were more likely to seek new additional
psychopharmacological treatments during the maintenance phase than were COMB
participants.
This study’s significant strength and value contributed positively to the EBP project. In
conclusion, the efficacy and durability of the use of CBT and an SSRIs were greatly supported
for treatment of severe childhood anxiety disorders (Piacentini et al., 2014). Combined CBT and
an SSRI was deemed as the best treatment for prompt benefit, but CBT only and an SSRI only
also gave promising benefits after 6 months of treatment. Therefore, these three interventions
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are all viable treatment choices, and availability, cost, burden, and family preference should also
be considered among deciding factors.
This level II RCT received a high quality appraisal after review. The sample size was
adequate and the largest to date of its kind (Piacentini et al., 2014). Generalizability of findings
was enhanced by high subject retention, age distribution, diverse population sample, broad
eligibility criteria, geographic distribution of study sites, and replication of “real world” delivery of
treatment. Study limitations were addressed including concomitant treatment usage and lack of
a placebo comparison group at weeks 24 and 36. Offering participants in the placebo group to
select treatment if they desired supported ethical care and beneficence. Characteristics and
demographics were similar among the four different groups. Instruments utilized were described
in detail and were valid and reliable. The majority of participants completed the follow up
questionnaires and outcomes measurements. Consistent recommendations and definitive
conclusions were drawn.
Level III evidence. A non-randomized controlled trial published by Calleo and
colleagues (2013) examined outcomes of CBT delivered by experienced and nonexperienced
counselors for older adults with GAD including feasibility, satisfaction, and clinical measures.
This pilot study was conducted prior to a similar study by Freshour and colleagues (2016) that
was previously discussed within level II evidence. A total of 47 participants recruited from
primary care clinics in the United States agreed to participate, and 19 received treatment based
on eligibility. At their initial visit, participants signed an informed consent, answered questions
regarding demographic information, and completed anxiety screening. Inclusion criteria,
exclusion criteria, and intervention were mirrored in the RCT by Freshour and colleagues
(2016). However, important differing outcomes were measured in each study, which provides a
rationale for the inclusion of both pieces.
Inclusion criteria included patients who were diagnosed with a principal or coprincipal
diagnosis of GAD. Exclusion criteria included patients who had mental impairment, active
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suicidal intent, active substance use, psychosis, or bipolar disorder. The CBT intervention was
delivered over a period of 3 months and included up to 10 skills-based sessions lasting 30-40
minutes each. The first two sessions were conducted in person with the remaining sessions
conducted via telephone or in person in accordance with patient preference. CBT homework
included workbook pages and practice exercises. All patients received anxiety education,
awareness training, motivational interviewing, deep breathing, and coping self-statements.
Additional skills that patients could select included behavioral activation, exposure, sleep
management, problem solving, progressive muscle relaxation, thought stopping, and cognitive
restructuring. CBT was administered by anxiety counselor specialists who had training and
experience in CBT, late-life mental health, or anxiety disorders or by counselors with no
previous mental health training or experience. Ten patients received CBT via an anxiety
counselor specialist with training, and nine patients received CBT via a counselor without
training. Ongoing communication with the primary care provider occurred.
Outcomes that were measured included feasibility, satisfaction, and worry/anxiety
outcomes (Calleo et al., 2013). Feasibility of the treatment was assessed via content and patient
delivery choice, attrition rates, comparison of provider/EMR and self-referral procedures, and
treatment credibility-expectancy. An exit interview with a 4-point Likert scale assessed patients’
satisfaction with the treatment and included topics such as how useful the program was in
helping them manage anxiety, how confident they were that they would continue to use the
skills, how well their therapist understood their anxiety, and how helpful they found written
materials. Positive outcomes were indicated by higher scores. The Penn State Worry
Questionnaire (PSWQ) was used to assess worry. This scale consists of 16 items and has
adequate psychometric properties for use among older adults. The Generalized Anxiety
Disorder Severity Scale (GADSS), a six-item, clinical-rated scale with adequate internal
consistency and validity, was used to assess GAD symptom severity. The Beck Anxiety
Inventory (BAI), a 21-item self-report scale, measured anxiety severity. The Structured Interview
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Guide for the Hamilton Anxiety Scale (SIGH-A) is a 14-item, clinician rated scale with higher
reliability than the Hamilton Anxiety Rating Scale and was also used to assess anxiety severity.
Outcomes were measured at baseline, 3 months after treatment initiation, and 6 months after
treatment initiation.
Data were analyzed using descriptive statistics and nonparametric tests for treatment
characteristics, attrition, and satisfaction (Calleo et al., 2013). Demographic information included
age, education, gender, ethnicity, comorbidities, and medication use. Approximately 57.8%
were Caucasian, 31.6% were African American, and 10.5% were Hispanic. Approximately
52.6% were female. In terms of feasibility, most patients perceived the treatment as highly
credible after the first session (mean [SD], 7.29 [1.76]) and believed that the treatment would be
successful (mean [SD], 6.79 [2.12]). A total of 75% of participants completed the exit interview.
Results indicated that patients reported that the treatment did successfully help them manage
anxiety (mean [SD], 3.61 [0.49]). Scores on the PSWQ and GADSS declined significantly from
baseline to 3 months for those who completed treatment. The other anxiety measured did not
yield statistically significant effect sizes changes. Patients who received CBT treatment by ACSs
and counselors experienced no significant differences in ratings of treatment expectancy and
credibility (credibility: mean, 7.39 for ACSs and 7.21 for counselors, p = 0.70; and expectancies:
mean, 6.33 for ACSs and 7.13 for counselors, p = 0.41).
In conclusion, this modified CBT intervention is promising for reducing worry and
sustaining outcomes in older adults with GAD (Calleo et al., 2013). Gains were maintained at 6
months. Patient preferences allowed for shared decision making and patient-centered care.
Television sessions provided improved access to treatment for patients with financial, health,
and geographic barriers. This study provided support that counselors with a bachelor’s degree
or less who have not had extensive mental health experience are still a viable option for the
administration of CBT and can provide a more cost-effective option. The feasibility,
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acceptability, and effectiveness of CBT were upheld by this study and provide valuable
information for culturally diverse primary care clinics across the country.
A quality rating of good was assigned to this level III non-randomized controlled trial
(Calleo et al., 2013). The results are generalizable and were shown to be consistent with a
larger primary care study previously conducted. However, the sample size of 19 participants
was small. Further limitations of the study were also described, including lack of control.
Instrument validity and reliability was discussed and was adequate for the outcomes measured.
Interrater agreements between evaluators were good. Definitive conclusions were appropriately
drawn from results.
Level V evidence. Campbell (2016) explored the best available evidence regarding
pharmacotherapy for patients with GAD via an evidence summary. This is considered a level V
piece of evidence due to the inclusion of one qualitative study. Among the other pieces of
literature included in the summary were seven systematic reviews, one evidence-based
guideline, one clinical guideline, and one prospective trial. There was strong support for the use
of SSRIs as first-line treatment for GAD. Fluoxetine (SSRI) was most strongly recommended for
its outcomes related to response and remission, and sertraline (SSRI) was most strongly
recommended for its tolerability as compared to other medications including duloxetine (SNRI),
escitalopram (SSRI), lorazepam (benzodiazepine), paroxetine (SSRI), pregabalin
(anticonvulsant), tiagabine (anticonvulsant), and venlafaxine (SNRI). Duloxetine also had high
rates of response, escitalopram was effective for remission, and pregabalin had high tolerability.
SSRIs and SNRIs elicited comparable outcomes of improved anxiety symptoms and response
rates. Benzodiazepines should not be used as first-line treatment. The evidence supported not
only pharmacotherapy for the treatment of GAD, but also psychological therapy and self-care.
The addition of CBT enhanced remission rates from symptoms of anxiety while omitting the
need for long-term pharmacotherapy. The use of CBT received a Grade B recommendation,
and the use of antidepressants (imipramine, venlafaxine, paroxetine, fluoxetine, sertraline,
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duloxetine, and escitalopram), second-generation antipsychotic (quetiapine) and anticonvulsant
pregabalin with individual consideration for each clinical situation received a Grade A
recommendation. Thus, this evidence summary provided great detail regarding the
effectiveness and tolerability of many specific medications used in the treatment of GAD and
made a strong case for the inclusion of SSRIs in treatment. This provided more clarity and
knowledge for the prescribing details of the intervention. Support was also expressed for the
CBT portion of the intervention.
A high-quality appraisal rating utilizing the AGREE II Instrument was assigned to this
level V evidence summary as the six domains received strong ratings, and the overall
assessment indicated such high quality as well as a recommendation to use this guideline for
research and practice (Campbell, 2016). The design, sample, and outcomes of included studies
were presented briefly, but clearly. The guideline recommended that clinical situation, risks, and
benefits be taken into account. Current literature yielded from a systematic search was utilized.
Recommendations were clearly linked to the corresponding source of evidence. Definitive
conclusions were stated and were logical based upon the outcomes of the included studies.
Construction of Evidence-based Practice
Synthesis of Critically Appraised Literature
The thorough literature review yielded overall consistent results and recommendations.
As only good and high quality evidence and a majority of high level pieces were included, strong
evidence was available to support best practice for GAD treatment across the lifespan. Several
common themes, or subtopics, were apparent within the literature selected. These recurrent
subtopics included a target population of school-age children through older adults, the use of
many of the same interventions throughout the literature, including CBT and SSRIs, and
outcome measurements of reduced anxiety symptoms and decreased GAD severity.
Population. The literature was consistent in including children aged 7 years and above,
adolescents, adults, and older adults 60 years of age and older within the population sample. As
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it was unable to be determined whether children ages 6 years and younger possess the
cognitive maturity to participate in CBT, they were often excluded (James et al., 2015). A
diagnosis of GAD according to DSM criteria was required for inclusion. Comorbidities were often
allowed to enhance generalizability as most patients with GAD have comorbidities. Patients with
active suicidal thoughts were frequently excluded. Patients recruited from outpatient primary
care or family practice settings were included while patients in inpatient settings were excluded.
Interventions. Although there was some variability in the format and delivery method of
CBT utilized among the evidence, there was a consensus that CBT was effective in reducing
anxiety symptoms, associated with long-term maintenance of gains, and acceptable to patients
(Calleo et al., 2013; James et al., 2015; Jayasekara, 2016a; Jayasekara, 2016b; Nguyen, 2017;
Piacentini et al., 2014; Sawyer & Nunez, 2014; Wetherell et al., 2013). Individual CBT
administered via bibliotherapy format using either guided self-help or unguided self-help
methods was found to not only be beneficial for patients with GAD, but also decreased barriers
associated with therapist-administered CBT, increased cost-effectiveness, and improved access
to and feasibility of CBT. CBT was not found to be more effective when delivered by expert
counselors (Freshour et al., 2016). Greater engagement in CBT materials was associated with
better outcomes (Glenn et al., 2013).
The literature also supported use of pharmacotherapy in the form of antidepressants for
treatment of GAD (Campbell, 2016; Kapczinski et al., 2003; Nguyen, 2017; Piacentini, et al.,
2014; Strawn et al., 2017; Wetherell et al., 2013). SSRIs were shown to be most effective, and
many pieces of evidence favored the effectiveness, tolerability, and safety of sertraline in
particular for children, adolescents, and adults. There was support for the effectiveness of
monotherapy CBT and monotherapy SSRI use. However, there was overwhelming support
within the literature that better outcomes were achieved with combination therapy of CBT and
an SSRI (Nguyen, 2017; Piacentini et al., 2014; Wetherell et al., 2013). Sequenced use of an
SSRI followed by CBT was shown to be effective. However, there was greater support for
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tandem CBT and SSRI use, which was linked to more prompt benefit. To support patientcentered care, patient preferences should be considered and discussed.
Outcomes. A significant number of both primary and secondary outcomes utilizing a
multitude of measurement tools were discussed among the included evidence (Calleo et al.,
2013; Campbell, 2016; James et al., 2015; Jayasekara, 2016a; Jayasekara, 2016b; Kapczinski
et al., 2003; Nguyen, 2017; Piacentini et al., 2014; Sawyer & Nunez, 2014; Strawn et al., 2017;
Wetherell et al., 2013). Such primary outcomes often included reduction in anxiety symptoms,
improved GAD severity, response to treatment, and remission. Secondary outcomes measured
often included reduction in depressive symptoms, improvement in worry severity and general
mental health, relapse rates, changes in GAD status, reduced rates of anxiety diagnoses,
diagnostic recovery, improvements in mental health quality of life and sleep, long-term
maintenance gains in worry, acceptability of treatment, reductions in worry, and improved
functioning. Many different scales were discussed to measure these outcomes, including the
HAM-A, PSWQ, GAD-7, PHQ, Mental Wellness Scale, Insomnia Severity Index, Hamilton
Anxiety Scale Revised, CGI-I, CGI-S, GADSS, Beck Anxiety Inventory and Structure Interview
Guide for Hamilton Anxiety Scale, 12-Item Brief Symptom Inventory, Sheehan Disability Scale,
PARS, Children’s Global Assessment Scale, and more. The evidence supported at least a
minimum measurement of outcomes at pre-intervention and post-intervention, but monthly
measurement was preferred.
High levels of evidence supported the use of the Generalized Anxiety Disorder 7-Item
(GAD-7) Scale to measure anxiety symptoms (Andersen et al., 2014). The Clinical Global
Impression-Improvement (CGI-I) Scale was often used within the literature to measure changes
in GAD status, such as “very much improved” (James et al., 2015; Kapczinski et al., 2003).
Much support was present for use of the Patient Health Questionnaire (PHQ-9) to measure
depressive symptoms. Acceptability of treatment was frequency measured within the literature
via the number of participants who dropped out prior to the completion of the study (James et
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al., 2015). Patient satisfaction upon completion of treatment was also measured via Likert scale
format (Calleo et al., 2013).
Best Practice Model Recommendation
The synthesis of critically appraised literature indicated that current best practice for the
treatment of GAD in the target population includes combination therapy with CBT, particularly
individual, self-help via bibliotherapy, and pharmacotherapy, particularly SSRI use. In
accordance with best practice, bibliotherapy in the form of CBT workbooks for GAD was utilized
as well as the prescribing of an SSRI, sertraline with a maximum daily dose of 200 mg, if
acceptable. The Cognitive Behavioral Workbook for Anxiety: A Step-By-Step Program (2014)
written by licensed psychologist, William J. Knaus, EdD, with over forty years of experience in
the treatment of anxiety and depression was utilized for adults 18 years and older. Education
was provided to patients, and close monitoring by providers occurred. Outcomes were
measured at baseline and monthly and included assessment of anxiety symptoms, depressive
symptoms, GAD status, acceptability, and patient satisfaction. This best practice intervention
protocol described was created in a document by the project manager from the best available
evidence and is presented in Appendix K.
How the Best Practice Model will Answer the Clinical Question
Based on this best practice recommendation, a protocol for the treatment of GAD in
adults 18 years of age and older, including treatment with CBT and an SSRI was developed to
answer the clinical question regarding the best treatment for decreasing symptoms of anxiety in
this target population. This best practice model sought to incorporate patient preferences,
effective interventions supported by quality evidence, and organized delivery of feasible and
accessible treatment. The implementation phase took place over a period of 12 weeks. In
accordance with the literature, participants received monthly telephone calls in order to provide
them with support, discuss progress, and measure outcomes. Clear measurements were
obtained prior to implementation of the intervention (baseline) and at monthly increments
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throughout the implementation phase until the completion of the intervention to assess
outcomes. These measurements were interpreted to provide definitive results and conclusions.
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CHAPTER 3
IMPLEMENTATION OF PRACTICE CHANGE
By creating and implementing an evidence-based protocol including SSRI and CBT use
for the best treatment of adult patients with GAD, a worthwhile practice change was initiated.
The project included the project manager’s collaboration with a family practice NP, office
manager, and medical assistants (MAs) who greatly value the significance and intent of the
practice change. A multitude of barriers, including the stigma associated with mental illness,
lack of available and affordable CBT, and inappropriate prescribing and use of medications
contribute to the hindrance of the provision of best practice recommendations in the
management of GAD. This EBP project aimed to help eliminate these barriers, educate
providers about best practice interventions, provide better treatment of patients with GAD,
decrease patient symptoms of GAD through the implementation of best practice, and improve
overall quality of life of affected patients. The purpose of this project was to improve treatment of
GAD by implementing an evidence-based protocol that includes CBT and SSRI use.
Participants and Setting
Conduction of the EBP project took place in a rural family practice office that provides
primary care services to patients across the lifespan. This facility is located in Northwest Indiana
and was the only site of project implementation. A masters-prepared NP who owns the office in
addition to two MAs provide care in this practice. The owner has 15 years of experience as an
NP and extensive experience as a registered nurse. The project manager is not and has never
been employed within this facility, which helped to eliminate the potential for selection bias.
Written permission for the project’s implementation was granted on May 21, 2018 by the
facility’s office manager who clearly stated her belief in the need for this project, its congruence
with the facility’s aims and patient population, its feasibility at this primary care location, and her
staff’s interest and welcoming attitude toward the project.
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Participants who were eligible to participate were recruited during their appointments,
either initial or follow up, at the family practice office from September 25, 2018 to December 6,
2018. The project manager and NP reviewed patient charts to determine initial eligibility based
on diagnosis and age. The patient was seen by the project manager and NP, and a diagnosis of
GAD based upon the DSM-5 criteria was confirmed or negated. Patients without a diagnosis of
GAD were excluded from the project. In addition to a diagnosis of GAD, inclusion criteria for
participation was an age of 18 years or older and the ability to speak and understand spoken
and written English.
The presence of comorbid anxiety and/or mental disorders, including depression, panic
disorder, social anxiety disorder, active substance abuse or dependence, current participation in
CBT outside of the project and/or sessions with a licensed therapist, and the use of other
classes of medications for the treatment of GAD were also allowed, but disclosed. This decision
was made on the premise of many factors. Many patients with GAD have comorbid diagnoses.
There is also a higher likelihood that patients with GAD have substance abuse and dependence
problems. Thus, excluding these patients would limit the sample size, hinder generalizability,
and limit important data that could be gathered among this population. Treatment with SSRI
medication prior to the start of project implementation was also allowed as many patients are
treated with SSRIs for GAD in the clinical setting and as this would still allow for the
implementation of both SSRIs and CBT.
It has become apparent through experience with patients with GAD that despite seeing
therapists and taking medications for anxiety for significant periods of time, symptoms of anxiety
may still persist, and further treatment is necessary. Thus, it is believed that this project had the
potential to benefit these patients by providing them with the additional treatment they needed. It
is illogical, unethical, and unsafe to expect patients, such as those taking benzodiazepines,
SNRIs, and other medications for anxiety, to cease current anxiety medications and change to
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only SSRIs immediately. These patients may benefit from the addition of CBT and SSRI use,
and their exclusion from participation could have significantly limited the sample size.
Additional exclusion criteria included patients with current suicide intent, psychosis,
cognitive impairment, inability to understand and speak English, and current pregnancy. Such
participants were excluded for safety reasons, time constraints, as well as lack of ability to
properly participate in the activities of the project. Patients eligible for participation were
provided a handout explaining the project. This explanation of project document for patients is
presented in Appendix C. After reviewing the information and having any questions answered,
patients decided whether or not they wanted to participate in the project. Upon deciding to
participate in the project, patients were asked to read and sign the informed consent document,
which is displayed in Appendix D. After providing their written informed consent, participants of
the project were asked to complete a demographic questionnaire, which is available in Appendix
E.
Outcomes
Multiple outcomes were selected for measurement in accordance with the literature. The
primary outcome measured was a reduction in anxiety symptoms via the GAD-7 scale.
Secondary outcomes measured included changes in GAD status as measured by the Clinical
Global Impression-Improvement (CGI-I) Scale, a reduction in depressive symptoms as
measured by the Patient Health Questionnaire (PHQ-9), patient satisfaction via the Patient
Satisfaction Questionnaire (PSQ), and acceptability of treatment measured by attrition rates,
including the number of participants who dropped out prior to completion of the entire
implementation phase and outcomes measurement. The GAD-7 and PHQ-9 Scales were
participant-reported scales that were completed via written documentation during each
participant’s initial appointment prior to the implementation of the intervention, and once every
month (every four weeks) during the three-month implementation period of the intervention via
telephone calls with the project manager. During such telephone follow up sessions every four
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weeks, the project manager recorded participant-reported answers for the GAD-7 and PHQ-9.
The CGI-I Scale was completed by the project manager monthly after the initiation of treatment
and was not applicable at baseline. The PSQ and attrition rates were measured upon
completion of the three-month implementation period. The project manager recorded
participant-reported answers for the PSQ during the final telephone follow up session and
calculated the attrition rate as a percentage of the total participant population. The preintervention scores and post-intervention scores were compared to determine whether the
intervention had an effect on GAD symptoms, GAD status of illness, and depressive symptoms.
Scores throughout the implementation phase were also compared to determine the progression
of the effect, including the amount of time necessary for noticeable change to begin.
Intervention
The intervention consisted of the development of a protocol based on best practice
recommendations from good and high quality pieces of evidence. The intervention protocol
included combination CBT bibliotherapy and an SSRI. The literature provided the most support
for the effectiveness of combination therapy, but also provided support for the effectiveness of
CBT monotherapy and SSRI monotherapy. Provides should also consider shared decision
making and patient safety. Because combination therapy was most effective and considered
best practice, it was implemented for this project.
Each participant who consented to participate in the project received combination SSRI
and CBT use. They were provided with self-help CBT bibliotherapy in the form of an ageappropriate CBT workbook for GAD at their initial appointment. The appropriate workbook
administered to adults 18 years of age and older throughout this project was The Cognitive
Behavioral Workbook for Anxiety: A Step-By-Step Program (2014) by licensed psychologist,
William J. Knaus. Participants were provided with written information from the project manager
describing CBT as well as its purpose, including restructuring of thoughts to allow for a more
positive mindset to cope with anxiety. Participants were also provided with further instructions
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regarding assigned workbook chapters and completion due dates. The Cognitive Behavioral
Workbook for Anxiety: A Step-By-Step Program for adults is divided into four parts. Therefore,
based on the 12-week period of the intervention, participants were instructed to complete Part I
by week 3 of the implementation phase, Part II by week 6, Part II by week 9, and Part IV by
week 12. To clarify via example, week 3 of the implementation phase is approximately 3 weeks
after the initiation of the intervention for the participant. Participants had different initiation dates
based on varying appointment dates throughout the implementation phase. In addition to CBT,
participants were prescribed an SSRI at their initial appointment. They were then required to go
to their selected pharmacy to pick up their prescription. They were educated about potential side
effects and adverse effects as well as when and how to take their medication including dosage
and frequency. They were advised to take their medication as directed and to not stop taking it
abruptly. Education was provided to patients verbally as well as via a written document created
by the project manager. This education document is presented in Appendix K.
The participants were informed that follow up would occur every four weeks by
telephone sessions with the project manager. Initially, follow up was planned via either in person
sessions or telephone sessions based on patient preference. However, this was not feasible
within the family practice office due to time and billing constraints per the NP. If patients had
appointments at the office during such designated follow up times, follow up could be obtained
at those appointments rather than by phone call. Patients’ follow up telephone sessions and
workbook homework completion schedule were included along with their education documents.
Follow up telephone sessions included completion of the GAD-7, PHQ-9, CGI-I, and PSQ when
appropriate. The project manager answered any questions that the participants had and
provided support and encouragement to the participants, but the main purpose of the follow up
telephone sessions was outcomes measurement. Additional topics covered included discussion
of patient thoughts, symptoms, functional impairment, and progress as well as inquiry of side
effects of SSRI medication and CBT, and assessment of workbook completion. The participants
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were scheduled for in-person follow up visits with the NP per clinic policy. For example, if SSRIs
were initiated for the first time at the start of project implementation, follow up visits with the NP
occurred after six weeks. If patients had been already been taking SSRIs at the start of project
implementation, follow up visits with the NPs occurred after 3 months.
Planning
A significant amount of time and effort was devoted to the planning phase of this EBP
project to ensure its completeness, strong grounding in evidence, and likelihood of successful
implementation. A need for practice change and best practice recommendations were
determined based on clinical practice experience and a thorough literature search of current
evidence. The project manager met and engaged with key stakeholders, including the family
practice NP, office manager, and MAs, and an overview of the intended project was discussed.
During this time, best practice information was shared with key stakeholders, and they reviewed
the protocol and provided their input for suggestions and changes. Support for the project and
permission to implement the project at the family practice clinic was granted by key
stakeholders in May 2018 at the beginning of project development. Project planning continued
with input from the project manager, key stakeholders, project advisor, program professors,
further research, available interventions, and additional worthwhile sources.
Data
Measures. The primary outcome measured was anxiety symptoms via the GAD-7
Scale, a 7-item self-report scale used to measure anxiety symptom severity in the primary care
setting (Beard & Bjorgvinsson, 2014; VISN 4 Mental Illness Research, Education and Clinical
Center, 2017). This scale involves use of DSM-5 criteria and is an effective tool for assessing
GAD cases. It helps to provide important information regarding the patient’s overall clinical
condition, guide treatment planning, track treatment progress or lack thereof, improve
communication between providers, and provide continuity among various patient care services.
It may be completed in the office by the patient or via the telephone using an interviewer to
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record patient responses. It can be administered via paper and pencil or electronic devices. It is
quick to administer, often taking 2-5 minutes to complete. Questions within the GAD-7 ask
patients to rate the frequency of their anxiety symptoms that they have experienced within the
last 2 weeks via a Likert scale from 0-3 for each of the seven items with 0 indicating not at all, 1
indicating several days, 2 indicating more than half the days, and 3 indicating nearly every day.
Total scores indicate anxiety severity and range from 0-21 with 1-4 indicating minimal
symptoms, 5-9 indicating mild symptoms, 10-14 indicating moderate symptoms, and 15-21
indicating severe symptoms. Thus, greater levels of symptoms are indicated by greater scores.
The GAD-7 is available in Appendix G.
The GAD-7 is considered a valid and reliable tool, and these findings have been
supported by numerous studies (Spitzer, Kroenke, Williams, & Lowe, 2006). There is evidence
to support its good sensitivity (89%) and specificity (82%) in primary care settings for the
assessment of GAD (Williams, 2014). It is also found to have greater sensitivity for identifying
changes in symptom severity as compared to other anxiety scales, such as the Penn State
Worry Questionnaire for Measuring Response. It has excellent internal consistency with a
Cronbach’s alpha of 0.92 and good test-retest reliability with an intraclass correlation of 0.83
(Spitzer et al., 2006). GAD-7 self-reported scores correlate well with clinician-reported scores,
indicating good procedural validity, and with similar anxiety scales, indicating good convergent
validity. Good construct validity is evident as higher scores are associated with higher levels of
functional impairment. Patients with a diagnosis of GAD typically have higher GAD-7 scores as
compared to those without a diagnosis of GAD, also demonstrating good construct validity
(Kertz, Bigda-Peyton, & Bjorgvinsson, 2013).The GAD-7 can also be described as having good
criterion and factorial validity. It is generalizable across the general population with no variation
among gender or age (Lippincott William & Wilkins, 2008). Thus, the GAD-7 is useful among
both men and women as well as younger and older individuals.
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A secondary outcome of depressive symptoms was measured via the PHQ-9, a selfreport tool used for diagnosing depressive disorder as well as determining depressive symptom
severity (Kroenke, Spitzer, & Williams, 2001). There are many variations of the PHQ, but the
PHQ-9 was selected as most appropriate for this project. The PHQ-9 can be administered
quickly, making it desirable in busy clinical practice settings. It consists of nine items that
address DSM-IV criteria for depressive disorder. Items within the PHQ-9 ask patients to rate the
frequency of their depressive symptoms within the last two weeks via a Likert scale from 0-3 for
each of the nine items with 0 indicating not at all, 1 indicating several days, 2 indicating more
than half the days, and 3 indicating nearly every day. Total PHQ-9 scores range from 0-27 with
scores of 0-4 indicating minimal symptoms, 5-9 indicating mild symptoms, 10-14 indicating
moderate symptoms, 15-19 indicating moderately severe symptoms, and 20-27 indicating
severe symptoms. Higher levels of symptoms are indicated by higher scores. The PHQ-9 is
presented in Appendix H.
Like the GAD-7, the PHQ-9 is also a valid and reliable tool (Kroenke et al., 2001). It has
a high sensitivity as well as a high specificity of 88% for the assessment of major depression. A
study implemented in the primary care setting supported that the PHQ-9 has excellent internal
reliability with a Cronbach’s alpha of 0.89 and an excellent test-retest reliability. External validity
is also high as findings from this study were able to be replicated among an obstetricsgynecology patient population. This also supports the generalizability of the PHQ-9 across
various outpatient settings. The PHQ-9 highly correlates with other tools used to measure
depression symptoms. High PHQ-9 scores correlate with worsening functioning among similar
scales, demonstrating high construct validity. The PHQ-9 also has high criterion validity and
high positive predictive value.
The CGI-I scale was utilized to measure another secondary outcome of changes in GAD
status. The CGI is composed of two scales including the CGI-S, which measures changes in
symptom severity, and the CGI-I, which measures improvement or worsening of the disorder as
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aforementioned (Busner & Targum, 2007). Only the CGI-I was used for this project as the
patient reported GAD-7 scores were used to measure symptom severity, and a concise number
of measurements was desired for the project. The CGI-I describes a patient’s change in
disorder status as a result of treatment. It represents the provider’s view of the patient’s disorder
as responses are provided by the provider based on knowledge of the patient’s history,
symptoms, behavior, and functional impact of the disorder. It also provides an overall clinical
interpretation beyond symptomology and displays trends in clinical progress and responses.
The CGI-I helps to identify interventions that have provided benefit to the patient’s condition as
well as identify those that have provided no benefit. The CGI-I can be easily and quickly
administered, often taking approximately 1 minute to complete. It consists of a seven-point scale
ranging from 1) very much improved since the initiation of treatment to 7) very much worse
since the initiation of treatment. Proper use of the CGI-I includes a comparison of the patient’s
current clinical presentation to the patient’s clinical presentation at the baseline visit, or the one
week period prior to initiation of treatment. Thus, changes are not compared from week to week,
but rather always compared to baseline. Important considerations for rating include present
symptoms, frequency of occurrence over the past 7 days, severity of symptoms, and functional
impact of the symptoms on the patient’s life. Information gathered to determine a CGI-I rating
may come from interviews with the patient, chart notes, family members, nurses, school
teachers, caseworkers, significant others, or additional sources. The rating is overall given
based on clinical judgement. Side effects of treatment should not be included in the rating. The
CGI-I is depicted in Appendix I.
The CGI-I is considered a well-established tool for assessing psychiatric disorders,
including anxiety and depression (Busner & Targum, 2007). The CGI-I is often used in FDAregulated and other trials, and its reliability and validity for measuring changes in GAD status
based on treatment response are well-supported (Busner & Targum, 2007; James et al., 2015;
Kapczinski et al., 2003). It correlates well with similar yet more complex tools, including the
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Health of the Nation Outcomes Scales, another clinician-rated scale (Berk, Ng, Dodd, Callaly,
Campbell, Bernardo, Trauer, 2008; Busner & Targum, 2007). There is also a high correlation
among CGI-S scores and CGI-I scores (Berk et al., 2008). Evidence has supported that the
CGI-I is sensitive to change, valid among diverse groups, and reliable when administered
appropriately by clinicians.
Patient satisfaction of the self-administered CBT utilized within this project was
measured via the Patient Satisfaction Questionnaire (PSQ), a six-item questionnaire developed
by the project manager. It addresses important aspects of patient satisfaction including
convenience, ease of use, efficacy, overall satisfaction, worthiness, and engagement. As this is
a newly developed tool, there is no information regarding its validity and reliability. The PSQ is
available in Appendix J.
Acceptability of treatment was measured via the number of participants who dropped out
of the project prior to completion or who did not complete outcome measurements, also known
as the attrition rate. This was calculated as a total percentage of participants.
Collection. Data collection took place both in the clinical setting and via telephone by
the project manager from September 25, 2018 to February 28, 2018. It commenced at the initial
patient appointment when the patient signed consent and received interventions of combined
CBT and SSRI therapy. Data collection included paper copies of instruments utilized for
outcomes measurement, including the GAD-7, PHQ-9, CGI-I, and PSQ. During telephone follow
up to assess outcomes, patient responses were recorded via paper copies of the scales by the
project manager. Data collection was completed at the final follow up after the patient received
the intervention for a duration of 12 weeks, or 3 months. As continuous recruitment took place,
this completion date varied among participants, but was consistently 12 weeks after treatment
commencement for each individual.
Patient confidentiality was protected by coding. Each participant was assigned a code
number at random determined by drawing a number from a bag. The code was recorded on all
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participant data collected in a designated area of the top right corner of each document
including the demographic form, GAD-7, PHQ-9, CGI-I, and PSQ. The code number served as
the method by which to identify the patient and was used to compare pre-intervention and postintervention data. A list of patient names with corresponding codes was kept in a locked box
with access to the project manager only. An example of this code sheet is available in Appendix
F. The project manager placed data collected in the clinical setting, including patient GAD-7,
PHQ-9, and PSQ scales and provider CGI-I scales, with code numbers into a folder clearly
marked with the project title located in an authorized personnel only area. The multiple
documents for each patient were paper clipped together for organizational purposes and to
ensure that each patient’s data gathered remained together. Telephone calls to patients were
made by the project manager in the safety of the project manager’s home when no one else
was home or in a private room with the door closed to ensure patient confidentiality. Data
collected during this time was stored in a folder clearly marked with the project title located in a
private and safe area of the project manager’s home with access only to the project manager.
Management and analysis. The project manager accessed the designated folder in
order to perform data analysis. Patient data with code numbers only was taken from the folder
at the office to the project manager’s home while the code list remained safely stored in the
locked box aforementioned. Patient names and other identifying information were never
disclosed, and only code numbers were referenced in discussions regarding the project.
Following completion of the project, including data analysis, the coding list was destroyed. Preintervention and post-intervention data were analyzed via a paired t-test. Demographic data
were also analyzed via Chi-square. Software utilized to run data analysis was IBM SPSS
Statistics Base 24.
Protection of Human Subjects
Protection of human subjects was upheld throughout the project. The project manager
was properly educated about protection of human subjects and completed an ethics course
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within the DNP curriculum during the fall semester of 2017 as well as an online training course
through the National Institutes of Health (NIH) titled “Protecting Human Research Participants”
in April 2018. A certificate of completion of the NIH course is available in Appendix A. The
project manager applied for approval from Valparaiso University’s Institutional Review Board
(IRB) by mailing in a detailed application explaining the project on August 12, 2018.
Suggestions for revisions to the project were provided by the IRB, and such revisions within the
project were made and made known to the IRB. Approval for the project was obtained by
Valparaiso University’s IRB on September 21, 2018. Consent from adult participants was
obtained. A thorough explanation of the project, including risks, benefits, and time commitment,
was provided to potential participants prior to obtaining consent. Questions from potential
participants were thoroughly answered. Potential participants were also informed that patient
confidentially would be upheld, participation is voluntary, and participants who do not want to
participate will still receive the standard of care. Patients were not coerced, nor pressured into
participating. Participants that consented were informed that they could withdraw from the
project at any time without retribution. Data were kept in a secure and private location, and the
coding list with patient names was destroyed by shredding upon project completion.
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CHAPTER 4
FINDINGS
The purpose of this EBP project was to implement an evidence-based protocol involving
combination therapy with CBT and SSRI medication in order to improve patient outcomes
through more accessible, standardized treatment of GAD. Patient outcomes, including anxiety
and depression symptoms, were measured via the GAD-7 Scale and PHQ-9 respectively in
order to compare baseline scores to follow up scores over a period of 12 weeks. Additional
outcomes, including change in GAD status, patient acceptability, and patient satisfaction were
also measured. Both participant demographic characteristics and outcomes were analyzed.
Participants
Size. Upon commencement of project implementation, 20 eligible participants consented
to participate, completed the demographic form, and completed self-report baseline measures
of the GAD-7 Scale and PHQ-9. SSRI medication was either initiated or continued at this time,
and self-administered CBT was initiated in accordance with the developed protocol. Participants
agreed to independently administer their SSRI medication as directed and complete the CBT
workbook independently as instructed. In total, 12 participants completed follow up at week 4 as
well as at week 8 for an attrition rate of 40% at each of these times of measurement. A total
number of 10 participants completed the final follow up at week 12 yielding a final attrition rate
of 50%.
Characteristics. Demographic characteristics for participants (n=10) were analyzed
using descriptive statistics. Pre-intervention demographic data for the initial 20 participants that
enrolled in the project and completed baseline data were collected. As outcomes were analyzed
for only the 10 participants who completed the project in full, including baseline, week 4, week 8,
and week 12 data, demographic data for only the remaining 10 participants were analyzed for
consistency. Analysis of the characteristic of age was reported via the mean and range while
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the remaining demographic characteristics were reported via frequencies. Participant ages
ranged from 18 to 75 years with a mean age of 49.60 years (SD = 17.86). The majority of
participants were female (70%) (Figure 4.1), Caucasian (100%) (Figure 4.2), and married (60%)
(Figure 4.3). The majority also had private insurance (70%) (Figure 4.4), held a high school
diploma or GED as their highest level of education (60%) (Figure 4.5), were employed full time
(30%) (Figure 4.6), made an annual household income of over $100,000 (30%) (Figure 4.7).
Descriptive statistics regarding demographic data are presented in Table 4.1.
Intervention Information. As aforementioned, the intervention protocol consisted of
combination therapy of an SSRI antidepressant medication with self-administered CBT in the
form of a workbook. Sertraline was recommended in accordance with the literature based on its
safety and tolerability, but the prescribing of any SSRI was acceptable within this project. Of the
10 participants who completed all follow ups throughout the 12 weeks of project implementation,
60% were prescribed sertraline, 20% were prescribed escitalopram, 10% were prescribed
fluoxetine, and 10% were prescribed paroxetine. All participants (100%) within the remaining
sample of 10 participants had already been taking an SSRI prior to baseline assessment. A total
of 95% of the original sample of 20 participants had been taking an SSRI prior to baseline
assessment while 5% of original sample started taking an SSRI immediately after baseline
assessment. Thus, CBT was added immediately after the baseline assessment in order to fulfill
the protocol of combination therapy. As it would have been unethical and unsafe to discontinue
as needed benzodiazepines immediately at the baseline appointment, participants who were
taking or began taking an SSRI medication were eligible even if they also had been prescribed
an as needed benzodiazepine. A total of 10% of the remaining 10 participants at week 12 had
been taking an as needed benzodiazepine.
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Table 4.1
Demographic Characteristics

Demographic

Number of participants

Frequency (%)

10 (100%)

Age
Mean/SD
Range

49.60/17.86
18 - 75

Gender
Male

3 (30)

Female

7(70)

Race
Caucasian
Native American

10 (100)
0 (0)

Marital status
Single

2 (20)

Married

6 (60)

Divorced

1 (10)

Widowed

1 (10)

Health insurance
No insurance

1 (10)

Medicare

2 (20)

Medicaid

0 (0)

Private

7 (70)
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Highest level of education
High school/GED

6 (60)

Some college

2 (20)

2-year degree

0 (0)

4-year degree

2 (20)

Employment status
Full time

3 (30)

Part time

0 (0)

Student

1 (10)

Retired

2 (20)

Homemaker

1 (10)

Self-employed

1 (10)

Unable to work

2 (20)

Annual household income
Less than $20,000

2 (20)

$20,000 - $34,999

1 (10)

$35,000 - $49,999

2 (20)

$50,000 - $74,999

0 (0)

$75,000 - $99,999

2 (20)

Over $100,000

3 (30)

GED = General Education Diploma; SD = Standard Deviation
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Figure 4.1. Gender Pie Chart

Figure 4.2. Race Pie Chart
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Figure 4.3. Marital Status Pie Chart

Figure 4.4. Health Insurance Pie Chart
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Figure 4.5. Highest Level of Education Pie Chart

Figure 4.6. Employment Status Pie Chart

101

GENERALIZED ANXIETY DISORDER PROTOCOL

Figure 4.7. Annual Household Income Pie Chart
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Changes in Outcomes
This EBP project addressed the following PICOT question, “Among adults presenting
with generalized anxiety disorder (GAD) in the family practice setting (P), does the introduction
of an intervention protocol to treat patients with a selective serotonin reuptake inhibitor (SSRI)
and self-administered cognitive behavioral therapy (CBT) via bibliotherapy (I) compared to the
current practice of no protocol (C), improve GAD symptoms as measured by patient-reported
scores on the Generalized Anxiety Disorder 7-item (GAD-7) scale (O) over a 12-week period
(T)?” The primary outcome of anxiety symptoms was measured using the GAD-7 Scale at
baseline, 4-weeks, 8-weeks, and 12-weeks post-intervention. Secondary outcomes, including
depression symptoms via the PHQ-9, change in GAD status via the CGI-I, and patient
satisfaction were also measured.
Statistical testing. Data were entered into the Statistical Package for Social Sciences
(SPSS) Version 25 for analysis. The text titled How to use SPSS: A step-by-step guide to
analysis and interpretation by Cronk (2017) was utilized to guide the process of analysis and
interpretation. A repeated measures ANOVA was used for comparison of anxiety symptoms and
depression symptoms at four different times, including baseline, 4-weeks post-intervention,
which is also referred to as week 4, 8-weeks post-intervention, which is also referred to as week
8, and 12-weeks post intervention, which is also referred to as week 12. A repeated measures
ANOVA was also used to analyze changes in GAD status, which was measured at three
different times, including week 4, week 8, and week 12. Statistical significance for all analyses
was determined as p < 0.05. Patient satisfaction data were measured via the PSQ at 12-weeks
post-intervention only and analyzed via descriptive statistics. Patient acceptability data were
measured via attrition rate and also analyzed via descriptive statistics.
Anxiety symptoms. Anxiety symptoms were scored using the GAD-7, which asked
participants to rate 7 items, or anxiety-related problems, on a Likert scale indicating their
frequency within the last 2 weeks of 0 (not at all), 1 (several days), 2 (more than half the days),
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or 3 (nearly every day). These items were tallied into a total score ranging from 0 to 21 with
higher scores consistent with higher levels of anxiety severity. Scores 0-4 indicate minimal
symptoms, scores 5-9 indicate mild symptoms, scores 10-14 indicate moderate symptoms, and
scores 15-21 indicate severe symptoms. A one-way repeated-measures ANOVA was calculated
comparing the exam scores of participants at four different times: baseline, week 4, week 8, and
week 12. No significant effect was found (F(3,27) = 1.94, p > 0.05). No significant difference
exists among baseline (M = 4.20, SD = 4.32), week 4 (M = 3.40, SD = 2.72), week 8 (M = 2.40,
SD = 3.13), and week 12 (M = 1.60, SD = 2.12) means. Repeated measures ANOVA data with
means and standard deviations for anxiety symptoms are presented in Table 4.2. A visual
representation of the decreasing trend in mean GAD-7 scores over 12 weeks indicating
improvement in anxiety symptom severity is depicted in a line graph in Figure 4.8.
In addition to the one-way repeated-measures ANOVAs that were calculated for total
GAD-7 scores, one-way repeated-measures ANOVAs were also calculated for each individual
item within the GAD-7 Scale. No significant difference was found among any of the individual
items, including Question 1 (F(3,27) = 0.669, p > 0.05), Question 2 (F(3,27) = 0.588, p > 0.05),
Question 3 (F(3,27) = 0.355, p > 0.05), Question 4 (F(3,27) = 1.736, p > 0.05), Question 5
(F(3,27) = 1.919, p > 0.05), Question 6 (F(3,27) = 2.197, p > 0.05), Question 7 (F(3,27) = 1.090,
p > 0.05), or Question 8 (F(3,27) = 1.636, p > 0.05).
Depression symptoms. Similar to anxiety symptoms, depression symptoms were
scored using the PHQ-9, which asked participants to rate 9 items, or depression-related
problems, on a Likert scale indicating their frequency within the last 2 weeks of 0 (not at all), 1
(several days), 2 (more than half the days), or 3 (nearly every day). These items were tallied
into a total score ranging from 0 to 27 with higher scores consistent with higher levels of
depression severity. Scores 0-4 indicate minimal symptoms, scores 5-9 indicate mild symptoms,
scores 10-14 indicate moderate symptoms, scores 15-19 indicate moderately severe symptoms,
and scores 20-27 indicate severe symptoms. A one-way repeated measures ANOVA was
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calculated comparing the PHQ-9 scores of participants at four different times: baseline, 4-weeks
post-intervention, 8-weeks post-intervention, and 12-weeks post-intervention. A significant effect
was found (F(3,27) = 4.34, p < 0.05). Repeated measures ANOVA data with means and
standard deviations for depression symptoms are presented in Table 4.2. Follow-up protected t
tests revealed scores decreased significantly from baseline (M = 4.80, SD = 3.58) to week 8 (M
= 2.90, SD = 2.02), baseline to week 12 (M = 1.90, SD = 2.81), week 4 (M = 3.90, SD = 2.77) to
week 8, and week 4 to week 12. Such post hoc paired t test data for depression symptoms are
displayed in Table 4.3. No significant difference exists among baseline and week 4 means or
week 8 and week 12 means. A visual representation of the decreasing trend in mean PHQ-9
scores over 12 weeks indicating improvement in depression symptom severity is depicted in a
line graph in Figure 4.8.
In addition to the one-way repeated-measures ANOVAs that were calculated for total
PHQ-9 scores, one-way repeated-measures ANOVAs were also calculated for each individual
item within the PHQ-9. No significant difference was found among any of the individual items,
including Question 1 (F(3,27) = 1.615, p > 0.05), Question 2 (F(3,27) = 0.915, p > 0.05),
Question 3 (F(3,27) = 1.761, p > 0.05), Question 4 (F(3,27) = 2.374, p > 0.05), Question 5
(F(3,27) = 2.656, p > 0.05), Question 6 (F(3,27) = 0.310, p > 0.05), Question 7 (F(3,27) = 2.769,
p > 0.05), Question 8 (F(3,27) = 1.976, p > 0.05), Question 9 (F(3,27) = no change), or Question
10 (F(3,27) = 0.783, p > 0.05).
Change in GAD status. Change in GAD status from baseline was determined using the
CGI-I scale and scored by the project manager as 1 (very much improved), 2 (much improved),
3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), or 7 (very much
worse). A one-way repeated measures ANOVA was calculated comparing CGI-I scores of
participants at three different times: week 4, week 8, and week 12. No significant effect was
found (F(2, 18) = 3.05, p > 0.05). No significant different exists among week 4 (M = 3.60, SD =
1.07), week 8 (M = 2.80, SD = 1.40), and week 12 (M = 2.30, SD = 1.57) means. Repeated

GENERALIZED ANXIETY DISORDER PROTOCOL

106

measures ANOVA data with means and standard deviations for change in GAD status are
presented in Table 4.2.
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Table 4.2
Repeated Measures ANOVAs with Means and Standard Deviations (n = 10)
Variable

Mean

SD

F

p

4.20
3.40
2.40
1.60

4.32
2.72
3.13
2.12

1.94

0.146

4.80
3.90
2.90
1.90

3.58
2.77
2.02
2.81

4.34

0.013*

3.60
2.80
2.30

1.07
1.40
1.57

3.05

0.072

Anxiety
symptoms
Baseline
Week 4
Week 8
Week 12

Depression
symptoms
Baseline
Week 4
Week 8
Week 12

Change in GAD
status
Week 4
Week 8
Week 12

* = Denotes statistical significance
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Table 4.3
PHQ-9 Post Hoc Paired t Tests (n = 10)
Variable

Mean

SD

t

df

p

Difference

Depression
symptoms
Baseline –
Week 4

1.33

3.80

1.22

11

0.249

Baseline –
Week 8

1.83

2.79

2.28

11

0.044*

Baseline –
Week 12

2.90

3.93

2.33

9

0.044*

Week 4 –
Week 8

1.27

1.56

2.71

10

0.022*

Week 4 –
Week 12

2.00

2.05

3.08

9

0.013*

Week 8 –
Week 12

1.00

1.70

1.86

9

0.096

* = Denotes statistical significance
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Figure 4.8. Improvement in Mean Anxiety (GAD-7) and Depression (PHQ-9) Symptom Severity
with Combination Therapy (n = 10)
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Acceptability. Patient acceptability of the combined SSRI and CBT protocol was
measured via the attrition rate from pre- to post-intervention, or baseline to week 12. As
aforementioned, 20 participants (N = 20) consented to project enrollment and completed
baseline measurements. At week 4, the participant response rate was 60% (n = 12) with an
attrition rate of 40%. At week 8, the participant response rate and attrition rate did not change
from the aforementioned values of week 4. At week 12, the participant response rate decreased
to 50% (n = 10) while the attrition rate rose to 50%.
Patient satisfaction. Patient satisfaction scores were measured at week 12 using the
PSQ and analyzed using descriptive statistics, including frequency, mean, and range. One
participant declined to complete the PSQ, and thus, nine remaining participants completed the
PSQ in total. The majority of participants rated use of the CBT workbook as very convenient
(33.3%) (Figure 4.9), easy (44.4%) (Figure 4.10), and very worthwhile (55.6%) (Figure 4.11).
The majority also reported their satisfaction with the CBT workbook’s impact on their anxiety
symptoms as a tie between satisfied (44.4%) and very satisfied (44.4%) (Figure 4.12) with an
overall satisfaction level with the CBT workbook of satisfied (44.4%) (Figure 4.13). Time spent
using the CBT workbook per week ranged from 15 minutes to 30 hours as reported by
participants. The mean amount of time spent using the CBT workbook per week was 301.11
minutes, or approximately 5 hours, with a standard deviation of 576.21 minutes, or
approximately 9.5 hours.
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Figure 4.9. Patient Satisfaction Questionnaire Convenience Pie Chart

Figure 4.10. Patient Satisfaction Questionnaire Ease of Use Pie Chart
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Figure 4.11. Patient Satisfaction Questionnaire Worthwhile Pie Chart

Figure 4.12. Patient Satisfaction Questionnaire Satisfaction with Impact on Anxiety Symptoms
Pie Chart
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Figure 4.13. Patient Satisfaction Questionnaire Satisfaction Overall
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Significance. To summarize, no statistical significance was achieved for evaluation the
primary outcome of anxiety symptoms via the GAD-7 Scale (F(3,27) = 1.94, p > 0.05) nor for
evaluation of the secondary outcome of change in GAD status via the CGI-I Scale (F(2, 18) =
3.05, p > 0.05). Statistical significance was achieved for evaluation of the secondary outcome of
depression symptoms via the PHQ-9 (F(3,27) = 4.34, p < 0.05).
Reliability and validity. The reliability and validity of each tool utilized to evaluate
outcomes was assessed. The GAD-7 was utilized to evaluate anxiety symptoms. There is much
evidence to support the GAD-7’s high reliability and validity (Spitzer et al., 2006). With a high
Cronbach’s alpha of 0.92, the GAD-7 demonstrates excellent internal consistency. It is also
noted to have good sensitivity (89%) and specificity (82%), good construct and convergent
validity, and good criterion and factorial validity (Kertz et al., 2013; Spitzer et al, 2006; Williams,
2014). A Cronbach’s alpha regarding the GAD-7 Scale relative to this project specifically was
calculated using SPSS software and found to be 0.87. This is similar to that reported within the
literature, and thus, high reliability of the GAD-7 was demonstrated within this project.
Similarly, the PHQ-9, used to evaluate anxiety symptoms, also demonstrates high
reliability and validity within the literature (Kroenke et al., 2001). It’s excellent internal reliability is
supported with a Cronbach’s alpha of 0.89 reported within the literature. The PHQ-9 also has
excellent test-retest reliability, high sensitivity and specificity, and high construct, criterion, and
external validity. Specifically regarding use of the PHQ-9 within this project, a Cronbach’s alpha
was calculated as 0.90. Thus, again, excellent internal consistency and reliability is supported.
The CGI-I, which was utilized to evaluate GAD status, also boasts high reliability and
validity supported by evidence (Busner & Targum, 2007). It correlates well with other tools and
has high sensitivity (Berk et al., 2008). It has high validity and is able to be used among diverse
groups. It has specific instructions to promote its appropriate use and high reliability.
The PSQ was developed by the patient manager to evaluate patient satisfaction with
self-administered CBT. Thus, validity cannot be established for the PSQ as it has not been
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reviewed by experts. Reliability tests were performed within SPSS in order to determine the
PSQ’s reliability. A Cronbach’s alpha was calculated as 0.84. Thus, this supports good internal
consistency and high reliability of the PSQ.
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CHAPTER 5
DISCUSSION
This EBP project served the purpose of answering the following PICOT question,
“Among adults presenting with generalized anxiety disorder (GAD) in the family practice setting
(P), does the introduction of an intervention protocol to treat patients with a selective serotonin
reuptake inhibitor (SSRI) and self-administered cognitive behavioral therapy (CBT) via
bibliotherapy (I) compared to the current practice of no protocol (C), improve GAD symptoms as
measured by patient-reported scores on the Generalized Anxiety Disorder 7-item (GAD-7) scale
(O) over a 12-week period (T)?” The project examined the impact of the combination therapy
protocol involving simultaneous self-administered CBT and SSRI antidepressant medication use
on decreasing anxiety and depression symptoms, improving GAD status, and demonstrating
patient acceptability and satisfaction among adults presenting to the family practice setting with
a diagnosis of GAD. This chapter will detail an explanation and interpretation of project findings
as well as an evaluation of the applicability of the theoretical framework and EBP model used to
guide the project. Project strengths and limitations will be explored as will consideration of
implications for future practice, theory, research, and education.
Explanation of Findings
Project findings support the effectiveness of combination therapy regarding CBT and
SSRIs for the treatment of GAD among adults. Such results were consistent with current
literature overall. Participant findings, including sample size, demographic characteristics, and
intervention information, will be discussed. Outcomes, including anxiety symptoms, depression
symptoms, change in GAD status, acceptability, patient satisfaction, and incidental qualitative
data, will also be explained.
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Participant Findings
Based on information reported within high quality, current literature, including the high
prevalence of GAD and larger sample sizes reported in studies within the literature review, a
larger participant sample size was expected. The sample size of this project was limited by
several factors that will be further discussed later on within this chapter. The sample population
was predominantly female (70%) within this project. This was an expected finding as women are
affected by GAD twice as often as men (Edmund & Sheppard, 2018). The majority of
participants earned an annual household income of over $100,000, which can be considered of
high socioeconomic status. Although the link between socioeconomic status and rates of GAD
is conflicting (McBride, 2015), the results of this project support that high socioeconomic status
could be linked to higher rates of GAD as compared with those of low socioeconomic status. As
the majority of participants were already taking an SSRI prior to baseline, this project allowed
the effects of the addition of self-administered CBT to be assessed and visible. The majority of
participants who completed follow up in its entirety were prescribed sertraline (60%), which was
recommended in the literature. Thus, this added strength to the project and also demonstrated
that patient safety, medication tolerability, and the best interests of participants were priorities.
A small number of participants had been prescribed an as needed benzodiazepine prior
to baseline and had this available for administration during the implantation phase of this
project. As aforementioned, it was decided that it would be unethical and unsafe to immediately
discontinue the benzodiazepine at baseline. Excluding these participants, those taking an SSRI
and benzodiazepine, from the project was decided against as it was determined that these
participants could also significantly benefit from the intervention. It was also hoped that the
benzodiazepine could eventually be discontinued due to the improvement from combination
therapy. As such a minimal number of the remaining participants were taking an as needed
benzodiazepine (10%), it is not thought that this had an effect on results. It was also not
confirmed as to how often, if at all, the participants were taking benzodiazepines during the
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implementation phase. It would have been helpful for the project manager to have asked
participants this information during follow up phone calls, but due to human error, this was not
done.
Anxiety Symptoms
Although a statistically significant decrease in anxiety symptoms was not achieved upon
project completion, mean GAD-7 scores did decrease every 4 weeks of project implementation.
Therefore, lack of statistical significance does not negate the positive impact of combination
therapy on anxiety symptoms and may be accounted for by project limitations. Mean GAD-7
scores indicating anxiety symptom severity among the 10 participants who completed final
follow up steadily decreased with mean scores of 4.20 at baseline, 3.40 at week 4, 2.40 at week
8, and 1.60 at week 12. Patient-reported GAD-7 Scale scores range from 0 - 21 with scores of 0
- 4 indicating minimal symptom severity, 5 - 9 indicating mild symptom severity, 10 - 14
indicating moderate symptom severity, and 15 - 21 indicating severe symptom severity. Thus,
mean scores were decreased from levels of symptom severity indicating minimal to mild
symptom severity at baseline to minimal symptom severity by week 12. This indicated that
anxiety symptoms decreased as a result of combination therapy. As these 10 participants had
been taking SSRIs prior to project implementation, this specifically indicated that the addition of
CBT yielded a positive effect in the form of a decrease in anxiety symptoms. Participants’ use of
SSRI medication prior to the implementation of the project may explain why participants’
symptom severity was minimal to mild when beginning the project, which did not allow for large
scale improvement. Also, it is important to note that many of the 10 participants who did not
follow up until project completion and were not included in data analysis rated high GAD-7
scores at baseline that indicated severe symptom severity. Therefore, results of this project in
no way indicate that the impact of GAD anxiety symptomology is less than what is described by
current literature. It was surprising that a statistically significant decrease in GAD-7 scores was
not achieved as often was reported within current literature. However, this was likely related to
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many limitations of the study. The small patient sample and attrition was unable to account for
the extreme symptom severity and debilitating potential of GAD, yet many participants reported
that their anxiety symptoms prior to project completion interfered with their lives and made it
difficult to work, take care of things at home, or get along with other people. Therefore, the
decreased anxiety symptoms displayed by steadily reduced mean GAD-7 scores over 12 weeks
of project implementation, although not statistically significant, were of great benefit to
participants.
Depression Symptoms
A statistically significant decrease in depression symptoms was achieved upon
completion of project implementation at week 12. Mean PHQ-9 scores indicating depression
symptom severity among the 10 participants who completed final follow up steadily decreased
with mean scores of 4.80 at baseline, 3.90 at week 4, 2.90 at week 8, and 1.90 at week 12.
Patient-reported PHQ-9 scores range from 0 - 27 with scores of 0 - 4 indicating minimal
symptom severity, 5 - 9 indicating mild symptom severity, 10 - 14 indicating moderate symptom
severity, 15 - 19 indicating moderately severe symptom severity, and 20 - 27 indicating severe
symptom severity. Thus, mean scores were decreased from levels of depression symptom
severity indicating minimal to mild symptom severity at baseline to minimal symptom severity by
week 12. Thus, results indicate that depression symptoms significantly decreased as a result of
combination therapy with CBT and SSRIs. Like anxiety symptoms, the low level of depression
symptoms at baseline may again be accounted for as the remaining 10 participants were all
taking SSRI medication prior to the start of project implementation. The statistically significant
decrease in depression symptoms achieved by completion of project implementation supports
the significant benefit of combination therapy with self-administered CBT and SSRI medication
for the treatment of adults with GAD. Such results also demonstrate the strong link between
depression and anxiety that was addressed in the literature and the need to address not only
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anxiety symptoms, but also depression symptoms, in patients presenting with GAD at every
visit.
Change in GAD Status
In congruence with anxiety symptoms, change in GAD status did not achieve statistical
significance. Again, the positive impact of combination therapy on change in GAD status is not
negated by lack of significance as the 10 remaining participants who completed week 12 follow
up demonstrated an improvement in GAD status. It was surprising that statistical significance
was not achieved in accordance with current literature. However, again, statistical significant
within this project likely would have been achieved had it not been for the limitations of the
project. This level of improvement or worsening of disease course was rated by the project
manager using the CGI-I Scale with a score of 1 indicating very much improved, 2 indicating
much improved, 3 indicating minimally improved, 4 indicating no change, 5 indicating minimally
worse, 6 indicating much worse, and 7 indicating very much worse. The CGI-I Scale was utilized
appropriately by always comparing change in GAD status to baseline GAD status. Mean CGI-I
scores decreased when measured every 4 weeks, indicating improvement in GAD status. Mean
scores decreased from 3.90 at week 4, 2.90 at week 8, and 1.90 at week 12. Thus, mean
change in GAD status improved from no change/minimally improved at week 4 to much
improved/very much improved at week 12. Therefore, project findings support that combination
therapy with SSRIs and CBT improves GAD status.
Acceptability
Participant acceptance of the combination therapy, particularly the addition of CBT, was
determined by the rate of attrition, or the number of participants lost to follow up. Attrition rates
were 40% at week 4, 40% at week 8, and 50% at week 12. Typically, attrition rates of 50% and
lower are considered acceptably low while attrition rates greater than 50% are considered high
(Deke, Sama-Miller, & Hershey, 2015). Thus, the attrition rates for this project are considered
low, indicating high levels of acceptability among participants regarding the intervention. The
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attrition can likely be explained by difficulties in reaching participants via phone, full or
nonfunctioning voicemail boxes, and busy participant schedules limiting availability for follow up.
The low attrition rate was expected and similar to that reported within high quality literature.
Patient Satisfaction
Patient satisfaction regarding CBT was rated by participant responses to the PSQ
created by the project manager. Findings indicated that participants were satisfied with the CBT
workbook, which coincides with high patient satisfaction yielded within the literature. The
majority of participants found the CBT workbook very convenient to use, easy to use, and very
worthwhile to use. In addition, the majority of participants were satisfied or very satisfied with the
impact that use of the CBT workbook had on their anxiety symptoms and satisfied with use of
the CBT workbook overall. There were large variations reported regarding the amount of time
that participants spent utilizing the CBT workbook per week with a wide range of 15 minutes to
30 hours per week. Participants spent an average of 5 hours per week utilizing the CBT
workbook. The most common response provided regarding approximate time spent utilizing the
CBT workbook per week was 1 hour. Thus, some participants spent a brief time utilizing the
CBT workbook per week while others spent extensive time utilizing the CBT workbook per
week.
Qualitative Data
During initial in-person patient visits at the clinic at baseline as well as follow-up
telephone encounters with the project manager at week 4, week 8, and week 12, participants
expressed comments regarding use of such combined CBT and SSRI intervention. These
patient comments are useful in depicting patients’ unique experiences, thoughts, and beliefs
with combination therapy. Several common themes emerged from this incidental qualitative
data. Such themes explore effectiveness, understanding, side effects, endorsement,
accessibility/ease of transport of self-administered CBT, applicability of self-administered CBT
components, and busy lifestyle. These themes will be discussed in further detail as follows.
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One common theme was that self-administered CBT and SSRIs were effective in
helping participants feel better by minimizing symptoms associated with GAD. For example,
participants noted positive changes with comments including, “I feel like the book and
medication are helping a lot. I notice a big difference from my last visit,” “The CBT is helping.
I’ve noticed a big change in myself. The [SSRI] also helps, and I notice when I don’t take it
because I feel more anxious,” and “I like to read the book. It is very beneficial. I feel better with
the [SSRI], and I feel the book helps, too.” Participants also reported improved productivity,
increased levels of patience, and decreased depression symptoms. One patient expressed, “I
accomplish more things now. I am feeling better from the start from talking to you and reading
the book. I reevaluate my thoughts. I feel good.” Another stated, “I can see the difference,
especially when it comes to irritation. I have more patience.” A third mentioned, “The [SSRI]
has changed me around a lot and made me less depressed.”
As a second commonly identified theme, self-administered CBT provided useful
education to participants and increased their understanding of GAD and coping skills.
Participants were quoted saying, “As I read more of the workbook, I understand generalized
anxiety disorder better.” Additional noteworthy patient reports included, “The book has helped
me understand a lot more and puts things into perspective,” “I feel like the book is teaching me
things I didn’t know and didn’t realize until now,” “It tells me things that I can do when my anxiety
comes on,” and “Now, I’m able to work through my anxiety. The workbook taught me things that
I wasn’t fully aware of and didn’t know how to do before.” Thus, participants were able to make
important realizations through use of self-administered CBT and utilize this learned information
to manage their anxiety and depression symptoms. Another participant stated, “I learned
everything I wanted to know from the workbook. It’s therapeutic and makes you think” while
another expressed, “I’m more conscious of things now because of the workbook.”
Another theme supported that participants experienced minimal to no side effects
associated with self-administered CBT and SSRIs. One participant reported, “I was getting
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sweaty palms from the [SSRI], but that’s the only side effect I’ve noticed. [The NP] told me to
take it at night instead of in the morning to help with this.” Another mentioned, “I haven’t had any
side effects.”
It was another commonly identified theme that participants endorsed self-administered
CBT through expressions of satisfaction, enjoyment, desire for earlier use, plans to continue
use, and plans to share self-administered CBT with others. Satisfaction and enjoyment were
supported by participant comments, including “I’m so glad you offered this to me,” “I’ve been
using the workbook more, and it’s helped a lot with my symptoms. I’m very satisfied,” “I like the
CBT workbook and find it useful. I am pleasantly surprised how much the book has helped. It’s
like a breath of fresh air. My symptoms are not as frequent,” and “I notice an improvement from
a month ago. I find it interesting. It’s been a while since I had to read a book and study. I enjoy
it.” Others shared their desire for earlier self-administered CBT use and intent to continue use
with, “I wish I’d had this book a long time ago. So is this all? Are we done? Because I want to
keep doing this. I plan to continue using this because I really like it. It was fun. Thank you for
this,” as well as “ I’m very excited about the workbook. This is great! I wish I had this when I
started the medication.” Many participants were excited to share CBT to allow others to benefit
from it as exemplified by the following quotations, “I was telling my boss about it and even she is
interested in the CBT workbook now,” and “My daughter also has anxiety, and I am going to
have her do this with me.” At the beginning of the project, one participant expressed, “I am
excited to do this workbook. I work as a nurse at an addiction center and am excited to use this
and learn from it in order to help my patients. This would be great for a lot of them,” and at the
end of week 12 follow up mentioned, “I have been telling the counselors at work about this CBT
and plan to share what I have learned with a class I teach.”
An additional common theme attested that the self-administered CBT was easy to keep
nearby the participant and to transport. For example, one participant reported, “I take the book
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with me wherever I go, including work and to my mother-in-law’s house.” Another noted, “I’ve
been keeping the book by my chair.”
Several participants expressed that some information within the CBT workbook applied
to them greatly while other information did not apply to them at all. A participant was quoted as
reporting, “Some of the things in this book don’t apply to me, like anxiety around crowds, but I
will keep reading it” while another stated, “The chapter about procrastination hit home and
helped me. I often procrastinate, which causes me more anxiety.” Another participant felt a
combination of these opinions with, “Some parts of the CBT workbook don’t pertain to me, but
some are spot on.”
Finally, busy lifestyles and stressful life events making it difficult to use self-administered
CBT was a common theme. This also contributed to difficulty achieving follow up and the
resulting attrition throughout the project. For example, a participant expressed, “I haven’t done
the CBT book yet because things have been so crazy since my accident, but I will get to it.”
Similarly, another patient reported, “I had major surgery recently, and I need to focus on
physical therapy so I have not used the book much yet.” Another stated, “I am driving now and
am busy with my three kids and their activities tonight. I will call you tomorrow.” However, the
patient did not call nor return calls. Unfortunately, another participant reported sad family
circumstances that hindered his ability for completion and follow up with the statement, “My dad
is dying. I read one chapter. Things have been hectic. I can’t answer questions now, but you
can call me back in a week.” Follow up was not achieved with this patient. Additional remarks
included, “It has been difficult to use because of my busy schedule, but I feel that the book is
helpful,” “I’m in the middle of something with my daughter and will call you back in a little bit,”
and “I haven’t used the book a lot recently because it’s finals weeks, but it is helping.”
Evaluation of Applicability of Theoretical and EBP Frameworks
The Neuman Systems Model served as the theoretical basis of the EBP project while the
Stetler Model was the EBP model that guided the project. Use of these models aided in
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successful implementation of the practice change by providing frameworks that the project
manager could follow. Incorporating such models allowed important components to be upheld
throughout the project as the principles of the Neuman Systems Model and the Stetler Model
aligned with those of the project.
Theoretical Framework
The Neuman Systems Model served as a very effective and applicable theoretical
framework to guide this EBP project (Neuman, 1982). Successful implementation of combined
self-administered CBT and SSRI medication was able to occur in the family practice setting by
utilizing this framework. Strengths of the Neuman Systems Model included its focus on the
patient achieving an optimal level of wellness. This was a goal congruent with the EBP project.
Through combination therapy to decrease anxiety and depression symptoms and improve GAD
status, wellness was promoted within this project. In addition to considering patient wellness,
the Neuman Systems Model assisted the project manager in considering lines of resistance and
defense. The SSRI medication was able to serve as a defense against any harm to patient
wellness through chemical changes within the brain to decrease feelings of anxiety. The CBT
workbook was able to provide a defense mechanism through teaching coping skills to deflect
stressors within the environment. The Neuman Systems Model brought concepts of the
environment, stressors, health, and nursing to the forefront in order to develop a project that
strived to address interactions between the patient and stressors within the environment,
implement a beneficial nursing intervention to modify the manner in which the patient responds
to such interactions, and improve patient’s health and wellness through collaboration via a
positive relationship between the patient and nurse practitioner providing care. Weaknesses of
the Neuman Systems Model included suggestions for prevention of invasion of stressors into
beyond the lines of resistance and defense that were inapplicable to this project. Examples
included blood pressure control and exercise. Although these are great interventions for the
reduction of anxiety, only CBT and SSRI medications were utilized within this project on the

GENERALIZED ANXIETY DISORDER PROTOCOL

126

basis of best practice. In addition, limitations of the Neuman Systems Model include the risk of
oversimplifying the theory as a whole during its application. Therefore, the need to thoroughly
explore and understand the theoretical framework is necessary in order to use it properly. The
Neuman Systems Model can be challenging to implement and consider all parts and subparts
addressed within the framework, particularly as there are complexities in considering the
interactions among an individual and the environment. Thus, an individual, holistic patient
approach and the consideration of a multitude of variables and dynamic nature of GAD is
necessary for proper use of the Neuman Systems Model.
EBP Framework
It can be concluded that the Stetler Model was a good fit as the EBP framework utilized
to guide this EBP project. As the project manager was a novice in regard to implementing
practice changes, the detailed steps of the Stetler Model aided in the consideration of important
information that otherwise could have been missed or omitted. The Stetler Model is comprised
of the following five steps: preparation, validation, comparative evaluation/decision making,
translation/application, and evaluation (Melnyk & Fineout-Overholt, 2015). The basic premise of
the project was formed using the preparation stage, which provided instructions to determine a
practice change that was in great need and perform a literature search. During experiences
within the clinical setting in family practice, the project manager noticed that GAD was extremely
prevalent and severely affecting the lives of patients. After wondering if there was a better way
to treat patients for GAD than the various medications that were being prescribed, lack of follow
through with referrals for counseling, or lack of recommendation for counseling provided, the
project manager found strong information within the literature to support the need for a change
in practice via self-administered CBT and SSRI medication use. Evidence was critiqued during
the validation stage, and much good and high quality and high level evidence was utilized to
support the project. Throughout the comparative evaluation/decision making stage, the project
manager further determined how to utilize the evidence in a feasible and beneficial manner.
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Numerous methods of CBT were recommended. However, self-administered CBT was
proposed as a cost-effective, accessible, effective method that would be feasible to implement
within the family practice setting.
Modifications were made to the plans outlined for the translation/application stage, which
included further planning and actual implementation of the project. Initially, the project manager
intended to include children ages 7 years of age and older, adolescents, and pregnant women
as participants in congruence with current literature. However, due to rigorous IRB requirements
for approval to include such vulnerable populations, time constraints regarding start of
implementation, and an anticipated small sample of this population at the project site, children,
adolescents under the age of 18, and pregnant women were excluded from the project. A
further change occurred when translating the plans of the project into practice. It was originally
planned that patient preferences would be upheld in the form of allowing participants to choose
between interventions of self-administered CBT only, SSRI use only, or combined selfadministered CBT and SSRI use. This would have created three different groups within the
project. A decision to change the available intervention solely to combination therapy with selfadministered CBT and an SSRI was made after the VU IRB suggested that as combination
therapy is best practice, it should be the only intervention offered. Additional modifications
included provider involvement in project participant recruitment. It was originally planned that
the two nurse practitioners in the family practice office at the project site would recruit eligible
participants every day that they were present in the office, which would have totaled 5 days per
week. This became altered when one NP left the practice shortly before project implementation
began. As the remaining NP then was taking on a greater workload unexpectedly, patient
recruitment became challenging for her due to time constraints. Therefore, the project manager
came to the office more frequently than initially planned in order to recruit participants.
The evaluation stage within the Stetler Model was also very useful to this project. Goals
were evaluated as well as the degree to which the project was implemented and adopted.
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Overall, the project was implemented in full as planned yet with revisions, and many goals were
met, including a statistically significant decrease in depression symptoms and high levels of
patient satisfaction reported. Goals that were not met included a sample population of at least
25 adults with GAD and achieving a statistically significant decrease in anxiety symptoms and
statistically significant improvement in GAD status. After completion of implementation, adoption
of the project at the project site was discussed. As the CBT workbooks were purchased by the
project manager using a generous grant from Sigma Theta Tau Zeta Epsilon Chapter, a new
method for acquiring the CBT workbooks was discussed with the NP who owns the practice.
The combination therapy protocol implemented via this project involving self-administered CBT
and SSRI use, patient education, and close monitoring is sustainable. It was decided that the
best way to adopt and sustain this practice change would be to provide patients with information
regarding self-administered CBT, its benefits associated with GAD treatment, where it is
available for purchase, and the potential cost. Best practice via the combined prescribing of
SSRI medication and the recommendation of CBT will continue to be incorporated into the
treatment of GAD at the project site. Such information will now be provided verbally as well as
via a patient handout for all adults with GAD in order to provide them with a helpful resource
encouraging them to purchase and utilize self-administered CBT, similar to the way in which
they would be instructed to purchase an over-the-counter medication. The practice is not
affiliated with nor receiving any funds from the companies listed based on the purchase of CBT.
The handout was developed by the project manager and given to the project site for use. Such
handout is presented within Appendix N. Thus, the project site has adopted the practice change
associated with this EBP project and plans to sustain the combination therapy protocol
implemented are in place. Future plans may include the making of a self-administered CBT
packet by the NP and project manager to provide to patients with GAD while at the office.
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Strengths and Limitations of the EBP Project
Overall, successful implementation and results of this EBP project were yielded.
Although there were numerous strengths of this project identified, there were also numerous
limitations identified. By addressing such aspects, results of this project may be explained and
future related projects can be strengthened.
Strengths
A strength of the project was its frequent follow up with participants every 4 weeks for a
period of 12 weeks. This provided much information regarding the typical time period required
for effects of self-administered CBT to become visible. It also allowed for participants to give
detailed feedback regarding their unique experience multiple times throughout implementation.
Another strength included measurement of a variety of outcomes, which provided much
information regarding the vast effects of the combination therapy protocol. Further project
strengths included the evaluation of both quantitative and incidental qualitative data. The site
facilitator greatly believed in the need for this practice change, and many participants showed
great interest and excitement for use of self-administered CBT. Many participants also
expressed satisfaction and compliance with administration of their prescribed SSRIs prior to the
start of project implementation. Another strength is that this project provided an alternative to
inaccessible, expensive treatment through a convenient, affordable method that patients could
utilize essentially anytime and anywhere. Although a statistically significant difference in anxiety
symptoms was not achieved from baseline to week 12, this in no way negates the positive
impact of this project and combined CBT and SSRI use. A statistically significant decrease in
depression symptoms was achieved from baseline to week 12, mean anxiety symptom severity
steadily decreased from baseline to week 12, and participants reported satisfaction with the
CBT workbook. Thus, overall results of this project were similar to those reported within high
quality evidence. Many participants noted their surprise at just how effective the addition of the
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CBT component was as well as their desire to continue to utilize self-administered CBT after
completion of this project.
Limitations
The small sample size was certainly a limitation of this project, and unfortunately, it was
not reflective of the high prevalence of GAD. This small sample size was limited by time
constraints for recruitment as well as site facilitator decisions regarding who could be
approached for participation within the project. Participants were recruited at a single-provider,
rural clinic. Due to the busy nature of the practice and recent loss of a second provider, the
remaining provider had limited time for project implementation. Therefore, participants were only
recruited when the project manager was present in the clinic. The project manager was unable
to be at the clinic more than typically two days per week during recruitment due to clinicals,
class, and work. As patients with GAD were seen 5 days per week at the clinic, there was a
large number of potential participants that could not be recruited. Also, the aforementioned sole
provider and site facilitator, the NP whom opened and owned the clinic, knew most of her
patients very well. There were some potentially eligible patients that the NP requested that the
project manager not approach regarding this project for various reasons, such as time
constraints or life events. This could have introduced some selection bias to the sample. The
sample size was also limited by excluding children, adolescents younger than 18, and pregnant
women as a result of IRB requirements and time constraints. Another limitation was the rather
homogenous sample population. Of the 10 participants who completed follow up, all were
Caucasian. Thus, there was a lack of racial diversity among participants, which could limit
generalizability. The sample size was further limited by ineligibility based on maintenance
medication use other than SSRIs as it would have been unsafe and unethical to immediately
discontinue and/or change medications in many cases. Finally, mean GAD-7 and PHQ-9 scores
indicated minimal anxiety and depression symptom severity at baseline. This was likely related
to the majority of participants already taking an SSRI prior to project implementation. The low
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scores limited the ability to see greater effects of the intervention protocol that may have been
apparent provided there had been greater room for improvement.
Implications for the Future
This EBP project provided worthwhile information for the advanced practice nursing
profession related to the effects of combination therapy of SSRIs and self-administered CBT.
Future implications for practice, theory, research, and education will be explored. Such
implications can be used to guide and improve future EBP projects and practice changes as
well as to positively shape the way GAD is treated both nationally and globally.
Practice
This combination therapy utilizing SSRIs and CBT has been established as best practice
in current, high quality literature. Unfortunately, it is not implemented in all primary care offices.
This project allowed for this combination protocol to become standardized practice at the project
site, and it is encouraged for all primary care offices to adopt this protocol. This project
supported the feasibility, low cost, effectiveness, and high levels of patient satisfaction
associated with combination therapy. A grant from Sigma Theta Tau Zeta Epsilon Chapter
covered the costs of the CBT workbooks at no expense to the family practice office nor
participants. It may not be feasible for offices to cover the expenses of the workbooks for
patients. Therefore, additional planning is necessary in order to determine how patients can
obtain the workbooks. This is still being discussed with the NP at the project site. Potential
options that have been proposed include the NP and project manager developing their own form
of self-administered CBT to pass out to patients with GAD, providing patients with a handout
indicating types of self-administered CBT, cost, and where to purchase them, or having selfadministered CBT available for patient purchase at the office.
There are many future EBP considerations to address. Future EBP projects related to
GAD with larger population sizes, greater diversity, and higher levels of anxiety and depression
symptom severity would be beneficial to further explore significance and generalizability.
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Additional recommendations for future projects include comparison of therapist-guided CBT
versus self-administered CBT outcomes. This would aide in the ability to compare and contrast
effectiveness and establish superiority regarding delivery method. It would also be beneficial for
future EBP projects to explore the effect of CBT and SSRIs on children and adolescents
younger than 18 years of age to further evaluate the effectiveness of this intervention across the
lifespan.
Theory
Use of the Neuman Systems Model as the theoretical foundation for this EBP project
aided in successful implementation of this EBP project. It allowed for a patient-centered
approach that considers the unique and individualized interactions that patients encounter with
the environment as well as the unique way in which they interpret and react to stressors within
the environment. This project was able to consider such reactions to stressors and provide
methods in which patients could become resilient and defensive against potential stressors
through the use of CBT and SSRI medication. These interventions were able to restructure the
way in which patients think about stressors and anxiety, leading to decreased symptoms of
anxiety as well as depression. The achievement of optimal wellness was a central component of
the Neuman Systems Model. Ultimately, a main goal of the EBP project was to promote quality
of life and improved disease status, or put more simply, to promote wellness. The Neuman
Systems Model was an excellent fit for this project, allowing for exploration and applicability of
the model on a deeper level while upholding a holistic, patient-centered, wellness focus as the
goal. As it assisted with successful development and implementation of this EBP project, the
Neuman Systems Model is recommended for future EBP practice projects that focus on
concepts of anxiety, stress, or depression. Future projects could also utilize the concepts of
primary, secondary, and tertiary prevention exemplified by the Neuman Systems Model. The
model describes the importance of primary prevention to strengthen the patient’s flexible line of
defense, or first barrier against stressors, secondary prevention to decrease the reaction that
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the patient has to the stressor within the lines of resistance, and rebuild wellness through
treatment when stressors have invaded the patient’s core. As this theoretical model is so
complex, future EBP projects could explore the model in even further detail and utilize as
applicable for improved patient outcomes.
Research
Further research is needed in order to explore the effects of therapist-guided CBT in
comparison to self-administered CBT. It may be that CBT guided by a therapist yields superior
outcomes to those of self-administered CBT. However, self-administered CBT is useful in
reducing the barriers associated with therapist-guided CBT, including lack of available
therapists, lack of insurance coverage, expense, time constraints, and patient reluctance. Thus,
self-administered CBT is beneficial for those who are unable or unwilling to go to CBT guided by
a therapist as it provides the opportunity for the patient to participate in CBT as opposed to no
CBT option. Self-administered CBT does not have to substitute therapist-guided CBT for
patients willing and able to attend, but rather could be implemented during the waiting period, if
one exists, between the time the patient is recommended for CBT and the patient’s established
appointment.
Education
Patient education is a vital part of the role and responsibly of the advanced practice
nurse. Educating participants about best practice treatment, side effects of medication, purpose
of therapy, and additional information was incorporated into the protocol implemented through
this project. Education was also a main component within the self-administered CBT workbook.
Participants expressed much increased knowledge about GAD and coping skills through use of
the CBT. Participants relayed that as a result of this education, their symptoms improved and
they felt better overall. This also allowed participants to become well-informed consumers and
take charge of their own health. Provider education is also extremely important regarding
treatment for GAD. SSRIs are safer than many other medications for treatment of GAD. For
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example, benzodiazepines are potentially addictive while SSRIs do not have this potential.
Many providers may also not be aware of the CBT resources available within their community
as well as globally. This project shines a light on the importance of familiarizing oneself with
such resources, recommending them to patients, providing support to patients, and assisting
them with accessing such resources.
Conclusion
This EBP project has allowed the NP site facilitator and project participants to see the
value of the addition of CBT to their treatment regimen. The site facilitator has expressed her
satisfaction with project results and her desire to continue to incorporate this combination
therapy of SSRI antidepressant medication and self-administered CBT at her practice. Methods
for sustainability were implemented at the project site. The site facilitator was receptive to such
informative handout for patients interested in self-administered CBT and plans to continue to
distribute this to eligible patients. Participants of the project also expressed their interest in
continuing to utilize self-administered CBT along with taking SSRIs after experiencing the
benefits first-hand. Such participants were encouraged to do so and provided with guidance
regarding additional self-administered CBT resources.
In conclusion, results of this project support the effectiveness of combination therapy
with self-administered CBT and SSRI medication for the treatment of adults with GAD in
decreasing anxiety and depression symptoms, improving GAD status, and yielding patient
acceptability and satisfaction, which is consistent with current literature. No statistical
significance was achieved for evaluation of anxiety symptoms nor for evaluation of change in
GAD status. However, mean GAD-7 and CGI-I scores decreased, indicating decreased anxiety
symptoms and improved GAD status. Statistical significance was achieved for the evaluation of
PHQ-9 scores, indicating a significant decrease in depression symptoms.
Patient education and close monitoring are also important components of such best
practice protocol that should be followed to assess patient safety and response to treatment as
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well as to facilitate patient understanding. Thus, this is a patient-centered protocol that upholds
the best interests of patients and has a holistic focus. Providers are recommended to
incorporate this combination therapy protocol including self-administered CBT and SSRI
antidepressant medication for the treatment of adults with GAD as a cost-effective, accessible,
effective method for improving GAD symptoms.
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SSRI: Selective Serotonin Reuptake Inhibitor
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STAI-T: State-Trait Anxiety Inventory
TAU: Treatment as Usual
UCLA: University of California, Los Angeles
U.S.: United States
VA: Veterans Affairs
WHO: World Health Organization
5-HT: 5-hydroxytrptamine
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Appendix C
Evidence-Based Practice Project Explanation
Anxiety is Something to Worry About: The Effects of a Cognitive Behavioral Therapy and
Selective Serotonin Reuptake Inhibitor Intervention Protocol on Generalized Anxiety Disorder
Dear Patient,
My name is Alesha McClanahan. I am a registered nurse and a student in the Doctorate
of Nursing Practice (DNP) program at Valparaiso University. Upon obtaining this degree and
certification, I will be a nurse practitioner (NP). To fulfill this program’s curriculum, I will be
implementing an evidence-based practice (EBP), or quality improvement, project at this clinic.
The providers at this clinic including, L. K***, NP, support this project and will be overseeing its
implementation. An evidence-based practice, or quality improvement project, aims to utilize
current best practice recommendations from research and integrate them into the practice
setting to improve clinical practice and patient outcomes.
My EBP project will assess the effectiveness of cognitive behavioral therapy (CBT) in
combination with a selective serotonin reuptake inhibitor (SSRI) on symptoms of generalized
anxiety disorder (GAD). I am serving as the project manager of this project. CBT is a
noninvasive, nonpharmacologic treatment that aims to change ways of thinking to elicit more
positive thoughts and develop methods for coping with anxiety. It will be delivered in the form of
an established CBT workbook written by a licensed psychologist. An SSRI is an oral
antidepressant medication used to treat GAD as well as depression, which is strongly linked to
GAD. Current, high quality evidence supports the combined use of CBT and an SSRI as the
best treatment for the management of generalized anxiety disorder in children, adolescents,
adults, and older adults. Therefore, if you would like to participate in this project, you will be
prescribed an SSRI and a CBT workbook.
The project will be implemented over a period of three months. Participants who agree to
participate will be asked to complete a consent form, demographic information, including age
and ethnicity, as well as an anxiety scale and a depression scale prior to treatment initiation and
monthly over the three month period of the project. Participants will be asked to complete a
satisfaction questionnaire upon project completion. For convenience, these measurements will
occur via telephone calls by the project manager. These phone calls will likely be 5-10 minutes
long. Participants will be asked to actively engage in the CBT workbook on their own and take
their SSRI medication as directed. You are invited to participate in this project. If you choose not
to participate in this project, there will be no penalty nor effect on the care provided to you today
or any other time at this clinic. Participation is voluntary, and you may withdraw at any time if
you wish. Patient confidentiality will be upheld, and patient information will be kept in a secure
and private location.
Thank you for your consideration,
Alesha McClanahan, BSN, RN, DNP Student Valparaiso University
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Appendix D
Informed Consent Form
Project Title: Anxiety is Something to Worry About: The Effects of a Cognitive Behavioral
Therapy (CBT) and Selective Serotonin Reuptake Inhibitor (SSRI) Intervention Protocol on
Symptoms of Generalized Anxiety Disorder (GAD)
Project Manager: Alesha McClanahan, BSN, RN, DNP Student Valparaiso University College
of Nursing and Health Professions
Purpose: This is a consent form for evidence-based practice participation. It contains important
information about the project and what to expect if I decide to participate. I understand that I am
being asked to join an evidence-based practice project for patients of this clinic that will examine
the effects of combined self-administered cognitive behavioral therapy (CBT) and selective
serotonin reuptake inhibitor (SSRI) medication use on symptoms of anxiety.
Voluntary participation/withdrawal: I understand that my participation is voluntary. I am being
asked to please read and consider the information carefully. I may ask questions before making
my decision regarding participation and at any time during and after the project’s
implementation. If I decide to participate, I will be asked to indicate my consent to participate
with my signature. I understand that I may leave the project at any time. If I decide to stop
participating in the project, there will be no penalty to me, and I will not lose any benefits to
which I am otherwise entitled. My decision will not affect my relationship with nor the care
provided to me at K*** Family Medicine today nor in the future.
Procedure: If I participate in this project, I will utilize the CBT workbook for anxiety and take the
prescribed SSRI medication. I understand that such CBT and SSRI use may be referred to as
interventions, therapy, or treatment throughout this project. The CBT utilized for this project may
be referred to as self-help or self-administered CBT as I will work on the workbook by myself, or
independently, rather than with a therapist. I understand that the evidence indicates that this
combined therapy yields the best outcomes for GAD. I will be asked to read and complete the
CBT workbook provided to me independently and as directed throughout the 3-month study
period. I will also be asked to take my SSRI medication regularly as directed throughout the 3month period. If I participate, I will sign consent to participate and answer a demographic,
anxiety, depression, and satisfaction questionnaire. The demographic questionnaire will need to
be answered once at the start of the project’s implementation, and the satisfaction questionnaire
will need to be answered once at the end of the project’s implementation. The anxiety and
depression questionnaires will need to be answered four times, including prior to the initiation of
treatment and monthly (every four weeks) for 3 months. The questionnaires will initially be
answered in the office during your scheduled appointment while the other three times in which
the same questionnaires will be answered will occur via telephone calls by the project manager.
If I participate in this project, I understand that I give consent for the project manager to call my
phone number(s) that I have provided, and I give consent for a message to be left if I am
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unavailable. I will make an effort to answer the project manager’s phone calls and to call the
project manager back shortly if I miss a call. The phone calls will typically last 5-10 minutes
each. Phone calls will include completion of the aforementioned questionnaires. I may also ask
the project manager any questions that I have during these phone calls and feel free to provide
any comments about the therapy, process, etc. I am asked to be open and honest and will not
receive any repercussions for my responses or comments.
Duration: I will tentatively participate in the study for 3 months (12 weeks). I will be regularly
evaluated by the project manager and NP for my safety and to evaluate the effectiveness of the
interventions. In addition to phone calls by the project manager, I may have follow up
appointments with the NP per office policy to evaluate the effects of the interventions, including
tolerability, side effects, and satisfaction with treatment. I will be instructed to complete certain
portions of the workbook by designated times and to complete the entire workbook within 3
months. I will be asked to complete the anxiety and depression questionnaires at 1 month (4
weeks), 2 months (8 weeks), and 3 months (12 weeks) after the start of the interventions.
Risks: The potential risks to participating in this project are minimal but include side effects and
adverse effects of SSRI medications which may include drowsiness, nausea, dry mouth,
insomnia, diarrhea, nervousness, agitation, restlessness, dizziness, headache, blurred vision,
sexual problems, reduced sexual desire, difficulty reaching orgasm, or inability to maintain an
erection. Additional safety concerns include potential drug interactions, serotonin syndrome, and
pregnancy or breastfeeding. You should inform your provider of all medications you are
currently taking. Serotonin syndrome may occur when levels of serotonin are too high in the
body, which typically occurs when multiple medications that raise serotonin levels are taken.
Seek medical attention if you have signs and symptoms of serotonin syndrome, including
anxiety, agitation, sweating, confusion, tremors, restlessness, lack of coordination, and a rapid
heart rate. Speak with your provider regarding antidepressant use and pregnancy or
breastfeeding if you are or plan to become pregnant or breastfeed as some antidepressants
may cause harm to your baby. Do not stop taking SSRI medication abruptly as this may pose
risks including withdrawal-like symptoms including uneasiness, nausea, dizziness, lethargy, and
flu-like symptoms. Although most antidepressants are safe, an increase in suicidal thoughts or
behavior can occur particularly upon initiation or dose change. Antidepressants are likely to
reduce suicide risk long-term. However, you should be closely monitored and contact your
provider or emergency services if you have suicidal thoughts. SSRIs are generally well
tolerated.
The potential risks to participating in this project associated with CBT are minimal but include
emotional vulnerability, emotional discomfort, frustration, crying, anger, feeling physically
drained, temporary stress, and temporary anxiety as CBT aims to address negative thoughts
that cause anxiety and fear and correct such maladaptive thoughts. Thus, CBT may involve the
confronting of sensitive thoughts and events which may evoke unpleasant thoughts and
emotions.
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Benefits: The benefits of participating in this project include receiving treatment based on the
recommendations of the best available evidence that aims to elicit the best outcomes and
increase quality of life for patients. A CBT workbook will be administered free of charge to those
who participate in this project. Researchers hope to gain valuable information regarding whether
incorporating CBT and an SSRI into the treatment plan will make an impact on anxiety
symptoms. The information provided may help to make advancements in nursing practice and
care provided.
Confidentiality: I understand that efforts will be made to keep my project-related information
confidential. However, there may be circumstances where this information must be released.
For example, personal information regarding my participation in this project may be disclosed if
required by state law. In the event that I indicate any potential for self-harm or harm of others, it
will be necessary to break confidentiality for my safety and the safety of others. Any information
containing my identifying information will be kept in a locked box with access only to the project
manager. My responses to questionnaires will be kept in a secure and private location with only
access to the project manager and office staff. The project manager and staff will work to
ensure that no one sees my questionnaire responses without my approval. A code will be used
in place of my name in order to further uphold confidentiality and reduce the risk that others can
view my responses. General information obtained from this project may be utilized in nursing
journals, presentations, or other publications, but no one will be able to identify me from this
information as no patient identifiers will be released.
Contacts and Questions: For questions and concerns about the project, I may contact the
project manager, Alesha McClanahan, at (219) 689-3369 or alesha.mcclanahan@valpo.edu. I
may also contact L. K***, NP, with questions at her office (219) 956-3004. Christina Cavinder,
the project’s faculty advisor, may be contacted at (219) 548-7797 or
christina.cavinder@valpo.edu. I may also contact Jennifer Winquist, Chair of the Institutional
Review Board at Valparaiso University at (219) 464-6841 or jennifer.winquist@valpo.edu if I
have questions or concerns regarding the conduction of the evidence-based practice project.
Consent to Participate: I have read (or someone has read to me) this form, and I am aware
that I am being asked to participate in an evidence-based practice project. I have had the
opportunity to ask questions and have had them answered to my satisfaction. I voluntarily agree
to participate in this project. I understand the information that has been presented to me. By
signing and submitting this form, I agree to participate in this project. I will be offered a copy of
this form for my records.
The project manager may call me at this phone number(s): ____________________________
___________________________
Participant’s Signature:
Printed first and last name:

Date:
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Demographic Form
Please answer the following questions about yourself.
1. What is your age? _____
2. Are you male or female?
a. Male
b. Female
3. What is the highest level of education that you have completed?
a. Less than high school
b. High school/GED
c. Some college (no degree)
d. 2-year college degree (Associates) (e.g. BA, BS)
e. 4-year college degree (Bachelors) (e.g. BA, BS)
f. Master’s degree (e.g. MA, MS, Med)
g. Professional degree (e.g. MD, DDS, DVM)
h. Doctoral degree (e.g. PhD, EdD)
4. What is your race?
a. African American
b. Asian-Pacific Islander
c. Caucasian
d. Hispanic
e. Native American
f. Other
g. Prefer not to answer
5. What form of health insurance do you currently have?
a. No insurance
b. Medicare
c. Medicaid
d. Private insurance
6. What is your marital status?
a. Single (never married)
b. Married
c. Separated
d. Divorced
e. Widowed
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Code Number:
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7. What is your annual household income?
a. Less than $20,000
b. $20,000 to $34,999
c. $35,000 to $49,999
d. $50,000 to $74,999
e. $75,000 to $99,999
f. Over $100,000
8. What is your current employment status?
a. Employed full time (40 or more hours per week)
b. Employed part time (up to 39 hours per week)
c. Unemployed and currently looking for work
d. Unemployed and not currently looking for work
e. Student
f. Retired
g. Homemaker
h. Self-employed
i. Unable to work
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Appendix F
Code Sheet

Patient Name (Last, First)

Code Number

1

2

3

4

5

6

7

8

9

10

11

12
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Appendix G

Code Number:

Generalized Anxiety Disorder 7-item (GAD-7) Scale
Over the last 2 weeks, how often have you been
bothered by the following problems?

Not at all

Several
days

More
than half
the days

Nearly
every
day

1. Feeling nervous, anxious, or on edge

0

1

2

3

2. Not being able to stop or control worrying

0

1

2

3

3. Worrying too much about different things

0

1

2

3

4. Trouble relaxing

0

1

2

3

5. Being so restless that it’s hard to sit still

0

1

2

3

6. Becoming easily annoyed or irritable

0

1

2

3

7. Feeling afraid as if something awful might
happen

0

1

2

3

Use “√ ” to indicate your answer.

For office coding: Add the score for each
column
Total score (add column scores) =
If you checked off any problems, how difficult have these problems made it for you to do your
work, take care of things at home, or get along with other people?
Not difficult at all

Somewhat difficult

Very difficult

Extremely difficult

Adapted from Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Lowe, B. (2006). A brief measure for assessing
generalized anxiety disorder. Archives of Internal Medicine, 166, 10920-1097. Retrieved from
http://www.archinternmed.com
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Generalized Anxiety Disorder 7-item (GAD-7) Scale Scoring

Scores on the GAD-7 range from 0-21 with each of the 7 items scored from 0-3. Each column is
added together in order to determine the total score. The total score indicates the level of
severity of anxiety symptoms.

GAD-7 Scale Score

Level of Anxiety Severity

0-4

Minimal symptoms

5-9

Mild symptoms

10-14

Moderate symptoms

15-21

Severe symptoms
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Appendix H

Code Number:

Patient Health Questionnaire (PHQ-9)
Over the last 2 weeks, how often have you been
bothered by the following problems?

Not at all

Several
days

More
than half
the days

Nearly
every
day

0

1

2

3

0

1

2

3

3. Trouble falling or staying asleep, or sleeping
too much

0

1

2

3

4. Feeling tired or having little energy

0

1

2

3

5. Poor appetite or overeating

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

Use “√ ” to indicate your answer.
1. Little interest or pleasure in doing things
2. Feeling down, depressed, or hopeless

6. Feeling bad about yourself – or that you are
a failure or have let yourself or your family
down
7. Trouble concentrating on things, such as
reading the newspaper or watching
television
8. Moving or speaking so slowly that other
people could have noticed? Or the opposite
– being so fidgety or restless that you have
been moving around a lot more than usual
9. Thoughts that you would be better off dead
or of hurting yourself in some way
For office coding: Add the score for each
column
Total score (add column scores) =

If you checked off any problems, how difficult have these problems made it for you to do your
work, take care of things at home, or get along with other people?
Not difficult at all

Somewhat difficult

Very difficult

Extremely difficult

Adapted from Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001). The PHQ-9: Validity of a brief depression
severity measure. Journal of General Internal Medicine, 16, 606-613. Retrieved from http://www.jgim.org/
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Patient Health Questionnaire (PHQ-9) Scoring

Scores on the PHQ-9 range from 0-27 with each of the 9 items scored from 0-3. Each column is
added together in order to determine the total score. The total score indicates the level of
severity of depression symptoms.

PHQ-9 Scale Score

Level of Depression
Severity

0-4

Minimal symptoms

5-9

Mild symptoms

10-14

Moderate symptoms

15-19

Moderately severe
symptoms

20-27

Severe symptoms
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Code Number:

Clinical Global Impressions-Improvement (CGI-I) Scale

1 – Very Much Improved

Nearly all better; good level of functioning;
minimal symptoms; represents a very
substantial change

2 – Much Improved

Notably better with significant reduction of
symptoms; increase in the level of functioning
but some symptoms remain

3 – Minimally Improved

Slightly better with little or no clinically
meaningful reduction of symptoms.
Represents very little change in basic clinical
status, level of care, or functional capacity

4 – No Change

Symptoms remain essentially unchanged

5 – Minimally Worse

Slightly worse but may not be clinically
meaningful; may represent very little change
in basic clinical status or functional capacity

6 – Much Worse

Clinically significant increase in symptoms
and diminished functioning

7 – Very Much Worse

Severe exacerbation of symptoms and loss of
functioning

Adapted from Busner, J. & Targum, S. D. (2007). The clinical global impressions scale: Applying a research tool in
clinical practice. Psychiatry (Edgmont), 4(7), 28-37. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/journals/901/
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Clinical Global Impressions-Improvement (CGI-I) Scale Scoring

Score

Change in Disease Status

1

Very much improved

2

Much improved

3

Minimally improved

4

No change

5

Minimally worse

6

Much worse

7

Very much worse
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Code Number:

Patient Satisfaction Questionnaire (PSQ)
Self-administered Cognitive Behavioral Therapy (CBT) Workbook

Please circle your responses.
1. How convenient or inconvenient is it for you to use the CBT workbook?
1)
2)
3)
4)
5)
6)
7)

Extremely Inconvenient
Very Inconvenient
Inconvenient
Somewhat Convenient
Convenient
Very Convenient
Extremely Convenient

2. How easy or difficult is it for you to use the CBT workbook?
1)
2)
3)
4)
5)
6)
7)

Extremely Difficult
Very Difficult
Difficult
Somewhat Easy
Easy
Very Easy
Extremely Easy

3. How satisfied or dissatisfied are you with the impact that use of the CBT workbook has had
on your anxiety symptoms?
1)
2)
3)
4)
5)
6)
7)

Extremely Dissatisfied
Very Dissatisfied
Dissatisfied
Somewhat Satisfied
Satisfied
Very Satisfied
Extremely Satisfied

4. How satisfied or dissatisfied are you with use of the CBT workbook overall?
1)
2)
3)
4)
5)
6)
7)

Extremely Dissatisfied
Very Dissatisfied
Dissatisfied
Somewhat Satisfied
Satisfied
Very Satisfied
Extremely Satisfied
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5. How worthwhile or worthless do you find use of the CBT workbook to be?
1)
2)
3)
4)
5)
6)
7)

Extremely Worthless
Very Worthless
Worthless
Somewhat Worthwhile
Worthwhile
Very Worthwhile
Extremely Worthwhile

Please fill in the blank.
6. How much time did you approximately spend completing the CBT workbook per week?
_______ minutes

OR

_______ hours

McClanahan, A. (2018). Patient Satisfaction Questionnaire.
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Patient Satisfaction Questionnaire (PSQ) Scoring

PSQ Scale Score

Level of Patient
Satisfaction

5

Extremely Dissatisfied

6-10

Very Dissatisfied

11-15

Dissatisfied

16-20

Somewhat Satisfied

21-25

Satisfied

26-30

Very Satisfied

31-35

Extremely Satisfied

This scoring system for the PSQ was created by the project manager and is optional. Results
may instead be reported per individual question via percentages as was ultimately done for this
project.
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Appendix K
Selective Serotonin Reuptake Inhibitor (SSRI) and Cognitive Behavioral Therapy (CBT)
Patient Instructions – Adult 18+ years
SSRI use
• The purpose of this medication is to help manage your anxiety by decreasing your
symptoms of anxiety.
• Take your prescribed medication as directed and attend regular follow up appointments.
• Do not discontinue your medication abruptly.
• Call your provider or seek emergency attention if necessary if you experience alarming
adverse effects.
• Side effects of the medication may include drowsiness, nausea, dry mouth, insomnia,
diarrhea, nervousness, agitation, restlessness, dizziness, headache, or sexual problems.
CBT use
• The purpose of this intervention is to help manage your anxiety by teaching you coping
mechanisms and changing negative and distorted thoughts into more positive and
realistic thoughts.
• A CBT workbook will be provided to you at the office for you to complete independently.
• This is CBT in the form of self-help, and thus, this is not guided by a therapist. However,
you are welcome to ask your provider or the project manager, Alesha, any questions.
• You will be enrolled in this project for 3 months (12 weeks), and the workbook is divided
into four parts. Please complete Part 1 by 3 weeks, Part 2 by 6 weeks, Part 3 by 9
weeks, and Part 4 by 12 weeks.
• Side effects of CBT may include emotional discomfort, frustration, crying, anger, feeling
drained, or temporary stress and anxiety when confronting sensitive thoughts.
Progress Measurement
• Your response to these interventions of SSRIs and CBT will be measured throughout
this project by the project manager, Alesha. These measurements will occur at baseline
(prior to starting these interventions) in the office and via phone calls by Alesha at 1
month, 2 months, and 3 months after starting these interventions. Phone calls will
typically last 5-10 minutes or less.
• Phone calls will include completion of the Generalized Anxiety Disorder 7-item (GAD-7)
Scale to assess for symptoms of anxiety and the Patient Health Questionnaire (PHQ-9)
to assess for symptoms of depression. You are welcome to share any comments,
concerns, or questions during these phone calls.
• These phone calls are important in order to measure these outcomes to determine the
effectiveness of the interventions and to further evidence-based nursing practice.
Alesha McClanahan, BSN, RN,
DNP Student Valparaiso University
219-689-3369
Alesha.mcclanahan@valpo.edu

•

Tentative dates of
measurement include:
▪ Baseline –
▪ 1 month –
▪ 2 months –
▪ 3 months –
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Appendix L
Best Practice Intervention Protocol
SUBJECT: Generalized Anxiety Disorder
Treatment Protocol
LOCATION: Primary Care Clinic
LAST REVISION: 9/12/18
APPROVED BY: Primary Care Clinic Nurse
Practitioner and Office Manger

REFERENCE #: 1
PAGES: 1
EFFECTIVE: 9/21/18
REVISED:
REVIEWED:

Purpose:
• To provide a protocol for nurse practitioners and other providers to follow in order to
provide best practice treatment of patients with generalized anxiety disorder (GAD)
Protocol:
• Primary care adult patients ages 18 years old and older with a diagnosis of GAD based
on DSM-5 criteria are eligible
•

Combination therapy with a selective serotonin reuptake inhibitor (SSRI) plus cognitive
behavioral therapy (CBT) is recommended for best outcomes
o

Age-appropriate self-help CBT bibliotherapy in the form of a workbook for anxiety
▪ Adults 18+: The Cognitive Behavioral Workbook for Anxiety: A Step-ByStep Program (Knaus, 2014)

AND
o

Prescribing of an SSRI
▪ Sertraline with a maximum daily dose of 200 mg PO is recommended
▪ Any type of SSRI will fulfill protocol requirements, and individual patient
factors should be considered, such as previous medications tried, drug
interactions, etc.

•

Education should be provided to patients regarding safe and proper use of CBT and
SSRIs and potential side effects

•

Close monitoring of patients taking SSRIs is recommended

•

Outcomes must be measured at baseline and monthly (every 4 weeks)
o Anxiety symptoms, depressive symptoms, GAD status, patient satisfaction, and
acceptability
o Generalized Anxiety Disorder 7-item (GAD-7) Scale, Patient Health
Questionnaire (PHQ-9), Clinical Global Impressions-Improvement (CGI-I) Scale,
Patient Satisfaction Questionnaire (PSQ), and attrition rate
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Appendix M

phone: 219.464.5798
fax: 219.464.5511
www.valpoirb.edu

To:

Institutional Review Board
212 Arts & Sciences Building
1400 Chapel Drive
Valparaiso, Indiana 46383-4520

Alesha McClanahan

From: Rasha Abed
Associate Director of Sponsored Research
RE: Anxiety is Something to Worry About: The Effects of a Cognitive Behavioral Therapy
(CBT) and Selective Serotonin Reuptake Inhibitor (SSRI) Intervention Protocol on
Symptoms of Generalized Anxiety Disorder (GAD)
Date: September 21, 2018
The IRB has approved the above study on September 20, 2018. The project was reviewed in
accordance with all research statues and regulations pursuant to Federal regulations, 45 CFR
46.101(b).
The researcher has approval of this project until one year from the identified date.
If additional protocol changes are needed, approval must be sought from the IRB prior to
implementing those changes. Please submit a new expedited request to the IRB for
consideration.
When the project is completed, notify the IRB. If the research protocol needs to extend beyond
one year, written approval must be sought from the IRB.
Good luck with your work. Please retain a copy of this letter for your records.
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Appendix N
Handout for Sustainability
Cognitive Behavioral Therapy for Generalized Anxiety Disorder Resources
Current, high quality evidence supports the combined use of cognitive behavioral
therapy (CBT) and selective serotonin reuptake inhibitor (SSRI) medication as the best
treatment for generalized anxiety disorder (GAD) in children, adolescents, and adults. The
purpose of both CBT and SSRIs for GAD is to help manage anxiety by decreasing symptoms of
anxiety and depression. An SSRI is an oral antidepressant medication used to treat GAD as
well as depression, which is strongly linked to GAD. SSRIs are typically well tolerated and safe.
CBT is a noninvasive, nonpharmacologic treatment that aims to change ways of thinking to elicit
more positive thoughts and teach ways to cope. Self-administered CBT via workbook is
recommended as an inexpensive, convenient, and effective form of CBT. Information regarding
cost, examples, and where CBT workbooks are available for purchase is listed below.
The Cognitive Behavioral
Workbook for Anxiety: A
Step-By-Step Program by
William J. Knaus, EdD
www.amazon.com
$18.85 Paperback
$12.49 Kindle
www.walmart.com
$18.85 Paperback
$16.59 eBook
www.target.com
$21.20 Paperback

The Generalized Anxiety
Disorder Workbook: A
Comprehensive CBT Guide
for Coping with Uncertainty,
Worry, and Fear by Melisa
Robichaud, PhD & Michel J.
Dugas, PhD
www.amazon.com
$18.62 Paperback
$9.99 Kindle
www.barnesandnoble.com
$25.95 Paperback
$12.49 Nook Book

Cognitive Behavioral
Therapy Made Simple: 10
Strategies for Managing
Anxiety, Depression, Anger,
Panic, and Worry by Seth J.
Gillihan, PhD
www.amazon.com
$9.75 Paperback
$0.00 Kindle
www.barnesandnoble.com
$15.99 Paperback
$14.99 Audiobook

The Anxiety & Worry
Workbook: The Cognitive
Behavioral Solution by David
A. Clack, PhD & Aaron T.
Beck, MD
www.amazon.com
$14.89 Paperback
$14.15 Kindle
www.target.com
$14.89 Paperback
www.walmart.com
$14.89 Paperback

There are a multitude of other CBT workbooks available for purchase both online and in
stores. Other methods of CBT to consider include mobile apps, free online resources including
CBT worksheets, and counseling with a licensed therapist. Consult with your provider if you
have any questions or would like more information. Combination therapy with CBT and SSRI
medication should be considered for the treatment of anxiety as it has been shown to decrease
anxiety and depression symptoms within current research and evidence-based practice.

Photo credit: (Amazon, 2019)

